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Abstract
Atherosclerosis is a chronic inflammatory disease and autoimmune mechanisms may 
contribute to its pathogenesis. Hsp27, a member of the small heat shock protein 
family, has been found to be expressed in atherosclerotic lesions. The aim of this 
study was to investigate whether Hsp27 may be involved in atherogenesis.
In vitro, Hsp27 treatment of the J774.2 murine macrophage cell line was associated 
with a significant decrease in macrophage interleukin (IL)-IO secretion (p<0.05). 
This effect was reduced when cells were pretreated with anti-toll like receptor-2 
(TLR2) blocking antibodies. Also, a significant increase in macrophage TLR-2 
surface expression was observed following treatment with Hsp27 (p<0.05).
In patients with an acute myocardial infarction, Hsp27 concentrations were lower in 
samples taken 12 hours post-infarction compared to samples taken on admission 
(p=0.02). There was also a concomitant decrease in the levels of anti-Hsp27 
immunoglobulin (Ig)M antibodies (p=0.02) and complement C3 in the 12 hour 
samples compared to samples taken on admission (p=0.02).
In a study group of young healthy controls and gymnasts, for the healthy controls 
only, there was a divergent association between Hsp27 antibody levels with physical 
activity, with Hsp27 IgM positively correlated (r=0.42, p<0.05) and the Hsp27 IgG 
negatively correlated (r=-0.43, p<0.05) with physical activity.
In patients with glucose intolerance (GI) and established cardiovascular disease 
(CVD) there was a significantly higher serum Hsp27 (p=0.02) concentration, and a 
significantly lower anti-Hsp27 IgM antibody level (p=0.02), compared to levels in 
healthy controls and a borderline significantly higher anti-Hsp27 IgG antibody levels 
compared to levels in GI patients without CVD. Serum anti-Hsp27 IgG antibody 
levels were positively correlated with levels of the inflammatory marker, intercellular 
adhesion molecule (ICAM)-l, r=0.28, p=0.03.
The pattern of high serum Hsp27, low IgM and high IgG autoantibodies in patients 
with cardiovascular disease and the association of the Hsp27 IgG antibodies with the 
inflammatory marker ICAM-1 suggest involvement of Hsp27 in atherogenesis. One 
way it may support lesion development is via its inhibitory action on macrophage 
production of the inflammatory cytokine, IL-10.
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1.0 General Introduction
1.1 Cardiovascular disease: An overview
According to the World Health Organization (WHO), cardiovascular disease (CVD) is 
the principal cause of death globally with an estimated 17 million deaths in 1999 and 
is responsible for 30% of all deaths worldwide each year (Bonow et ah, 2002). The 
main causes of deaths were due to coronary heart disease (CHD) and cerebrovascular 
disease. CVD was at one time a disease of affluent nations, however it has also 
affected the less affluent nations and 80% of CVD deaths were reported to take place 
in low- and middle-income countries.
CVD is a general term that covers all diseases that affect the heart and blood vessels. It 
includes coronary artery disease (CAD) or CHD, cerebrovascular disease, rheumatic 
heart disease, congenital heart disease, deep vein thrombosis and embolic disease. 
CHD affects the coronary arteries supplying blood to the heart which can result in 
clinical events that include: stable and unstable angina and myocardial infarction. 
Acute events encompassing the spectrum from unstable angina to myocardial 
infarction are also commonly refered to as acute coronary syndromes (ACS). 
Cerebrovascular disease affects arteries supplying blood to the brain and can result in 
clinical events such as stroke and transient ischaemic attacks. A high proportion of 
CVD mortality is due to CHD and stroke and the term CVD is often synonomously 
used to refer to these diseases (Yusuf et ah, 2001a).
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A CVD risk factor is a parameter that is associated with an increased risk of 
developing CVD. Some of these factors are positively associated with risk e.g. 
hypertension, while others are negatively associated with risk e.g. serum high density 
lipoprotein (HDL) cholesterol concentrations. The first large-scale comprehensive 
study of the causes of CVD was the Framingham Heart Study which began in 1948 
fSvtkowski et al.. 1990T and from which, several CVD risk factors were identified. 
In summary these can be divided into modifiable and non-modifiable risk factors, 
Table 1.1.
The most significant of these risk factors are: hypertension, tobacco use and high 
levels of cholesterol; these are considered to be the top 3 causes of cardiovascular 
death in industrialized countries (Dahlof, 2010). Risk factors also tend to cluster in 
individuals and interact synergistically to increase an individual’s total risk of CVD 
(Kannel, 1976; Meigs et al., 1997; Wilson et al., 1999; Zanchetti, 1997). The 
identification of risk factors in individuals is of importance so that those at high risk 
can be identified and interventions can be provided to reduce the risk of future 
events.
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Table 1.1 Cardiovascular disease risk factors
Non-Modifiable risk factors Modifiable risk factors
Increasing Age (Lakatta, 2002)
Family history of CVD (Barrett-Connor 
and Khaw, 1984)
Gender (Male sex) (Lerner and Kannel, 
1986)
Ethnic origin (Yusuf et al., 2001b) 
Menopause (Jensen et al., 1990)
Hypertension (Stokes III et al., 1989) 
Hypercholesterolemia (Kannel et al., 
1971a)
Low HDL cholesterol (Kannel et al., 
1971b)
Hypertriglyceridemia (Hokanson and 
Austin, 1996)
Smoking (Neaton and Wentworth, 1992) 
Physical inactivity (Tell and Vellar, 
1988)
Obesity (Hubert et al., 1983)
Diabetes (Type 1 and 2) (Kannel and 
McGee, 1979)
1.2 Atherosclerosis
Atherosclerosis is a thickening and hardening of the arterial wall associated with a 
loss of elasticity. It is initially due to infiltration of the intima by mononuclear cells, 
smooth muscle cells and increased extracellular matrix deposition and is 
characterized by the occurence of foam cells, which are lipid-laden macrophages and 
smooth muscle cells (Wick et a l, 2004). Atherosclerosis affects large and medium­
sized muscular arteries such as the coronary artery and aorta. Clinically,
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atherosclerosis manifests itself as CHD, cerebrovascular disease and peripheral 
artery disease. Heart attacks and strokes are usually caused by a disturbance of the 
blood supply to the heart and brain respectively. Disruption of the blood supply is 
usually due to vascular occlusion which occurs when there is an acute narrowing 
(stenosis) of the arterial lumen usually due to a platelet thrombus, that is 
superimposed upon an atherosclerotic plaque of the affected blood vessel (Falk, 
2006) or from a clot which has been formed elsewhere in the body as in an embolic 
stroke (Donnan et al., 2008b). Disruption of the blood supply can also be due to 
rupture of a blood vessel which can give rise to haemorrhagic stroke (Donnan et al., 
2008a).
1.2.1 Pathogenesis of atherosclerosis
Over the years, various proposals have been put forward to explain the events in 
atherogenesis. Among these are three hypotheses that have gained substantial 
support; the response to injury hypothesis, the response to retention hypothesis and 
the oxidative modification hypothesis. These hypotheses are discussed in more detail 
in the following sections.
1.2.1.1 The response to injury hypothesis
The response to injury hypothesis of atherosclerosis was first formulated by Ross and 
Glomset in 1973 (Ross and Glomset, 1973) and subsequently modified to give 
emphasis to endothelial dysfunction as the first step in atherosclerosis (Ross, 1999). 
The hypothesis was based on the concept that atherosclerosis forms in response to
26
localized injury to the arterial wall, primarily the endothelium leading to endothelial 
dysfunction. The sources of injury could be due to hypercholesterolaemia, 
hypertension, cigarette smoking, diabetes, obesity and so on.
1.2.1.2 The response-to-retention hypothesis
The response-to-retention hypothesis proposed by Williams and Tabas in 1995 
(Williams and Tabas, 1995) states that the retention of atherogenic lipoproteins 
associated with the extracellular matrix in the arterial intima is an initial event in 
early atherogenesis. It proposed that this process begins with predisposing stimuli 
such as mechanical strain and cytokines, which enhance local synthesis of 
proteoglycans with high binding affinity for lipoproteins and that atherogenic 
lipoproteins enter the arterial intima and are bound and retained by the 
proteoglycans. The lipoprotein-proteoglycan complexes exhibit increased 
susceptibility to modifications, such as oxidation and aggregation, and that these 
modifications lead to uptake by macrophages to form foam cells. Furthermore, 
oxidized lipoproteins enhance the production of proteoglycans with a high affinity to 
lipoproteins, thus perpetuating the process.
1.2.1.3 The lipid oxidation hypothesis of atherosclerosis
The oxidative modification hypothesis of atherosclerosis states that low density 
lipoprotein (LDL) in its native state is not atherogenic, however, LDL modified 
chemically is readily internalized by macrophages through a so-called scavenger 
receptor(s) pathway leading to the formation of foam cells, a hallmark of early
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atherosclerotic lesion (Henriksen et al., 1981; Hessler et al., 1979; Morel et al., 1984; 
Steinbrecher et al., 1984; Goldstein et al., 1979).
It is hypothesised that when LDL traverses the subendothelial space, its lipids are 
subjected to oxidation, and as a consequence, apolipoprotein (Apo) B-100 lysine 
groups are modified so that the net negative charge of the lipoprotein particle 
increases (Haberland et al., 1982). This modification of Apo B-100 renders LDL 
susceptible to macrophage uptake via a number of scavenger receptor pathways 
producing cholesterol ester-laden foam cells (Haberland et al., 1984). The process of 
LDL oxidation is also associated with a number of other potentially proatherogenic 
events. For example, in vitro, oxidized LDL (oxLDL) has been shown to be 
chemotactic to monocytes and T lymphocytes perhaps as the result of 
lysophosphatidylcholine formed during oxidation (McMurray et al., 1993; Quinn et 
al., 1987; Steinbrecher et al., 1984). OxLDL has also been shown to stimulate the 
proliferation of smooth muscle cells and to be immunogenic by eliciting the 
production of autoantibodies (Parums et al., 1990; Salonen et al., 1992; Stiko-Rahm 
et al., 1992). The recruitment of inflammatory cells may result in the continued 
oxidation of LDL, setting the stage for catalytic expansion of the atherosclerotic 
lesion and the full-blown spectrum of atherosclerosis.
In summary, although each hypothesis points to its own critical initiating event, one 
common feature is that each involves a significant component of inflammation, and it 
is now widely accepted that atherosclerosis is a chronic inflammatory disease (Ross, 
1999; Hansson et al., 2006).
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1.3 Atherosclerosis - a chronic inflammatory disease
Inflammation is the reaction mounted by the tissues in response to injury, irritation or 
infection caused by biological, physical or chemical agents (Rankin, 2004). The 
reaction brings cells and molecules of the immune system to the sites of infection or 
injury to limit the spread of infection and to eliminate the cause of and repair tissue 
damage. Inflammatory processes have been recognized to occur in artery walls for 
longer than a century, initially by the pathologist Rudolf von Virchow (Wick et al., 
2004), however it is only in the last 30 years that this has also been applied to 
atherogenesis. Clinical investigations, population studies, cell-culture experiments 
and experiments in animals have provided important clues to the pathogenesis of 
atherosclerosis (Hansson, 2005; Hansson et al., 2006) and the following sections will 
highlight the role of inflammation in the initiation of the atherosclerotic lesion.
Atherosclerosis preferentially occurs at sites of haemodynamic strain where patterns 
of hemodynamic flow (low average shear but high oscillatory shear stress) cause 
increased expression of intercellular adhesion molecule (ICAM-1) on endothelial 
cells (Walpola et al., 1995). When LDL infiltrates the intima, is retained and 
modified, an inflammatory response is initiated in the artery wall. Modification of 
LDL via oxidation generates phospholipids on the LDL molecule that can activate 
endothelial cells. Activated endothelial cells express adhesion molecules that include 
vascular cell adhesion molecule-1 (VCAM-1) and E and P selectins (Dong et al., 
1998; Li et al., 1993a) that facilitate the attachment of monocytes and lymphocytes 
to the endothelium which is normally resistant to leukocyte adhesion.
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Once adherent to the endothelium, migration of leukocytes into the intima can be 
facilitated by the chemokine; monocyte chemoattractant protein-1 (MCP-1), which is 
expressed by cells in the atheroma (Nelken et al., 1991). In hypercholesteroaemic 
mice, reduced lesion formation is observed when signaling through MCP-1 is 
interrupted (Gu et al., 1998). MCP-1 attracts monocytes bearing their specific 
receptor CCR2, a monocyte subpopulation which is normally involved in 
inflammation (Tsou et al., 2007). Macrophage colony-stimulating factor-1 (MCSF-1) 
is a cytokine expressed in atherosclerotic lesions (Clinton et al., 1992) and may be 
responsible for the maturation of the monocytes into macrophages and the 
subsequent increase in macrophage expression of pattern recognition receptors (de 
Villiers et al., 1994).
Another type of immune cell that appears early on in the development of 
atherosclerotic lesions is the T lymphocyte (T cell). The entry of T cells into the 
intima is also facilitated by the adhesion molecules VCAM-1 and ICAM-1 and the 
chemokine MCP-1 (Carr et al., 1994; Chen et al., 1999a; Hansson, 2001). Most of 
the T cells in advanced atherosclerotic lesions are the CD3+ CD4+ (T cell receptor, 
TCR) »13+ cells and express cell surface markers indicative of memory cells in an 
activated state (Stemme et al., 1992; Zhou et al., 1996). These cells recognize protein 
antigens presented to them by professional antigen presenting cells (APCs) such as 
macrophages or dendritic cells (DCs). In the vicinity of the T cells, major 
histocompatibility (MHC) class II-expressing macrophages and DCs are detected, 
indicating immune interaction between T cells and APCs (Jonasson et al., 1986; 
Kishikawa et al., 1993).
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1.3.1 Candidate antigens in atherosclerosis
Several antigens have been proposed as inflammatory agents/antigens involved in 
atherosclerosis and these include oxLDL and several Heat shock proteins (Hsps); 
Hsps60, 70 and 90.
In atherosclerosis, cholesterol accumulation occurs in macrophages and smooth 
muscle cells leading to the formation of foam cells. This is mediated by the uptake of 
modified forms of LDL, such as oxLDL, via scavenger receptors. Importantly, these 
receptors are not downregulated by high levels of intracellular cholesterol, in contrast 
to LDL receptor expression. LDL extracted from atherosclerotic lesions was found to 
resemble LDL that has been oxidatively modified in vitro (Yla-Herttuala et al., 1994) 
and such forms of LDL have shown inflammatory properties such as induction of 
adhesion molecules on lesion cells (Kita et al., 2001). In addition, antibodies to 
oxLDL have been detected in atherosclerotic patients and animals (Hulthe et al., 
2001b; Hulthe, 2004; Salonen et al., 1992; Tsimikas et al., 2001).
Hsp70 and 60 were found to be expressed on all major cell types in lesion-prone sites 
during atherogenesis in animal models (Kanwar et al., 2001) and in humans 
(Berberian et al., 1990; Bobryshev and Lord, 2002; Kleindienst et al., 1993). There is 
a high degree of homology in the amino acid sequence among members of the 
HSP60 family across species, and serum antibodies to Hsp60 of microorganisms 
(Mycobacterium tuberculosis, Escherichia coli and Chlamydia pneumoniae) that 
have been detected in atherosclerotic lesions have been shown to cross react with the 
human Hsp60 (Mayr et al., 1999; Xu et al., 1993). This suggests that immune
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reactions to self Hsp60 may be due to molecular mimicry, a process where sequence 
similarities between foreign and self-peptides can result in the activation of the host 
immune response to self proteins (Oldstone, 1998). Both Hsp60 and Hsp70 can also 
activate innate immune cells to produce proinflammatory cytokines such as tumor 
necrosis factor (TNF)-a and interleukin (IL)-l (Pockley et aL, 2008). Hsp90 
expression has also been detected in carotid atherosclerotic plaques and furthermore 
plaque T-lymphocytes isolated from these patients have been shown to proliferate in 
response to Hsp90 in vitro (Businaro et aL, 2009).
1.4 Innate and adaptive immune response in atherosclerosis
The immune system can be divided into innate and adaptive immune responses. In 
atherosclerosis, macrophages and other components of the innate immune response 
may contribute to disease pathogenesis whilst the T-lymphocytes and other 
components of the adaptive immune response modulate disease activity and 
progression (Hansson et aL, 2002), Fig.1.1.
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Fig.1.1 Possible interaction between the innate and adaptive immune response in 
atherosclerosis.
Atherosclerotic lesions contain both cells of the innate and adaptive immune response, 
namely macrophages and T-cells respectively. Initiation of the inflammatory response 
involves recruitment of monocytes to the lesion and subsequent differentiation to 
macrophages and foam cells. Progression of lesion may involve recognition by T cells of 
antigens presented by macrophages and subsequent production of cytokines by the T cells. 
Taken from  Yan & Hansson, Immunol Rev. 2007 Oct;219:187-203
1.4.1 The innate immune response
The innate (inborn/natural) im mune response constitutes the first line o f  the body’s 
defense against invading pathogens. It is a non-specific but rapid response to 
invasion. The elem ents o f  innate im m unity include anatom ical barriers and hum oral 
and cellular com ponents. Anatom ical barriers include the skin and internal epithelial 
layers, the m ovem ent o f  the intestines and the oscillation o f  broncho-pulm onary cilia
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(Lentz and Feezor, 2003). Humoral components include the complement and 
coagulation system while cellular components include dendritic cells, macrophages, 
natural killer cells, mast cells and eosinophils (Bcutler, 2004).
1.4.1.1 The complement system
The complement system consists of a collection of thirty circulating and membrane 
associated proteins that form part of the innate immune response (Rus et aL, 2005). 
Many of these proteins are proteolytic enzymes and complement activation involves 
sequential activation of these enzymes resulting in a cascade. The complement 
cascade may be activated by one of three pathways; the classical pathway, the 
alternative pathway and the lectin pathway. The classical pathway is triggered by 
immune complexes; the alternative pathway is triggered by spontaneous hydrolysis 
of the C3 complement protein while the lectin pathway is triggered by microbes 
coated with mannose-binding lectin. Complement activation is important for 
opsonisation (tagging) and removal of particles such as immune complexes 
opsonised by complement activation products (Navratil et aL, 1999; van Lookeren et 
aL, 2007).
1.4.1.1.1 Classical pathway
When the Fab portion (the variable region) of IgM or IgG binds antigen, the 
conformation of the Fc (constant) region is altered (Haeney, 1998). This allows 
binding to Clq of the Cl complex which is the first step in the activation of the 
classical pathway, Fg.1.2. Cl is a complex comprising of the recognition unit C lq
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and two molecules each of C lr and Cls, the enzymatic units of the complex. 
Activation of C lq triggers autocatalytic activation of C lr which then cleaves Cls to 
activate it. Cls cleaves the plasma protein C4 causing the release of the smaller 
fragment C4a, leaving the larger fragment C4b which binds to the complex. C4b then 
binds to C2 and causes C2 to be cleaved by Cls releasing the smaller fragment C2b 
and leaving the larger fragment C2a still associated with C4b. The C4b2a complex is 
also known as the classical pathway C3 convertase. C3 is the common point at which 
other pathways of complement activation converge.
C2a can cleave C3, releasing C3a and leaving C3b covalently bound to the activating 
surface. The C4bC2aC3b complex is the classical pathway C5 convertase. This 
complex can bind C5 and present it for cleavage by C2a thereby releasing C5a and 
leaving C5b still associated with it. C5b then binds to C6 and subsequently to C7. 
The resultant C5b67 complex can stably associate with a membrane and recruit C8 
from the plasma. Multiple copies of C9 are then incorporated into the complex to 
form the membrane attack complex (MAC). MAC creates a rigid pore in the 
membrane, allowing free flow of solutes and electrolytes across the cell membrane 
which causes the cell to swell and sometimes burst (Rus et aL, 2005). A schematic 
diagram of the the activation cascade described above is shown in Fig. 1.2.
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Fig.1.2 Schematic diagram of complement activation via the classical pathway
An antigen-antibody complex activates Cl which then acts on C4 to split it up to C4a and 
C4b. C4b then combines with C2 to form C4b2. Cl acts on this to release C2b leaving the 
C4b2a complex which is known as the classical pathway C3 convertase. C3 is the common 
point at which other pathways of complement activation converge. Activation of C3 leads to 
further steps downstream which eventually lead to the formation of the membrane attack 
complex (MAC).
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1.4.1.2 Macrophages
Macrophages form part of the cellular component of the innate immune response. 
These cells are distributed throughout the body in various organs, tissues and body 
fluids making them effective as the first line of defence against pathogens 
(Rutherford et aL, 1993). Macrophages develop from monocytes once they have 
reached the target organs. They are phagocytes since they perform their 
immunological function by internalizing foreign materials into their cytoplasm. The 
internalized pathogens may then be presented to cells of the adaptive immune 
response and hence because of this activity, macrophages are also known as antigen 
presenting cells.
To facilitate their functions, macrophages express a large variety of surface 
molecules which enables them to recognise pathogens. These surface molecules; 
called pattern recognition receptors (PRR) recognize pathogen- associated molecular 
patterns (PAMPs) present on pathogens. These conserved PAMPs are essential for 
microbial survival and hence cannot be substantially altered by innate immune 
system selection pressure (Janeway, Jr. and Medzhitov, 2002). The two main types 
of PRRs of potential importance in atherosclerosis are the scavenger receptors (SRs) 
and the toll-like receptors (TLRs).
SRs are classified functionally as endocytic PRRs that promote the attachment, 
engulfment and destruction of microorganisms by phagocytosis (Krieger and Herz, 
1994). Included in this group are the class A SRs consisting of SR-AI and SR-AII; 
class B SRs consisting of CD36 and SR-B1 and SR-BII, and the rest of the class
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including CD68 and lectin-like oxidized LDL receptor-1 (LOX-1) (Greaves and 
Gordon, 2005). These receptors mediate the uptake of oxLDL by macrophages, and 
animal models of atherosclerosis which do not express the SR-AI, SR-AII and CD36 
have reduced atherosclerotic lesion development (Febbraio et aL, 2000; Moore and 
Freeman, 2006; Suzuki et aL, 1997).
TLRs belong to the signaling type pattern recognition receptor. In mammals there are 
at least ten members of the TLR family, TLR1-10 (Takeda et aL, 2003), with 
macrophages expressing most of these receptors except for TLR3 (Muzio et aL, 
2000). Ligation to TLRs transmits transmembrane signals into the intracellular 
compartment which leads to activation of intracellular signaling pathways such as the 
nuclear factor kappa B (NF-rcB) and mitogen-activated-protein kinase (MAPK) 
signal transduction pathways (Pan, 2004). These in turn induce transcription of a set 
of genes for proteases, cytokines, chemokines, complement factors, procoagulant 
factors and radicals (Hansson and Berne, 2004) and thereby mediates inflammation. 
Importantly, in diseased arteries, there is upregulated expression of TLR1, TLR2, 
TLR4 and TLR6 with most macrophages expressing both TLR2 and TLR4 (Edfeldt 
et aL, 2002).
1.4.1.2.1 Macrophage activation
Macrophages can change their physiology depending on the environmental signals to 
which they are exposed. These changes give rise to different population of cells with 
distinct functions, Fig.1.3.
38
Activation of macrophages by lipopolysaccharide (LPS) or interferon (IFN)-y gives 
rise to macrophages of the Ml phenotype (Mosser, 2003). These macrophages are 
oriented to mediate resistance against intracellular parasites and tumors and to elicit 
tissue disruptive reactions. Characteristic properties of these macrophages include 
the production of inflammatory mediators such as reactive nitrogen and oxygen 
intermediates and the proinflammatory cytokines TNF-a, IL-1, IL-6 and IL-12.
Alternative activation of macrophages gives rise to the M2 phenotype of 
macrophages. M2 macrophages are further subdivided depending on the activation 
stimulus: IL-4/IL-13; immune complexes and ligands of MyD88-using receptors; IL- 
10. In general, M2-activated cells share a high expression of scavenger, mannose and 
galactose receptors and an IL-12low, IL-10hlgh, IL-1 decoy receptor type 2 (ILlR2)hlgh, 
IL-1 receptor antagonist (ILlRN)hlgh phenotype (Mantovani et al., 2009; Martinez et 
al., 2008). M2 activated macrophages are oriented to the promotion of tissue 
remodelling and angiongenesis, parasite capsulation, regulation of immune 
responses, and tumor promotion.
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Fig.1.3 M l and M2 macrophage phenotypes.
Schematic diagram of the classical, M l, macrophage activation and the alternative, M2, 
macrophage activation showing the activators and cytokines produced by each phenotype. 
Key: LPS, lipopolysaccharide; IFN-y, interferon gamma; IL -1/4/6/10/12/13, interleukin- 
1/4/6/12/10/13; 1C, immune complex; TNF-a, tumor necrosis factor alpha 
Adapted from Martinez et al (2008). Front. Biosci. 13:453-61
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1.4.2 The adaptive immune response
The adaptive immune response is also known as the acquired or specific immune 
response. It is stimulated by pathogens and adapts to the presence of these pathogens 
and is therefore acquired on recognition of antigenic epitopes on pathogens (Hansson 
et aL, 2002). In contrast to innate immunity which recognises common molecular 
patterns, PAMPS, the adaptive immune response has a very large repertoire of 
specific antigen receptors that can recognize antigenic epitopes on pathogens. The 
two types of adaptive immunity are humoral and cell-mediated immunity.
Humoral immunity is mediated by antibodies that are produced by B-cells. These 
lymphocytes respond to pathogens present in the circulation and other body fluids by 
producing antibodies specific to these pathogens. B cells are not as common in 
atherosclerotic lesions but their products, antibodies, may play a modulatory role in 
atherogenesis via formation of immune complexes with their cognate antigens 
(Jonasson et ah, 1986; Pengiran Burnt et ah, 2010b).
Cell-mediated immunity is provided by T lymphocytes and provides defense against 
intracellular pathogens. T cells are recruited to tissues in an antigen-independent 
manner; their activation initiates proliferation and expansion of antigen-specific 
clones and is dependent upon recognition of their specific antigens and simultaneous 
ligation of co-stimulatory receptors. T-cells generally recognize antigens as peptides 
bound to antigen-presenting molecules called major histocompatibility complex 
(MHC) molecules on APCs such as macrophages and dendritic cells (Berzofsky et 
aL, 1989; Ljunggren and Thorpe, 1996). In early atherosclerotic lesions of apoE-
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knockout mice, there is an oligoclonal expansion of the T-cell population suggesting 
that clonal proliferation occurred via activation of local antigen (Paulsson et aL, 
2000).
1.4.2.1 T cells
T cells are also abundant in human atherosclerotic plaques (Jonasson et aL, 1986). 
Both types of T cells, CD4+ and CD8+ T cells are found in human lesions with 
CD4+ T cells making up approximately two thirds of the T-cell population.
CD4+ T cells can differentiate into either the T-helper (Th)l or Th2 subsets 
depending on the predominant local cytokine present (Zhu et aL, 2010). IL-12, which 
is produced by macrophages and other cells in the lesions acts as the Thl stimulus 
causing them to secrete the proinflammatory cytokines IFN-y, TNF-a, IL2 and IL-1. 
These cytokines are abundant in the lesions. Th2 cells are rarely detected in 
atherosclerotic lesions, however, their induction is promoted in a severe 
hyperlipidémie context and their inducer IL-10 is present in atherosclerotic lesions 
(Daugherty and Rateri, 2002; Mallat et aL, 2009). Th2 cells secrete the anti­
inflammatory cytokines IL-4, IL-5 and IL-10. T h l7 cells have only been recently 
identified as a distinct subset of CD4+ T cells (Mangan et aL, 2006). These cells are 
induced by transforming growth factor (TGF)-(3 and IL-6 or IL-23 and secrete IL-17 
which has proinflammatory properties (Park et aL, 2005; Veldhoen et aL, 2006). IL- 
17 is produced by coronary artery-infiltrating T cells and act synergistically to 
induce proinflammatory responses in vascular smooth muscle cells (Bid et aL, 2009).
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Another population of CD4+ T cells found in the lesions is the regulatory T cells, 
also called Tregs (Heller et aL, 2006). Tregs produce the cytokines IL-10 and TGF-p 
which are both anti-inflammatory cytokines and Treg cells have been found to be 
inhibitors of atherosclerosis in several mouse models and therefore may perform a 
protective role in atherosclerosis (it-Oufella et a l, 2006; Mor et a l, 2007).
CD8+ T cells are found at varying proportions in human lesions (Hansson, 2001; 
Jonasson et aL, 1986). Most of the cytotoxic activity associated with T cells is 
attributed to this subpopulation that is activated by cells that express proteasomally 
processed peptide fragments of nascent proteins in the context of MHC class I 
(Ljunggren and Thorpe, 1996). Little data exist regarding the precise role of CD8+ T 
cells in atherogenesis and no change in lesion formation has been observed in ApoE- 
/-CD8-/" mice compared with ApoE-/-mice (Elhage et aL, 2004). However, it was 
found that intimai CD8 T-cell numbers increase with increasing severity of 
atherosclerotic lesions and in advanced plaques, they represent up to 50% of the 
infiltrating leukocytes (Gewaltig et aL, 2008), which suggests an involvement in 
lesion development.
1.4.2.2 Immune complexes
An immune complex (IC) is formed between an antibody and its corresponding 
antigen. The ratio of antibody to antigen in a complex is variable and in vivo there is 
a heterogenous mixture of complexes of the same antigen and antibody present.
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Formation of ICs is a physiological process and is potentially beneficial; being 
necessary for the removal of pathogens via activation of the classical pathway of the 
complement system. However, inappropriate complement and Fc (fragment, 
crystallisable) receptor activation might exacerbate and promote the progression of 
atherogenesis (Pengiran Burnt et ah, 2010b).
ICs can be formed between any antibody and its corresponding antigen, however the 
classical pathway is only activated by complexes formed between immunoglobulin 
(Ig) M, IgGl, IgG2 and IgG3 and their cognate antigens. Tissue bound 
immunoglobulins, immunoglobulins associated with lesion LDL and ICs of IgG with 
apolipoprotein (Apo) B have been isolated from human atherosclerotic lesions (Yla- 
Herttuala et aL, 1989; Yla-Herttuala et aL, 1994). In vitro studies appear to indicate 
that complexes formed by IgM mediate protection in atherosclerosis, partly by 
facilitating removal of pathogenic and apoptotic material from developing lesions 
(Lewis et aL, 2009). ICs formed by IgG antibodies might be proatherogenic due to 
their ability to activate Fc receptors on immune cells such as macrophages. Fc 
receptor activation leads to the release of inflammatory mediators such as the 
cytokines TNF-a, IL-1, IL-6 and 11-12 which promotes inflammation and thus 
inflammatory processes in the lesion (Saad et aL, 2006; Kiener et aL, 1995).
1.4.3 Cytokines and atherogenesis
Cytokines are soluble, low molecular weight, secreted proteins that regulate both the 
amplitude and duration of the immune/inflammatory responses. In atherosclerostic 
lesions, cytokines produced by immune cells such as macrophages and T-cells, can
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exert both pro- and anti-inflammatory effects. Analysis of local vascular 
inflammation and the cytokines expressed in atherosclerotic plaques has revealed 
that there is a balance between pro-inflammatory and anti-inflammatory cytokines 
and that this balance is crucial for lesion development. For example, cytokines 
secreted from CD4+ Thl cells such as IL-2, IL-12, IFN-y, TNF-a and TNF-P are pro- 
inflammatory and exacerbate atherosclerotic disease. Conversely, Th2 cytokines 
such as IL-5 and IL-10 are considered to be mainly atheroprotective and can 
counteract Thl cytokine activity/production (Calcagni and Elenkov, 2006; Robertson 
and Hansson, 2006; Walch et aL, 2006). The key cytokines suggested to be involved 
in atherogenesis are summarised in Table 1.2. The following detail some of the 
studies and possible actions of an inflammatory cytokine, TNF-a, and an anti­
inflammatory cytokine, IL-10.
TNF-a is primarily produced by monocytes and macrophage and has been detected 
in human lesions (Barath et aL, 1990; Kishikawa et aL, 1993). It is a pleiotropic 
cytokine with multiple, dose-dependent actions on both local and systemic 
inflammation. TNF-a is involved in atherosclerotic progression from the initial 
stages of intimai thickening to the subsequent vessel occlusion (Barath et aL, 1990). 
It stimulates selectins and adhesion molecules expression by endothelial cells, 
smooth muscle cells and macrophages; promoting interaction between the 
endothelium, leucocytes and platelets, thus creating a pro-inflammatory and 
prothrombotic local environment. TNF-a has also been implicated in modulating 
plaque morphology and is associated with plaque rupture. It stimulates production of 
matrix metalloproteinase (MMP)-l- 9, 11 and 13 in the endothelium, SMCs and 
macrophages (Galis et aL, 1995; Young et aL, 2002). Locally, within the
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atherosclerotic plaque, TNF-a increases expression of tissue factor, a potent 
thrombogenic protein, by macrophage-derived foam cells and the endothelial cells 
(Taubman et aL, 1997). The proinflammatory cytokine pathway is a cascade that 
involves activation by TNF- a and IL-1 to IL-6 expression (Introna and Mantovani, 
1997) and also to secretion of pentraxins such as CRP (Gewurz et aL, 1995).
IL-10 is produced by a variety of inflammatory cells and was initially described as a 
cytokine synthesis inhibitory factor because of its ability to directly inhibit Thl 
cytokine production (Fiorentino et aL, 1989). This role makes IL-10 one of the key 
regulators of both local and systemic inflammatory/immune responses, and it has 
been shown to confer a protective effect in atherosclerosis. This is illustrated by the 
study of Mallat and co-workers, who demonstrated that IL-10-deficient mice fed an 
atherogenic diet had a threefold increase in lipid accumulation compared with their 
wild-type counterparts (Mallat et aL, 1999a). Furthermore, Namiki et al showed that 
intramuscular IL-10 gene transfer significantly reduced the atherosclerotic plaque 
area in such mice, with an associated decline in IL-12 and IFN-y mRNA expression 
in the spleens of the study group animals (Namiki et aL, 2004). IL-10 is found in 
advanced human atherosclerotic plaques where it has been associated with decreased 
apoptosis in the lipid central core, thereby reducing the likelihood of rupture (Mallat 
et aL, 1999b). Lower IL-10 levels coupled with higher proinflammatory cytokine 
levels were observed in patients with unstable angina who subsequently developed a 
cardiovascular event (Anguera et aL, 2002; Smith et aL, 2001), while higher IL-10 
levels have been associated with a favourable prognosis in patients with acute 
coronary syndromes (CAPTURE trial) (Heeschen et aL, 2003).
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Table 1.2 Cytokines and their functions in atherosclerosis
Cytokine Function Reference
TNF-a Proinflammatory, stimulate expression of 
selectins, adhesion molecules, tissue 
factor and production of matrix 
metalloproteinase (MMP)-l-9, 11 and 13.
(Barath et aL, 1990; Galis 
et aL, 1995; Taubman et 
aL, 1997; Young et aL, 
2002)
IL-1 a Proinflammatory, promote expression of (Hansson, 2001; Saren et
IL-lp adhesion molecule and MMP-9 a/., 1996)
IL-5 Antiinflammatory, stimulates production 
of protective antibodies
(Robertson and Hansson, 
2006)
IL-6 Proinflammatory, stimulate expression of 
chemokine and intercellular adhesion 
molecule (ICAM)-l
(von der Thusen et aL, 
2003)
IL-10 Antiinflammatory, inhibits inflammatory 
genes such as inducible nitric oxide 
synthase and cyclooxygenase 2 and the 
inflammatory T helper 1 (Thl) pathway
(Fiorentino et aL, 1989; 
Fiorentino et aL, 1991b)
IL-12 Proinflammatory, stimulates Thl 
differentiation and facilitates the release 
of IFN-y by Thl cells
(Lee et aL, 1999)
IFN-y Proinflammatory, promote expression of 
monocyte chemoattractant protein 
(MCP)-l, vascular cell adhesion 
molecule (VCAM)-l, ICAM-1
(Chung et aL, 2002; Li et 
aL, 1993b; Valente et aL, 
1998)
TGF-p Antiinflammatory, dampens T cell 
activation
(Robertson et aL, 2003)
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1.5 Heat shock proteins
Hsps comprise several families of proteins whose expression is increased when cells 
are exposed to stress such as heat stress. They are evolutionarily conserved, and are 
ubiquitous in nature, being expressed in all organisms and in different subcellular 
compartments (Lindquist and Craig, 1988).
The existence of Hsps was first discovered in 1962 by Ritossa and colleagues when 
they observed a characteristic pattern of ‘puffing’ on the chromosomes of Drosophila 
busckii when exposed to heat stress (Ritossa, 1962). This puffing effect was due to 
the upregulation and rapid synthesis of the multigene family of proteins which were 
later identified and named heat shock proteins (Tissieres et aL, 1974).
Heat shock is not the only stimulus that can induce and increase the synthesis of 
Hsps. Heavy metals, amino acid analogues, inflammation, oxidative and ischemic 
stress can also produce the same effect and hence these proteins are also called stress 
proteins. Although stress-inducible, low levels of Hsp expression occurs under 
normal physiological conditions (constitutive expression) constituting 5-10% of the 
total protein content in healthy growth conditions (Lindquist and Craig, 1988; Welch, 
1993).
The evolutionary conservation of Hsps and their induction upon stress suggest that 
they perform many vital functions in the cell. This has been found to be true 
especially in the process of protein biogenesis; hence they are also known as
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molecular chaperones. A molecular chaperone is a protein that mediates the correct 
assembly of other polypeptides, but is not part of the final structure (Hendrick and 
Haiti, 1993).
1.5.1 Nomenclature and classification of heat shock proteins
Since heat shock was the first discovered trigger of the response leading to enhanced 
transcription of their genes, the gene products have been called heat shock proteins. 
Following the Cold Spring Harbor Meeting of 1996, heat shock genes are designated 
as hsp genes, their related proteins are called Hsps and the family was designated 
HSP (Hightower and Hendershot, 1997). The majority of the genes and proteins have 
names that are associated with the molecular mass indication of the protein, e.g. 
Hsp70 and Hsp60. Some proteins that were originally discovered in a non-related 
domain have retained their names that do not correspond to the conventional 
nomenclature, e.g. the major structural ocular lens protein aB-crystallin. Other Hsps 
have names preceded by an indication of the compartment in which they reside, like 
mitochondrial (mt)-Hsp75.
Sometimes, a distinction is made between the proteins almost absent under 
nonstressed conditions, but synthesised immediately after cellular stress, called 
inducible proteins, and those that are constitutively synthesised in the tissue, called 
cognate proteins, e.g. Hsc70. This distinction is now recognised as arbitrary since in 
various cell types, low but measurable concentrations have been found of so-called 
inducible Hsps, while on the other hand the synthesis of some cognate proteins is 
also increased upon stress (Place et aL, 2004; Snoeckx et aL, 2001).
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The classification of various Hsps in families is based on their related function and 
size, the latter of which can vary from 10 to 170 kDa, the families being HSP 110, 
HSP100, HPS90, HSP70, HSP60, HPS40, HSP10 and the small HSP family. For 
example, in the HSP70 family the proteins range in weight between 70 and 78 kDa 
(Kiang and Tsokos, 1998). All HSP70 family members bind ATP (Milarski and 
Morimoto, 1989). Constitutive or cognate members are Hsc70, Hsp75, and Grp75, 
while the inducible member is Hsp72, commonly called Hsp70.
1.5.2 The heat shock response
In eukaryotic cells, the heat shock response involves transcriptional activation 
mediated by a transcription factor known as heat shock factor (HSF) (Morimoto, 
1993). Four different HSFs have been identified, HSF1-HSF4, with HSF1 being 
primarily involved in the stress response (Snoeckx et aL, 2001; Rabindran et aL, 
1991). In unstressed cells, HSF1 is present in both the cytoplasm and nucleus in a 
monomeric form that has no deoxyribonucleic acid (DNA) binding activity. In 
response to heat shock and other physiological stresses, HSF assembles into a trimer 
and accumulates within the nucleus. In the nucleus, HSF binds to the heat shock 
element (HSF), a specific DNA recognition sequence located in the 5'-flanking 
sequences of heat shock-responsive genes. The heat shock response is rapid and can 
be detected within minutes of temperature elevation (Perisic et aL, 1989; Sarge et aL, 
1993; Westwood et aL, 1991).
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1.5.3 Small heat shock proteins
Small Hsps (sHsps) are a diverse family of intracellular molecular chaperones that 
are found in all organisms (de Jong et al., 1993). sHsps are ubiquitous in terms of 
cellular localisation as well as the biological world. For example, they are located in 
cytoplasm, nucleus, chloroplast, mitochondria and endoplasmic reticulum in higher 
plant cells. Often, multiple members of the sHsp family are present in one cellular 
compartment. In humans, sHsps are found in many tissues at varying concentrations 
depending on the stage of development and the level of physiological stress, and 
from examination of the human genome, ten sHsps have been identified (Kappe et 
al., 2003).
The sHsps are distinguished by the presence of a conserved a-crystallin domain of 
approximately 90 amino acid residues located toward the carboxy terminus. The 
presence of these residues signifies membership within this group of molecular 
chaperones (Ingolia and Craig, 1982; Russnak et al., 1983), Fig.1.4. sHsps have a 
WDPF domain in their N-terminal part and a non conserved flexible domain 
constituting the C-terminal part of the proteins, Fig.1.4, which has been suggested to 
participate in the interaction with target proteins, to be involved in oligomerization, 
and to be important for solubility (Gusev et al., 2002; Lelj-Garolla and Mauk, 2005). 
The WDPF domain owes its name to the presence of the amino acid residues W 
(tryptophan), D (aspartic acid), P (proline) and F (phenylalanine).
sHsps are expressed constitutively and regulate processes as diverse as actin 
polymerisation and caspase protein inactivation. However, sHsp expression is also
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significantly increased during conditions of cellular stress that cause protein 
unfolding. In vitro experiments have shown that small Hsps bind proteins in non­
native conformations, thereby preventing protein aggregation (Jakob et al., 1993). 
sHsps bind a wide range of cellular substrates and are implicated in many different 
cellular functions and cellular defenses against many different stresses, such as high 
temperature and oxidative stresses (Nakamoto and Vigh, 2007). sHsps share the 
property to form globular oligomeric structures that are characterised, in mammalian 
cells, by molecular masses ranging from 50 to about 700-800 kDa. The dynamic 
organisation of sHsps oligomers appears to be a crucial factor which controls the 
activity of these proteins.
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Fig.1.4 Conserved domains in the small heat shock protein family members
The sequences of a few selected members o f the small heat shock protein family were 
aligned to illustrate the position of the WDPF motif and a-crystallin domain 
Adapted from Lambert et al, JB io l Chem 274: 9378-9385, 1999
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1.6 Heat shock protein 27 (Hsp27)
Mammalian Hsp27 (HspBl) belongs to the family of small Hsps. Hsp27 can be 
detected in most cells; some cells express undetectable or relatively low levels, while 
other cells express Hsp27 abundantly. In addition to being overexpressed in stress 
conditions, Hsp27 also has a tissue/cell specific expression in the absence of stress 
which can be detected in the healthy adults as well as during organism development 
(Ciocca ef o/., 1993).
Hsp27 can be phosphorylated and may therefore be under the control of several 
transduction pathways. This rapid phosphorylation modulates its activities in 
response to a wide variety of stimuli and occurs in the N-terminal part of the 
polypeptide, in the WDPF domain and close to the a-crystallin domain (Theriault et 
al., 2004). Hsp27 is phosphorylated at serines 15, 78 and 82 by mitogen-activated 
protein kinases associated protein (MAPKAP) kinases 2,3 which are themselves 
activated by phosphorylation by p38 mitogen-activated protein (MAP) kinase (Rouse 
et al., 1994; Stokoe et al., 1992). Hence, Hsp27 phosphorylation can be modulated 
by signals such as those mediated by growth factors, differentiating agents, tumor 
necrosis factor, oxidative stress or heat shock. When phosphorylation is induced in 
response to stress, increased phosphorylated Hsp27 is detectable several minutes 
after exposure to stress, followed by a subsequent increase in the expression levels of 
the protein within several hours (Landry et al., 1991).
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Hsp27 can oligom erise into large aggregates up to 800 kDa, but it can also form  
heterom eric structures w ith other small Hsp fam ily m em bers (e.g. H sp20), and 
com plexes w ith additional proteins such as p38 M A P kinase, M A PK A P kinase 2 and 
Akt. O ligom erization is regulated by phosphorylation w hich prom otes dissociation o f 
the large Hsp27 oligom ers to the sm aller ones and eventually to tetram ers and dim ers 
(Bukach et al., 2009; W elsh and G aestel, 1998; R ogalla et a l ,  1999), Fig.1.5.
Besides its m olecular chaperone function, other functions attributed to Hsp27 include 
providing increased resistance to cells against oxidative stress, control o f  F-actin  
cytoskeletal integrity and providing increased cellular resistance to apoptosis.
Hsp27(HspBl)
Phosphorylation decreases the size of the oligomers
Dimers 700-800 kDa100 kDa
Fig.1.5 Phosphorylation sites for human Hsp27 and its effects on structure
Hsp27 is phosphorylated at serine residues 15, 78 and 82 by MAPKAP kinases 2,3. 
Phosporylation leads to reduction in oligomer size leading to the formation of smaller 
oligomers and eventually to dimers.
P: phosphorylated serine residues. Adapted from Arrigo et a l , FEBS Lett (2007), 581(19), 
3665-3674
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1.6.1 Hsp27 as a molecular chaperone
Molecular chaperones are traditionally defined as a family of unrelated classes of 
proteins that mediate the correct assembly of other polypeptides, but are not 
themselves components of the final functional structure (Ellis and van der V, 1991; 
Hendrick and Hartl, 1993).
In vitro data have indicated that small Hsps can act as ATP-independent molecular 
chaperones by binding to partially unfolded proteins, preventing their aggregation 
(Jakob et a l, 1993). In contrast to the higher molecular weight Hsps such as Hsp70, 
sHsps such as Hsp27, do not refold denatured proteins, instead Hsp27 binds the non 
native proteins to prevent their aggregation and they may then be passed on to ATP- 
dependent chaperones such as Hsp70 and Hsp90 for subsequent refolding or 
degradation by the proteasome (Arrigo, 2007; McDonough and Patterson, 2003). The 
proteasome is a protein complex present in cells which function to degrade damaged 
proteins (Baumeister et al., 1998).
Conflicting data exist regarding which form of Hsp27 performs the chaperone 
activity. Some studies suggested that the unphosphorylated high molecular weight 
oligomeric structures act as tanks to store misfolded polypeptides (Arrigo et al., 
2007; Lelj-Garolla and Mauk, 2006; Rogalla et al., 1999). While recently, it was 
suggested that the small Hsp27 oligomers (as small as dimers) appear to be the 
active, substrate-binding species (Hayes et al., 2009).
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1.6.2 Hsp27 in cells exposed to oxidative stress
Hsp27 is also able to modulate the ability of cells to respond to oxidative stress 
(Arrigo, 2001). In cells exposed to oxidative stress, expression of Hsp27 leads to an 
upregulated level of total glutathione and a significantly decreased basal level of 
intracellular reactive oxygen species (ROS) (Baek et al., 2000; Mehlen et al., 1996a; 
Paul and Arrigo, 2000; Preville et al., 1999). Expression of Hsp27 also enhances the 
activity of several key enzymes that regulate intracellular redox state such as 
glucose-6-phosphate dehydrogenase (G6PDH), glutathione reductase and glutathione 
transferase (Preville et al., 1999). G6PDH reduces nicotinamide adenine dinucleotide 
phosphate (NADP+) to NADPH(H)+ , thus cells expressing high levels of G6PDH 
display an increased level of reduced glutathione (GSH) and show resistance to 
oxidative stress. The protective activity of Hsp in response to oxidative stress due to 
TNF-a or H2O2 correlates with the formation of large oligomers of Hsp27, followed 
by the phosphorylation-dependent dissociation of Hsp27 into small oligomers 
(Mehlen et al., 1995; Mehlen et al., 1997a; Preville et al., 1999). The transient 
accumulation of Hsp27 in the form of large oligomers is hypothesised to activate the 
presentation of irreversibly oxidized proteins to the ubiquitin-independent 20S 
proteasome. The small oligomeric forms on the other hand may either inactivate 
Hsp27 chaperone activity or induce its recycling through the dynamic deaggregation- 
oligomerization of the protein (Arrigo et al., 2005).
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1.6.2.1 Oxidative Stress
An imbalance between oxidants and antioxidants in favour of the oxidants, 
potentially leading to damage, is termed 'oxidative stress' (Sies, 1997). Oxidants are 
formed as a normal product of aerobic metabolism but can be produced at elevated 
rates under pathophysiological conditions. Examples of oxidants include free 
radicals, which are any species capable of independent existence that contains one or 
more unpaired electrons (Stocker and Keaney, Jr., 2004). Examples of free radicals 
include reactive oxygen species (ROS) such as oxygen ions, superoxide anions and 
peroxides. An antioxidant is defined as a substance being effective against oxidative 
damage when present in a much smaller quantity than the substance that it protects 
against (Stocker and Keaney, Jr., 2004). The antioxidant defenses comprise several 
mechanisms, both enzymatic and non-enzymatic. Antioxidant enzymes include 
superoxide dismutase, catalase and glutathione peroxidases. Non-enzymatic 
antioxidants include tocopherols, carotenes, ascorbate and glutathione.
1.6.3 Hsp27 and inhibition of apoptosis
Cells exposed to mild stress may either repair the damage caused or commit to 
suicide through an apoptotic process. The execution phase of apoptosis occurs 
through the proteolytic activation of specific proteases called caspases (Nicholson 
and Thornberry, 1997; Thornberry and Lazebnik, 1998). Several pathways lead to 
the activation of caspases, such as those triggered by death receptors and those that
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depend on the mitochondria-apoptosome machinery (Green and Reed, 1998; Reed, 
1997; Scaffidi et al., 1998).
Hsp27 can counteract apoptosis induced by staurosporine, actinomycin D, 
camptothecin, Fas/APO-1 receptor, cisplatin, the topoisomerase II inhibitor 
etoposide, and doxorubicin (Garrido et al., 1997; Garrido et al., 1999; Hansen et al., 
1999; Mehlen et al., 1996b).
Hsp27 is also a negative regulator of TNF-a and Fas ligand-mediated cell death 
(Arrigo, 1998; Mehlen et al., 1996b). Only the phosphorylated dimeric form of 
Hsp27 has been shown to interact with DAXX, a mediator of Fas-induced apoptosis, 
preventing the interaction of DAXX with both Fas and apoptotic signaling kinase 1 
(Askl) and therefore blocking DAXX-mediated apoptosis (Charette et al., 2000). In 
the case of ROS-dependent necrotic cell death generated by TNF-a, the formation of 
the large unphosphorylated oligomers of Hsp27 which bear chaperone activity is 
observed.
Previous research also found that Hsp27 is a negative regulator of several different 
pathways that converge to the mitochondria and trigger the release in the cytosol of 
apoptogenic factors such as cytochrome c and Smac/Diablo (Chauhan et al., 2003; 
Paul et al., 2002). Hsp27 also acts downstream of mitochondria. For example, it was 
shown to interact with cytochrome c once this apoptogenic polypeptide is released 
from mitochondria. Once bound to Hsp27, cytochrome c loses its ability to trigger 
apoptosome formation (Bruey et al., 2000; Garrido et al., 1999). Hsp27 has also been 
reported to bind pro-caspase 3 and to interfere with its activation; however, the
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structural organization of Hsp27 responsible of this event is not known (Pandey et 
al., 2000).
Hsp27 is transiently expressed during the early differentiation of several cell types 
(Arrigo, 1995). Inhibition of Hsp27 accumulation results in differentiation failure, a 
phenomenon often accompanied by induction of massive apoptosis (Chaufour et al., 
1996; Mehlen et al., 1997b; Mehlen et a l, 1999). This activity correlates with the 
formation of large Hsp27 oligomers which may function to reduce the accumulation 
of junk protein structures that trigger aberrant differentiation processes and 
apoptosis.
1.6.4 Hsp27 and modulation of actin dynamics
Stress such as heat shock or oxidative have the ability to cause collapse of the F-actin 
cytoskeleton. In this situation, the survival rate of cells over-expressing Hsp27 is 
enhanced by the stronger stability of the actin microfilaments and their accelerated 
recovery after disruption (Huot et al., 1996; Lavoie et al., 1993a; Lavoie et al., 
1993b; Lavoie et al., 1995). Actin cytoskeleton protection by Hsp27 is also observed 
when cells are exposed to mitogens, cytochalasin D, carcinogenic, or anticancer 
drugs (Arrigo, 2000; Mounier and Arrigo, 2002).
Inhibition of actin polymerisation in vitro appears to require nonphosphorylated 
monomers (Schneider et al., 1998; Benndorf et al., 1994), whereas actin cytoskeleton 
dynamics and protection seem to require phosphorylatable oligomers of Hsp27 
(Lavoie et al., 1995). In response to stress there is a transient formation of larger
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Hsp27 oligomers and the phosphorylation of Hsp27; the latter event then triggers the 
subsequent disruption of the aggregates and the accumulation of small oligomers. It 
is proposed that the small oligomers would coat the microfilaments, protect them 
against further disruption by preventing or neutralising the action of actin-severing 
proteins activated by the stress response, and then participate in promoting their 
subsequent recovery (Lavoie et a l, 1995; Mounier and Arrigo, 2002). 
Nonphosphorylated monomeric sHsps might cap the plus end of the actin filament 
and exert the capping activity when performing its protective role (Mounier and 
Arrigo, 2002; Pichon et al., 2004).
1.7 Hsp27 and inflammation
Available data with regards to the role Hsp27 might play in inflammation shows 
conflicting results. Intracellular Hsp27 has been found to enhance LPS-induced 
inflammatory responses in THP-1 cells and is required for pro-inflammatory gene 
expression in HeLa cells and human fibroblasts (Alford et al., 2007; Liu et al., 2010). 
Also, mice that overexpressed human Hsp27 had increased renal expression of 
mRNAs for the pro-inflammatory mediators TNF-a, ICAM-1 and MCP-1, following 
renal ischemia reperfusion injury (Chen et al., 2009). These findings point towards a 
proinflammatory role of Hsp27. However, downregulation of Hsp27 increased the 
release of the pro-inflammatory cytokine IL-18 in kératinocytes (Sur et al., 2008). 
Furthermore, in the heart, Hsp27 expression supressess angiotensin Il-induced 
activation of the pro-inflammatory transcription factors SP-1 and AP-1 and
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stimulates DNA binding activities for the anti-inflammatory cytokine transcriptional 
repressor OCT-1 (Chen and Currie, 2005).
Extracellular Hsp27 has been found to cause decreased acetylated LDL-induced 
release of the proinflammatory cytokine IL-1(3 and increased the acetylated LDL- 
induced release of the antiinflammatory cytokine IL-10 in murine macrophages 
(Rayner et al., 2008). Hsp27 can also induce high levels of IL-10 and prostaglandin 
E2 (PGE2); an immunosuppressive substance, in human monocytes (Banerjee et al., 
2011). However, in the same study Hsp27 was also found to induce release of 
proinflammatory mediators IL-lp, TNF-a and MCP-1. Furthermore, exogenous 
Hsp27 has also been shown to stimulate dendritic cells to produce the inflammatory 
cytokines II-Ip, IL-6, IL-12 and TNF-a (Yusuf et al., 2009). This suggests a complex 
and sometimes antagonistic role for Hsp27 in inflammatory processes.
1.8 Hsp27 and atherogenesis
Little has been published on Hsp27 in relation to atherosclerosis, nevertheless a 
review of the available literature is provided herein and a table summarising the main 
findings is provided in Table 1.3.
In the first reported study on Hsp27 and atherosclerosis, it was found that secretion 
of Hsp27 was decreased in atherosclerotic plaques compared with control arteries 
and that the plasma Hsp27 concentration of patients with carotid stenosis was also
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decreased compared to healthy controls (Martin-Ventura et al., 2004). In another 
study, it was reported that Hsp27 expression decreases as the stage of coronary 
atherosclerosis progresses (Miller et al., 2005). It was also reported that intracellular 
Hsp27 provided protection against plasmin-induced anoikis in human vascular 
smooth muscle cells and was inversely localised with apoptotic cells within culprit 
atherosclerotic carotid plaques (Martin-Ventura et al., 2006). Park et al. compared 
Hsp27 expression in carotid plaque core areas, normal-appearing areas from the 
same vessel specimens and nonatherosclerotic renal and internal mammary reference 
arteries. They found that Hsp27 expression is increased in the normal-appearing 
vessel adjacent to the atherosclerotic plaque compared to both the plaque core area 
and the reference arteries. Also, they reported that phosphorylated Hsp27 expression 
was decreased in diseased arteries compared to reference specimens (Park et al., 
2006). Meanwhile, in human coronary artery specimens, it was found that there was 
decreased abundance of phosphorylated Hsp27 in specimens from patients with 
ischaemic heart disease (IHD) compared to specimens from controls without 
evidence of CAD (Robinson et al., 2010).
From animal studies, it was found that apoE KO-mice overexpressing Hsp27 had a 
35% reduction in atherosclerotic lesion area compared to control apoE KO-mice 
(Rayner et al., 2008). This effect was observed primarily in female mice and was 
suggested to be due to estrogen induced release of Hsp27 and subsequent inhibition 
by Hsp27 of cholesterol uptake by macrophages observed in that study.
From population studies, it was reported that plasma Hsp27 concentrations were 
significantly higher in acute coronary syndrome patients compared with normal
63
reference subjects (Park et al., 2006). This was in contrast to that found in patients 
with carotid stenosis who had decreased plasma Hsp27 compared to healthy controls 
(Martin-Ventura et al., 2004). The different results obtained between the 2 studies 
could be due to the different patient groups used, patients with carotid stenosis in 
Martin-Ventura’s group and patients with ACS in Park’s group. Hsp27 has been 
found to be increased in cardiomyocytes exposed to hypoxia (Efthymiou et al., 2004) 
which might account for the higher level found in patients with ACS, while the lower 
secretion of Hsp27 found in the arterial specimens from patients with carotid stenosis 
correlate with the result of lower serum Hsp27 in these patients. In the study by Park 
et al, it was found that plasma concentration of Hsp27 was significantly correlated 
with serum concentration of total cholesterol, and was not correlated with age, sex, 
smoking, diabetes, and hypertension. However in a prospective nested case-control 
study of 255 initially healthy individuals who later developed CVD and matched 
controls it was found that Hsp27 plasma concentrations were inversely associated 
with age but not with other established cardiovascular risk factors and that baseline 
plasma Hsp27 concentration was not associated with incident cardiovascular events 
(Kardys et al., 2008). The association of age with Hsp27 may only affect women 
since the study by Kardys et al was done on women only and the result may be 
affected by oestrogen which has been found to influence Hsp27 levels (Rayner et al., 
2008), which is maybe why the association with age has so far not been observed in 
mixed gender studies.
With regard to Hsp27 antibodies, it has been reported that Hsp27 IgG antibodies are 
significantly higher in patients with acute coronary syndromes, stroke and coronary 
artery disease than in control subjects (Azarpazhooh et al., 2010; Ghayour-Mobarhan
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et al., 2008; Shams et al., 2008). This was similar to that found for other candidate 
antigens in atherosclerosis, Hsp60 and oxLDL, where higher serum antibody levels 
were found in patients with CAD compared to controls (Prohaszka et al., 2001; 
Tsimikas et al., 2003).
In summary, mixed outcomes have been found with regard to studies on the 
relationship between Hsp27 and its antibodies in atherosclerosis which might be due 
to the use of different source of tissue specimens or patients with different clinical 
history (CAD or carotid stenosis). Further studies are therefore needed to investigate 
the potential role of Hsp27 in atherosclerosis.
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Table 1.3 Studies investigating Hsp27, its antibodies and atherosclerosis
Study group/tissue used Outcome Reference
Patients with carotid 
stenosis
Healthy volunteers
n=28
n=12
Plasma levels o f Hsp27 are decreased 
in patients compared to healthy subjects
(Martin-Ventura 
et al., 2004)
Carotid
endarterectomy
specimens
Hsp27 was expressed in normal and 
carotid plaques primarily by smooth 
muscle cells
Carotid
endarterectomy
specimens
Hsp27 was mainly present in the cap 
and media o f atherosclerotic plaques
(Martin-Ventura 
et al., 2006)
Coronary artery 
specimens
Expression o f Hsp27 diminishes as the 
stage o f coronary atherosclerosis 
progresses
(Miller et al., 
2005)
Patients with ACS 
Healthy Subjects
n=27
n=29
Plasma levels o f Hsp27 are increased in 
patients compared to controls
(Park et a l ,  
2006)
Carotid
endarterectomy
specimens
Expression of Hsp27 was increased in 
atherosclerotic arteries compared to 
reference arteries
Healthy female 
subjects
n=255 Baseline Hsp27 plasma concentration 
was not associated with incident 
cardiovascular events
(Kardys et a l,  
2008)
ApoE KO mice 
overexpressing 
Hsp27
Significant reduction in atherosclerotic 
lesion area compared to control ApoE 
KO-mice
(Rayner et al., 
2008)
Patients with ACS 
Controls
n=94
n=81
Anti-Hsp27 IgG elevated in patients 
with ACS
(Ghayour- 
Mobarhan et al., 
2008)
Patients with ACS 
Controls
n=63
n=63
Anti-Hsp27 IgG higher in patients (Shams et al., 
2008)
Patients with stroke 
Controls
n=168
n=80
Anti-Hsp27 IgG higher in patients (Azarpazhooh et 
al., 2010)
Patients with CAD 
Controls
n=300
n=83
Anti-Hsp27 IgG higher in patients (Pourghadamyari 
et al., 2010)
Coronary artery 
specimens
Phosphorylated Hsp27 was decreased 
in specimens from patients with IHD
(Robinson et al., 
2010)
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1.9 Hypothesis
It is hypothesised that Hsp27 expression is induced in the arterial endothelial cells in 
conditions that promote atherosclerosis and once released from the endothelial cells, 
Hsp27 antigen elicits an autoimmune response which involves both the adaptive and 
innate immune systems.
1.10 Aims and Objectives
The overall aim of this research is to investigate the effect of Hsp27 on both the 
adaptive and innate immune response and its relationship to atherogenesis.
The specific aims of this thesis are as follows:
• To optimise assays for the detection of Hsp27 and anti-Hsp27 IgG and IgM 
antibodies in serum.
• To investigate changes in plasma IgM and IgG autoantibodies to Hsp27 
following an acute coronary ischaemia.
• To investigate the IgG and IgM autoantibody response to long term exposure 
to Hsp27 in patients with established cardiovascular disease
• To assess the relationship between circulating Hsp27, anti-Hsp27 IgG and 
IgM antibodies with markers of inflammation in patients with established 
cardiovascular disease.
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• To assess the relationship between circulating Hsp27, anti-Hsp27 IgG and 
IgM antibodies with markers of inflammation in active and inactive 
adolescent girls.
• To investigate whether a macrophage cell line recognizes and responds to 
Hsp27 by affecting the production of mediators of inflammation.
Chapter 2 
Materials and Methods
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2.0 Materials and Methods
2.1 Consumables
2.1.1 ELISA
For the enzyme-linked immunosorbent assays (ELISAs), Tween-20, goat serum, 
bovine serum albumin and carbonate buffer tablets were purchased from Sigma- 
Aldrich, Poole, UK, whilst phosphate buffered saline tablets were purchased from 
Oxoid Ltd, Hampshire, UK. The 96-well Maxisorp microtitre plates used were 
purchased from Nunc, Fisher Scientific, Loughborough, UK, and the 
tetramethylbenzidine (TMB) substrate reagent pack was from R&D systems, 
Abingdon, UK.
2.1.2 Western blot
For the Western blotting procedure, the polyvinylidene fluoride (PVDF) membrane, 
0.45 pm pore size, was purchased from Millipore, Watford, UK. NuPAGE® LDS 
sample buffer (NP0007), NuPAGE® Novex® 12% Bis-Tris precast gels (NP0341), 
MagicMark™ XP Western Protein Standard 20-220 kDa (LC5602), NuPAGE® 
MOPS SDS running buffer (NP0001), NuPAGE® transfer buffer (NP0006) and the 
WesternBreeze® Chemiluminescent Kit Anti-mouse (WB7104) were purchased 
from Invitrogen Ltd, Paisley, UK.
The WesternBreeze® kit contained the following;
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Blocker/diluent A: Buffered saline containing detergent 
Blocker/diluent B: Concentrated Hammerstein casein solution 
Secondary antibody solution: Alkaline phosphatase-conjugated, affinity purified, 
anti-mouse IgG
Wash solution: Buffered saline containing detergent
Chemiluminescent substrate: CDP-Star® substrate for alkaline phosphatase
2.1.3 Antibodies and recombinant protein
Hsp27 recombinant protein (SPP-715), mouse anti-human Hsp27 monoclonal 
antibody (G3.1, SPA-800) and rabbit anti-human Hsp27 polyclonal antibody (SPA- 
803) were purchased from Cambridge Bioscience, Cambridge, UK. Goat anti-rabbit 
horseradish peroxidase (HRP)-conjugated antibody (A0545), goat anti-human IgM 
HRP-conjugated antibody (A6907) and goat anti-human IgG HRP-conjugated 
antibody (A6029) were purchased from Sigma-Aldrich, Poole, UK.
2.1.4 Buffers
Please refer to Appendix 1 for list of buffers used in the assays.
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2.2 Western Blotting method for the detection of Hsp27 in serum samples
Western blotting was initially used to detect the presence of Hsp27 in serum samples 
using the monoclonal Hsp27 antibody that would be used for the Hsp27 sandwich 
ELISA. Western blotting is an analytical technique used to detect specific proteins in 
a given sample. The technique uses gel electrophoresis to separate native or 
denatured proteins based on the length of the polypeptide (denaturing conditions) or 
by the 3-D structure of the protein (native/ non-denaturing conditions) (Berg et al., 
2002). Separated proteins are then transferred to a membrane (typically nitrocellulose 
or PVDF), where they are probed using antibodies specific to the target protein 
(Renart et al., 1979; Towbin et al., 1979).
2.2.1 Gel electrophoresis
Sixteen pi of each serum sample (diluted 1:10 in PBS) was mixed with 2.5 pi of 
sample buffer and 1.6 pi of reducing agent (mercaptoethanol). The total mixture was 
then heated at 100 °C for 5 minutes to denature the protein. Samples were then left to 
cool before loading into the gel. Neutral, 12% pre-cast polyacrylamide mini-gels 
were used for electrophoresis. The gel tank was assembled and filled with 
electrophoresis running buffer. Ten pi of each sample and 2.5 pi of protein ladder 
(molecular weight protein standard) were loaded into individual wells. 
Electrophoresis was then performed at a constant voltage of 200V for approximately 
1 hour, or until sufficient ladder band separation was achieved.
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2.2.2 Transfer of proteins from gel to membrane
Follow ing electrophoresis, 4 sponges, 2 W hatm ann filter papers, and one 0.45 pm  
PVDF m em brane, cut to the sam e dim ensions as the gel, were soaked in transfer 
buffer. The PVDF m em brane w as activated by placing in 95%  ethanol for 30 
seconds before soaking in transfer buffer. On the cathode core plate, a sandw ich o f 
sponge/ filter paper/ gel/ PVDF m em brane/ filter paper/ sponge w as constructed, and 
placed into the transfer tank filled w ith transfer buffer, Fig.2.1. T ransfer was 
achieved by electro-blotting for 2 hours at 30V.
Anode (+)
< -.............
Filter Paper
PVDF Membrane
Gel
Cathode (-)
Fig.2.1. Schematic diagram of the arrangement of sponge/filter paper/gel/PVDF 
membrane/filter paper/sponge for the western blot procedure.
For gel transfer o f  separated proteins onto a m em brane, the sponge, filter paper, 
m em brane and gel were placed on the cathode core o f the blot m odule and arranged 
as above.
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2.2.3 Membrane Blocking and Detection of Hsp27
For this stage, the WesternBreeze® Chemiluminescent Kit Anti-mouse was used 
following manufacturers instructions.
The transfer membrane was washed in distilled water and placed in 10 ml blocking 
solution for at least 30 minutes at room temperature. The PVDF membrane was then 
washed by soaking in distilled water and incubated with mouse monoclonal Hsp27 
antibody G3.1 (1 pg/ml) for 1 hour. After washing as above, secondary anti-mouse 
antibody (anti-species IgG) conjugated with alkaline phosphatase was then added 
and incubated with the membrane for 1 hour. Chemiluminescent substrate was added 
to the top (protein) side of the washed membrane and incubated at room temperature 
for about 5 minutes. Protein bands were visualized by covering the membrane with a 
transparent clean plastic sheet and exposing to X-ray film luminography ( 5 - 1 5  
minutes).
2.3 Enzyme-linked immunosorbent assays (ELISAs)
2.3.1 The principle of the ELISA
The ELISA technique is based on the principle of an immunoassay with an enzyme 
that is conjugated to an antibody as the detection method. Briefly, an antigen or 
antibody is passively adsorbed to a solid phase such as plastic. This makes the
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separation o f  bound and free com ponents in a m ixture possible by using w ashing 
procedures. The end result is colour form ation as the end point o f  a reaction 
catalysed by the conjugated enzym e to produce a coloured product from  a colourless 
substrate (e.g.TM B). The m ain steps involved in an ELISA are outlined in Fig.2.2.
Coat 96 -w e ll  p late with  
an tigen /an t ib od y (1)
Block with blocking buffer (2)
Add in serum (3)
f t
Add in en zym e-label led  
antibody (4)
f t
Add in TMB substrate (5)
f t
Stop the reaction with HCI (6)
Read ab sorb ance  o f  p late at  
4 5 0  nm (7)
Fig.2.2 Flow diagram representing the basic steps in the ELISA.
The basic steps in an ELISA are outlined as above. For ELISAs used in the project, 
TM B was the substrate used throughout and absorbance o f  the plate was read at 450 
nm.
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Two types of ELISA were used in this project; the sandwich ELISA and the indirect 
ELISA. A sandwich ELISA is a technique that measures the amount of antigen 
trapped between two layers of antibodies (i.e. capture and detection antibody). The 
antigen to be measured must contain at least two antigenic sites capable of binding to 
the antibody. The Hsp27 ELISA used in this thesis is based on this technique and is 
outlined in Fig.2.3(a). The sandwich ELISA using two antibodies that recognize the 
antigen of interest offers the advantage over other immunoassays that use one 
monoclonal antibody of eliminating interference that can occur with blood 
constituents that recognize constituents of the immunoassay, such as the Fc portion 
of antibodies (Vaisanen et al., 2006). Hsp27 can exist in different oligomeric forms 
and the monoclonal antibody used in this study were shown to detect different forms 
of Hsp27 (Park et al., 2006). In the indirect ELISA, the antiserum against the antigen 
is not labelled with an enzyme; instead, a second antibody specific for the particular 
species in which the first antibody was produced is labelled. The anti-Hsp27 IgM and 
IgG antibody ELISAs used are based on this technique which is shown 
diagramatically Fig.2.3(b). The presence of rheumatoid factors may compromise 
results found for the anti-Hsp27 IgM assays, however rheumatoid factors are 
normally associated with chronic conditions such as rheumatoid arthritis and 
systemic lupus erythematosus which were not present for the participants selected for 
the study. The presence of rheumatoid factors can cause high false positive results 
which can be countered by excluding outliers from any statistical analysis.
For quantitation, absorbance was read at 450 nm, which is the maximal wavelength 
of absorbance for the acidified TMB substrate. All results were expressed as Specific 
Binding (SB) for which
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SB= TB-NSB
Where TB is the Total Binding (coated wells) and NSB is the Non-Specific Binding 
(uncoated wells). All assays were done in duplicate and coefficients of variation 
(CVs) for duplicates determined. Samples which gave CVs above 10% were 
repeated.
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(a) (b)
Substrate
Labelled anti-rabbit 
antibody
Rabbit anti-human Hsp27 
polyclonal antibody
Hsp27 in serum sample —
Mouse monoclonal anti­
bum an Hsp27 antibody
Substrate
Labelled anti-bum an 
IgM/IgG antibody —
Anti-lgM/lg6Hsp27 
in serum sample”
Recombinant Hsp27.
Fig.2.3 A schematic diagrams of the (a) Hsp27 sandwich ELISA and (b) the anti- Hsp27 
IgG and anti-Hsp27 IgM indirect ELISA.
For detection o f  Hsp27, the m onoclonal Hsp27 antibody (G 3.1) w as used as capture 
antibody and a rabbit anti-hum an polyclonal antibody as detection antibody. An 
H R P-conjugated anti-rabbit antibody was then used to detect the latter antibody.
For detection o f  anti-H sp27 IgG and IgM antibodies, recom binant Hsp27 was coated 
onto the plate. Serum  sam ples were then added and any antibody present will 
recognise and bind to the coated protein. The antibodies are detected using an H RP- 
conjugated anti-IgG  or IgM antibody.
Reactions were developed using TM B substrate and stopped by the addition o f HC1.
78
2.3.2 ELISA for the determination of Hsp27, anti-Hsp27 IgG and anti-Hsp27 
IgM
2.3.2.1 Hsp27 ELISA
Coating of the plate with Hsp27 monoclonal antibody
A 96-well microtitre plate was coated with 100 pi of monoclonal Hsp27 antibody 
(2.5pg/ml in PBS). The plate was then incubated overnight at 4°C.
Blocking of the plate
After an overnight incubation, the plate was washed 3 times with washing buffer 
(PBS containing 0.05% Tween-20) and then blocked with blocking buffer (4% goat 
serum in PBS) for 1.5 hours.
Detection of Hsp27
After washing the plate 3 times, 50 pi of standards (0.94, 1,875, 3.75, 7.5 and 15 
ng/ml of recombinant Hsp27) and samples diluted 1:3 in blocking buffer were added 
into duplicate wells. Plates were then incubated for 30 minutes at room temperature, 
washed and 50 pi of rabbit anti-human Hsp27 polyclonal antibody (1:6000) was 
added. After a 30 minute incubation period and 3 cycles of washing, 50 pi of goat 
anti-rabbit horseradish peroxidase (HRP)-conjugated antibody (1:6000) was added 
and incubated for a further 30 minutes. After a final wash of 4 cycles, 50 pi of the
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TMB substrate solution was added. The reaction was stopped after 20 minutes by the 
addition of 50 pi of 2M HC1 and the absorbance read at 450 nm using a microplate 
reader (Multilabel Counter VICTOR model 1420 from PerkinElmer, UK).
Each sample was assayed in duplicates and with corresponding uncoated wells to 
estimate the extent of non-specific binding. All duplicates are checked for their 
coefficient of variations (CVs) and any samples with CVs above 10% will be 
repeated. Results are reported as absorbance units in SB = TB (coated wells) - NSB 
(uncoated wells).
2 3 .2.2 Anti-Hsp27 IgG and anti-Hsp27 IgM indirect ELISA
A 96 well microtitre plate was coated with 50 pl/well of recombinant Hsp27 (6 
pg/ml, in carbonate coating buffer pH 9.6) and incubated overnight at 4°C. After 
overnight incubation the plate was then washed 3 times and 200 pi of blocking buffer 
(3% BSA in PBS) was added. The plate was then incubated at 37°C for 1.5 hours at 
room temperature.
The plate was washed again 3 times and 50 pi of serum samples (1:100) was added 
and the plate incubated for 30 minutes. After 3 wash cycles, 50 pi of anti-human IgG 
or anti-human IgM (1:2000) was then added for the determination of IgG and IgM 
respectively. Incubation was performed for 1 hour. After a final wash of 4 cycles, 50 
pi of TMB substrate solution was then added and the plate incubated for a further 15 
minutes. The reaction was stopped with 50 pi of 2M HC1 and the absorbance of the
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plate was read at 450 nm. Each sample was assayed in duplicates and with 
corresponding uncoated wells to estimate for non-specific binding. Results are 
reported as absorbance units in SB as described in section 2.4.1.
2.5 Statistical analysis
Uni- and bivariate statistical analysis was undertaken using Graphpad Prism version
5.0 for Windows (Graphpad Software Inc, USA), while multivariate analysis was 
performed using SPSS software version 16 (SPSS Inc, Chicago, Illinois, USA). 
Comparison between groups for skewed data was performed using the Mann- 
Whitney test and data reported as median and inter-quartile range about the median. 
Comparison between groups for normally distributed data was achieved using the t- 
test and data reported as mean with standard deviation. Fisher’s exact and Chi-square 
tests were used to compare categorical variables. Spearman’s rank and Pearson’s 
correlation analysis was used to investigate the relationship between variables and 
stepwise multiple linear regression analysis used to investigate the influence of 
variables on Hsp27 concentration. Results were considered significant with p<0.05. 
The statistical tests used in each experiment are indicated in the figure legends 
provided.
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Chapter 3
Changes in serum Hsp27 antigen and anti-Hsp27 IgM antibody 
levels following an acute coronary event
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3.0 Changes in serum anti-Hsp27 IgM antibody levels following an 
acute coronary event
3.1 Introduction
Heat shock protein (Hsp) 27 belongs to the small heat shock protein family of Hsps. 
Over-expression of Hsp27 has been shown to provide cellular protection against a 
variety of stressful situations in vitro. This protection is achieved due to its ability to 
act as an ATP-independent molecular chaperone (Bryantsev et al., 2007), and to 
provide cellular reducing power in the form of NADPH, thus conferring increased 
resistance to oxidative stress (Preville et aL, 1999). Furthermore, Hsp27 modulates 
F-actin filament dynamics (Mounier and Arrigo, 2002) and has also been shown to 
inhibit apoptosis (Arrigo, 2000). In adults, Hsp27 is expressed at high levels in 
several tissues including the heart (Ciocca et ah, 1993) where it is located within 
cardiomyocytes, and in endothelial and vascular smooth muscle cells of the coronary 
circulation (Lutsch et ah, 1997).
In vitro studies show that hypoxia induces an increased expression of Hsp27 in 
cardiomyocytes (Efthymiou et al., 2004; Martin et al., 1997), and that this is 
associated with protection of the myocardium from ischaemic injury, although the 
exact mechanism of this protection is still unclear. Increased plasma levels of Hsp27 
have been reported in patients with acute coronary syndrome (ACS) (Park et aL, 
2006) which suggests that Hsp27 is released from the myocardium in conditions of 
ischaemia. Autoantibodies to Hsp27 have also been found in patients with ACS
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which indicates that once outside the cell, Hsp27 is able to stimulate an autoimmune 
response by the body. Autoantibodies to other Hsps such as Hsp60 and Hsp70 have 
also been found in the circulation (Xu, 2002). One of the reasons for the autoimmune 
response against Hsps has been suggested to be due to the high degree of 
phylogenetic conservation which leads to molecular mimicry by infecting 
microorganisms.
Molecular mimicry is defined as the sharing of antigens between microbe and host 
with dual recognition of these antigens by the host immune system (Ang et aL, 
2004). Molecular mimicry may occur when there is sharing of identical amino 
acid sequences and homologous but non-identical amino acid sequences (Fujinami 
and Oldstone, 1985). Small heat shock proteins share a homologous and highly 
conserved amino acid sequence of 80 -  100 residues at the C terminus called the a- 
crystallin domain. This domain exhibits between 20 and 80% homology among the 
family members (Van Montfort et al., 2001).
Humans can express five different antibody isotypes, immunoglobulin (Ig) G, IgM, 
IgA, IgD and IgE (Spiegelberg, 1974; Tonegawa, 1985; Wang et al., 2007). The IgG 
antibodies can be further subdivided into the IgGl, IgG2, IgG3 and IgG4 subclasses. 
The two main antibody isotypes in serum are the IgG antibodies which constitute 
about 80% and IgM which constitutes about 8% of the antibodies in serum. The basic 
structure of each immunoglobulin molecule is a unit consisting of two light 
polypeptide chains and two heavy polypeptide chains. The type of heavy chain 
determines the isotype and subclass of the antibody. The IgG antibody consists of a 
monomeric four-chain molecule of mass 146-170 kDa while the IgM is a pentamer
of the basic four-chain structure with a mass of approximately 970 kDa. 
Physiologically, recognition of antigens by their respective antibodies leads to 
clearance of these antigens. Clearance is achieved via the formation of immune 
complexes (ICs) between antigen and antibody molecules and activation of the 
classical pathway of complement. The resulting complement byproducts are then 
transported to the liver, via complement receptors on cells such as red blood cells, for 
processing. Clearance of antigens by this pathway can be mediated via the IgG 
(IgGl, IgG2 and IgG3) and IgM antibodies (Lucisano Valim and Lachmann, 1991; 
Whaley and Ahmed, 1989).
To date, no studies have examined the relationship between Hsp27 antigen and its 
antibody levels. In cardiovascular disease (CVD) the studies have focused on either 
the protein or the Hsp27 IgG antibodies (please refer to Table 1.3). So far, none of 
the studies on Hsps have looked at the IgM antibodies despite the fact that IgM 
antibodies against oxLDL have been suggested to be playing a protective role in 
atherogenesis (Binder et aL, 2003). The hypothesis is that IgM performs this 
protective role by clearing antigens from the circulation via the formation of immune 
complexes. The aim of this current study was to optimise assays to detect Hsp27, 
anti-Hsp27 IgG and IgM antibodies and to use them to investigate both the IgG and 
IgM immune responses to what is likely to be an acute release of Hsp27 from the 
myocardium into the circulation in patients following an acute myocardial infarction 
(AMI).
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3.2 Subjects
A total of seventy four subjects were involved in this study. The patient group 
consisted of 37 individuals who were enrolled from the Accident and Emergency 
department of the Royal Surrey County Hospital, Guildford, UK, between June 2005 
and July 2006, with a diagnosis of an AMI according to established guidelines; 
having ischaemic symptoms on admission, changes in ECG indicative of an MI and a 
positive troponin I test result (Alpert et a l, 2000). The control group consisted of 37 
healthy volunteers without overt disease, recruited from among employees at the 
University of Surrey and the Royal Surrey County Hospital.
The research protocol was reviewed and approved by the South-West Surrey 
Research Committee (EC35/02) and the University of Surrey Advisory Committee 
on Ethics (AEC/2002/26/SBLS).
Common exclusion criteria for control subjects were:
a. Prior history of cardiovascular disease.
b. Having any pre-existing medical condition requiring medication.
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3.3 Material and Methods
3.3.1 Materials
Consumables, reagents and antibodies for the Hsp27, anti-Hsp27 IgG and Hsp27 
IgM enzyme-linked immunosorbent assays (ELISA) can be found in Chapter 2, 
section 2.1 and buffers used in Appendix 1.
3.3.2 Blood Collection
Blood samples were collected from patients at two time points. The first time point, 
upon patient admission to the emergency department for chest pain, was labelled ‘on 
admission’. The second set of blood samples was taken approximately 12 hours after 
the onset of chest pain and this sample was referred to as ‘12 hours’. Due to 
difficulty in obtaining 12 hr samples, only n=14 samples were obtained for this time- 
point. A single time-point blood sample was collected from the control subjects. 
Samples were sent to the routine pathology laboratory for analysis of serum cardiac 
troponin I and complement C3 and C4 proteins. Serum samples for Hsp27 and anti- 
Hsp 27 IgM and IgG antibodies were collected at the same time and aliquots stored 
at -80°C until analysis.
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3.3.3 Hsp27, anti Hsp27 IgG and anti-Hsp27 IgM ELISA optimisation
3.3.3.1 Hsp27 ELISA optimisation
A number of parameters were evaluated in order to optimise assay conditions. Two 
commonly used blocking buffers, goat serum (GS) and bovine serum albumin 
(BSA), were tested for their ability to produce low background readings and reduce 
non-specific binding. The concentration of capture antibody, the detecting polyclonal 
antibody dilution and the conjugated antibody dilution were also optimised. Where 
applicable, a condition was considered optimal if it fell on the linear portion of the 
reaction curve which was applied when choosing the antibody or antigen coating 
concentration. Saturating concentration of coating material was not used to avoid 
high background readings. Other considerations when optimising the ELISA 
included the assay’s ability to produce a high signal (total binding) with low 
background (non-specific binding) reading. Recombinant Hsp27 was used during 
optimisation of the parameters. A western blot was initially done to detect Hsp27 in 
serum samples using the monoclonal capture antibody (please refer to Chapter 2, 
Section 2.1.2 for materials for the Western blot and Section 2.2 for the method)
3.3.3.2 Anti-Hsp27 IgG and IgM ELISA development
A number of assay parameters were evaluated in order to optimise assay conditions, 
including: an assessment of 2 commonly used blocking buffers to test for their 
efficacy to produce low background reading and reduce non-specific binding, the 
coating antigen concentration, serum sample and detecting antibody dilutions. Pooled
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serums of samples with high IgM and IgG values screened earlier were used during 
the optimisation process.
3.3.4 Determination of serum Hsp27 and its anti-Hsp27 IgG and IgM antibody 
levels
Hsp27, anti-Hsp27 IgG and IgM antibody levels were measured by ELISAs. Please 
refer to Chapter 2, section 2.3 for details.
3.3.5 Determination of cardiac troponin and serum complement C3 and C4 
levels
Serum troponin I concentrations were measured using a cardiac troponin I Test Pak 
(Dade Behring) on a Stratus CS Stat Fluorometric analyser with a 10% CV and a 
detection limit of 0.1 pg/1 (Panteghini et aL, 2004).
Serum complement C3 and C4 were measured using an immunonephelometric 
method on the Behring BN11 nephelometer. The assay has a typical sensitivity of 
0.02 g/1 and a total CV of less than 5%.
3.3.6 Statistical analysis
Statistical analysis was performed using Graphpad Prism version 5.0 for Windows 
(Graphpad Software Inc, USA). Differences between groups for skewed data were 
evaluated using the Mann-Whitney and the Wilcoxon Signed Rank test and data
89
reported as median and inter-quartile range about the median. Unpaired and paired 
Student’s t-tests were used to evaluate differences between groups for normally 
distributed data and results expressed as mean ± SD. The Chi-squared test was used 
to evaluate differences between genders. A p value of <0.05 was considered 
statistically significant.
3.4 Results
3.4.1 ELISA optimisation
3.4.1.1 Hsp27 ELISA
Choice of Blocking Buffer
For the goat serum, concentrations lower than 4% had been tested in our lab for other 
assays and were not found to be suitable as a blocking agent while for BSA, 3% is a 
common concentration used in ELISAs. Of the two, it was found that 4% GS gave 
better blank readings of an average of 0.065 compared to 3% BSA that produced 
average blank readings of 0.07. 4% GS was therefore chosen as the blocking buffer. 
The blank corresponded to wells which have not been added serum.
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M onoclonal Hsp27 detection o f  H sp27 in serum  sam ples
M ouse m onoclonal antibody to be used in the assay w as shown to detect H sp27 in 
serum  sam ples from  patient and control specim ens as show n in Fig.3.1.
3 0  KDa m a rk e r____
R e co m b in an t  Hsp27 >•
20  KDa m a rk e r ------
Fig.3.1 Western blot of serum samples using the monoclonal Hsp27 antibody
A protein gel electrophoresis and western blot was done on serum samples from different 
patients. For all samples tested, detection o f Hsp27 was obtained as indicated by the 
recombinant Hsp27 and the ladder used, and the above is an example.
M onoclonal Hsp27 coating concentration optim isation
M ouse m onoclonal H sp27 antibody (diluted in PBS) was tested at increasing 
concentrations in the 0.25 -  8.0 pg/m l range. The linear portion o f  the curve was 
found to occur betw een 2.0 -  4.0 pg/m l, Fig.3.2(a). 2.5 pg/m l was therefore chosen 
as the coating concentration.
Serum samples
Rabbit anti-human polyclonal antibody dilution optimisation
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The rabbit anti-human polyclonal detection antibody was tested at different dilutions; 
1:3000, 1:4000, 1:5000 and 1:6000 (diluted in blocking buffer). A dilution of 1:6000 
was chosen as it gave the lowest non-specific binding, Fig. 3.2(b).
Goat anti-rabbit peroxidase conjugated antibody dilution optimisation
As above, the goat anti-rabbit peroxidase conjugated antibody concentration was 
optimised and and 1:6000 dilution was selected, Fig.3.2(c).
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Hsp27 m onoclonal antibody cone, (pg/ml)
(b)
I TB NSB □  SB
1 :4 0 0 0  IrSOOO
A ntibody D ilution
(c)
1:4000 1:5000
A n tib o d y  D ilu tion
1:3000 1:6000
Fig.3.2 Optimisation of the Hsp27 ELISA (a) Capture antibody concentration (b & c) 
rabbit anti-human polyclonal antibody and the goat anti-rabbit antibody dilutions.
A concentration o f 2.5 pg/ml was chosen for capture antibody as this was in the linear 
portion of the curve and dilution of 1:6000 for both rabbit anti-human and goat anti-rabbit 
antibodies were selected as this had the most favourable signal : noise ratio.
SB = TB (coated wells) -  NSB (uncoated wells)
TB: Total Binding, NSB: Non Specific Binding, SB: Specific Binding
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3.4.1.2 Anti-Hsp27 IgG ELISA assay development
Choice of Blocking Buffer
For the blocking buffer, it was found that 3% BSA gave better blank and NSB 
readings than goat serum and therefore 3% BSA was used in the final ELISA assays.
Coating antigen concentration optimisation
Recombinant Hsp27 diluted in 0.05 M pH 9.6 carbonate coating buffer was tested at 
increasing concentrations ranging from 0.5 - 16 pg/ml. From the graph, Fig.3.3(a), 6 
pg/ml concentration (300 ng/50 pl/well) was selected as it lies on the linear portion 
of the curve.
Serum sample dilution optimisation
Serum samples were serially diluted in blocking buffer as follows:,!: 12.5, 1:25, 1:50, 
1:100, 1:200, 1:400 and 1:800. The results showed that a serum dilution of 1:100 was 
optimum for the ELISA, Fig.3.3(b).
Anti-human IgG peroxidase conjugated antibody dilution optimisation (4)
Anti-human IgG antibody was diluted in blocking buffer at dilutions of 1:1000, 
1:2000, 1:3000 and 1:4000. It was found that a dilution of 1:2000 gave a good NSB 
with high SB, Fig.3.3(c).
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1:800 1:400 1:200 1:100 1:50 1:25 1:12.5
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(c)
S  0.30
5<  0.10
ITS NSB O S S
1:1000 1:2000 1:3000
Antibody Dilution
Fig.3.3 Optimisation of the anti-Hsp27 IgG ELISA.
(a) Recombinant Hsp27 coating concentration. A recombinant coating concentration o f 6 
pg/ml was chosen, (b) Working dilution for serum samples. A dilution of 1:100 was chosen,
(c) Anti-human IgG antibody dilution. A dilution of 1:2000 was chosen.
SB = TB (coated wells) -  NSB (uncoated wells)
TB: Total Binding, NSB: Non Specific Binding, SB: Specific Binding
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3.4.1.3 Anti-IgM Hsp27 ELISA assay development
Choice of Blocking Buffer
Of the two blocking buffers, 3% BSA gave better blank and NSB readings than goat 
serum and was therefore chosen as the blocking buffer.
Coating antigen concentration optimisation
Recombinant Hsp27 diluted in carbonate coating buffer was tested at different 
quantities between 0.5 -  16 pg/ml. From the graph, Fig.3.4(a), 6 pg/ml was chosen 
as it lies on the linear portion of the curve.
Serum sample dilution optimisation
Serum samples diluted serially in blocking buffer were tested at the following 
dilutions; 1:12.5, 1:25, 1:50, 1:100, 1:200, 1:400 and 1:800. From the graph, a serum 
dilution of 1:100 was chosen as it lies on the linear part of the curve, Fig.3.4(b).
Anti-human IgM peroxidase conjugated antibody dilution optimisation
Anti-human IgM antibody was diluted in blocking buffer at dilutions of 1:100, 1:500, 
1:1000 and 1:2000. It was found that a dilution of 1:2000 gave a good NSB with high 
SB, Fig.3.4(c).
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Fig.3.4 Optimisation of the anti-Hsp27 IgM ELISA.
(a) Recombinant Hsp27 coating concentration. A recombinant coating concentration of 6 
pg/ml was chosen, (b) Working dilution for serum samples. A dilution of 1:100 was chosen,
(c) Anti-human IgM antibody dilution. A dilution of 1:2000 was chosen.
SB = TB (coated wells) -  NSB (uncoated wells)
TB: Total Binding, NSB: Non Specific Binding, SB: Specific Binding
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3.4.1.4 Validation of assay
3.4.1.4.1 Sensitivity
Sensitivity refers to the low er lim it o f  detection o f  the assay w hich is the lowest 
quantity o f  a substance that can be distinguished from  the blank value.
(i) Hsp27 ELISA
Fig.3.5 shows a standard curve for the Hsp27 ELISA . The linear portion o f  the curve 
was betw een 0.94 ng/m l to 15 ng/ml. The low er lim it o f  detection thus corresponded 
to approxim ately 0.94 ng/m l.
0 . 5 0 '
E
I
0 . 4 0 '
0 . 30 '
0 . 2 0 '
O
5 0 . 1 0 '
0 .00 :
150 2001000 50
R ecom binant H sp27 co n cn . (ng/ml)
Fig.3.5 Hsp27 standard curve.
To determine the linear portion of the curve, serial dilution of recombinant Hsp27 from 200 
ng/ml to 0.5 ng/ml was done and the absorbance obtained plotted against recombinant 
concentration. It was found that the linear portion corresponded to 0.94 ng/ml to 15 ng/ml. 
This values correspond to the working standard curve to be used during the assays for the 
quantification of Hsp27 in the samples, the lower limit of detection therefore corresponds to 
0.94 ng/ml.
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(ii) Anti-Hsp27 IgG and anti-Hsp27 IgM ELISA
For the anti-IgG and anti-IgM Hsp27 ELISA, five blank readings were obtained and 
the standard deviation (SD) calculated. Lower limit of detection of the assay is 
determined as mean blank +3SD. The results are summarised in Table 3.1.
Table 3.1 Calculation of the sensitivity of the ELISA for the determination of IgG and 
IgM Hsp27.
Blank Specific Binding (Absorbance) Mean LLD
IgG 0.004 0.003 0.002 0.000 0.000 0.000 0.0015 0.0018 0.007
IgM 0.002 0.003 0.002 0.001 0.005 0.000 0.0022 0.0017 0.007
LLD : Lower limit of detection
3.4.1.4.2 Inter-assay and intra-assay variations (precision)
In order to check that comparable results are obtained in different assays, it is 
necessary to run controls and to determine inter (between)-assay and intra (within)- 
assay coefficients of variation (CV).
Intra-assay variation was determined by placing 2 different samples in 5 different 
wells on the same plate. Inter-assay variation was determined by analyzing 2 samples 
on 3 different days. The means and SDs of the results were then used to determine 
the CV with the following formula:
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CV = (SD/Mean) x  100
The results are summarised in Table 3.2.
Table 3.2 Calculation of the intra-assay and inter-assay CV for the Hsp27, IgG and 
IgM ELISA.
INTRA-ASSAY
Mean
(Absorbance) SD CV (%) Ave. CV (%)
Hsp27 (1) 0.01 0.16 4.97
5.9
Hsp27 (2) 0.01 0.11 6.78
IgG (l) 0.346 0.021 6.1
4.7
IgG (2) 0.066 0.002 3.28
IgM (1) 0.108 0.0054 5.03
4.3
IgM (2) 0.091 0.0032 3.54
INTER-ASSAY CV
Mean Ave. CV (%)
Hsp27 (1) 
(ng/ml) 53.6 2.22 4.15 5.3
Hsp27 (2) 
(ng/ml) 16.1 1.04 6.48
IgG (l)
(Abs) 0.933 0.067 7.17 6.1
IgG (2)
(Abs) 0.063 0.003 5.08
IgM (1) 
(Abs) 0.101 0.008 8.3 7.7
IgM (2) 
(Abs)
1.118 0.080 7.1
100
3.4.2 Demographic and baseline characteristics of the study group
Table 3.3 shows the demographic and baseline characteristics for both patient (n=37) 
and control (n=37) groups. The patient group consisted of 53% males and 47% 
females with an average age of 76 ± 9.6 years. The control group comprised 39% 
males and 61% females with an average age of 51 ± 10.6 years. The patient group 
was significantly older than the control group, pO.OOl. There was no significant 
difference in gender distribution between both groups.
Serum Hsp27 concentrations were significantly higher for the patient group on 
admission compared to the healthy controls [16.1(6.8 -  28.3) vs 4.9(3.0 -  8.6), 
pO.OOl], though there was no significant difference between Hsp27 levels in the 
control group and patient samples taken at 12 hours after the onset of chest pain, 
Fig.3.6. There was no significant difference in the baseline levels of either anti- 
Hsp27 IgM or IgG antibodies between the two groups, Table 3.3.
101
Table 3.3 Demographic characteristics and baseline values of Hsp27, anti-Hsp27 IgM 
and anti-Hsp27 IgG antibodies for patient and control groups
Variable Controls Patients p-value
N 37 37
Mean age (years) 50.8 ±9.6 76.1 ± 10.6 pO.OOl
Male (%) 61 53 ns
Hsp27 (ng/ml) 4.9(3.0 -  8.6) 16.1(6.8-28.3) pO.OOl
Hsp27 IgM (Abs) 0.04(0.02-0.09) 0.04(0.02-0.07) ns
Hsp27 IgG (Abs) 0.05(0.03-0.12) 0.08(0.04-0.14) ns
Patient data came from samples taken on admission.
Data are presented as mean ± SD and median (interquartile range), ns: not significant 
Abs: Absorbance.
3.4.3 Serum Hsp 27, anti-Hsp27 IgM and IgG levels on admission and 12 hours 
after onset of symptoms
For patients with AMI, the change in serum Hsp27, anti-Hsp27 IgM and IgG was 
investigated by measuring their serum concentrations at two time points, on 
admission and approximately 12 hours after the onset of chest pain. For serum 
Hsp27, there was a significant decrease in serum Hsp27 levels at 12 hours compared 
to levels on admission [6.2 ± 2.9 vs 14.6 ±11.9 ng/ml, p=0.02], Fig. 3.6. There was 
also a significant decrease in serum anti-Hsp27 IgM concentrations at 12 hours 
compared to those on admission [0.02 (0.02 - 0.05) vs 0.04 (0.02 -  0.07), p=0.02], as 
shown in Fig. 3.7(a). There was no significant difference in serum anti-Hsp27 IgG 
levels between the two time points Fig.3.7(b).
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Fig.3.6 Scatter plot of serum Hsp27 concentrations.
Comparison of Hsp27 levels between control (n=37) and patient (n=37) groups on admission 
was done using Mann-Whitney test, and between samples on admission and 12 hours after 
onset of chest pain for the patient group was done using the paired t-test.. Serum Hsp27 was 
significantly higher in patients compared to controls on admission [16.1(6.8 -  28.3) vs 
4.9(3.0 -  8.6), pO.OOl] but was not significantly different in 12 hr samples. For patients 
only, there was a significant decrease in serum Hsp27 levels at 12 hours compared to levels 
on admission [6.2 ± 2.9 vs 14.6 ±1 1 . 9  ng/ml, p=0.02]. Median levels are represented by 
horizontal bars.
103
(a) IgM
p=0.02
Si
^  a
■s.o
1.00-1 
0.55-1 
0.10-1 
0.1 T
0.0
#
#
#
•  •  
•  •
• •
O n a d m is s io n 12 h r
(b) IgG
8<D
CD Û
no
0.20
0.15
0.10
0.05
0.00
On admission 12 hr
Fig.3.7 Scatter plots of (a) serum IgM and (b) serum IgG antibody levels on admission 
and 12 hours after onset of chest pain for the patient group.
The median (interquartile range) levels for IgM on admission and 12 hrs after onset o f chest 
pain are 0.04 (0.02 -  0.07) and 0.02 (0.02 - 0.05) respectively, with significant difference 
obtained at p=0.02. The mean ±SD levels for IgG on admission and 12 hrs after onset of 
chest pain are 0.08 ±0.05 and 0.08 ±0.04 respectively. Median and mean levels are 
represented by horizontal bars for IgM and IgG respectively. Wilcoxon Signed rank test was 
used for (a) while paired t-test was used for (b).
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3.4.4 Serum complement C3 and C4 levels on admission and 12 hours after 
onset of chest pain
Serum complement C3 and C4 were also determined upon admission and 
approximately 12 hours after onset of chest pain. There was a significant reduction in 
the complement protein C3 levels in the 12 hour samples compared to levels in 
samples taken on admission, [1.19 (1.06 -  1.43) vs 1.51 (1.19 -  1.57) g/1, p=0.02], as 
shown in Fig.3.8. No significant change was observed for serum complement C4 
(data not shown).
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Fig.3.8 Scatter plot of serum complement C3 levels for the patient group on admission 
and 12 hours after onset of chest pain.
Using Wilcoxon Signed rank test, it was found that there was a significant difference in 
complement C3 levels between on admission and at 12 hr post chest pain (p=0.02). Median 
levels are represented by horizontal bars.
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3.5 Discussion
3.5.1 Higher serum Hsp27 in patients with acute myocardial infarction
The results show that there were higher levels of serum Hsp27 in patients who had 
suffered an MI compared to healthy controls. These results are consistent with the 
results previously reported by Park et al (Park et al., 2006) and similar to the results 
reported for another Hsp, Hsp70, which was also found to be increased in the serum 
of patients with ACS (Dybdahl et al., 2005; Satoh et al., 2006; Zhang et al., 2010). 
Though the patients were significantly older than the controls in this study, it has 
recently been reported that plasma Hsp27 concentrations are inversely associated 
with age (Kardys et al., 2008), hence, age should not be a confounding factor in this 
current comparison. Previous studies have also reported that there is an increased 
expression of Hsp27 in cardiomyocytes exposed to ischaemia. Prolonged ischaemia 
would lead to necrosis of the cardiomyocytes and since necrotic cells have been 
found to release heat shock proteins into the circulation (Basu et al., 2000), this 
would be one explanation for the increased serum Hsp27 in patients who have had an 
acute myocardial infarction.
3.5.2 The IgG and IgM autoimmune response to Hsp27
Once released into the circulation, it is likely that Hsp27 elicits an autoimmune 
response. Previous studies have shown that Hsp27 can produce an autoimmune 
response, associated with higher concentrations of IgG autoantibodies, and that in 
patients with acute coronary syndrome the autoantibody levels were reported to be
higher compared to the control group (Ghayour-Mobarhan et al., 2008). Whilst a 
significantly higher anti-Hsp27 IgG antibody level in patients has not been 
demonstrated here, this is probably due to the smaller sample size used in this study, 
and hence an inability to detect a difference between the groups. The results however 
did show that there was no change in IgG levels between the first and second time 
point, which is consistent with the finding of a previous study (Shams, 2008). In 
contrast, it was found that in the first 12 hours after the onset of chest pain, IgM 
antibody concentrations fell in parallel with serum Hsp27 antigen concentrations. 
This fall in IgM antibody levels may be due to the formation of immune complexes 
between the IgM antibody and Hsp27 and subsequent activation of the classical 
complement pathway.
3.5.3 Involvement of complement activation in the clearance of serum Hsp27
The parallel fall in serum Hsp27 and anti-Hsp27 IgM levels suggests that IgM 
antibodies may form immune complexes with Hsp27 released from myocardial cells. 
It is then possible that these complexes may activate the complement system to 
facilitate their clearance via complement receptors on erythrocytes. This theory is 
supported by the data showing that there was a significant decrease in serum 
complement C3 levels in the 12 hr samples, in accordance with the decrease in 
Hsp27 antigen and Hsp27 IgM levels in the same samples. Of note, besides the 
complexes between Hsp27 and its autoantibodies activating the complement system, 
there is also the possibility that immune complexes are formed by other molecules 
released by the necrotic cardiomyocytes which might also play a part in the decrease 
in C3 oberved in the study.
Though in vitro studies have shown that IgG antibodies are also complement 
activators (Lucisano Valim and Lachmann, 1991), it appears that within the time 
frame of the present study it was the IgM antibodies that were principally involved in 
the clearance of the released Hsp27. There could be a number of possible reasons for 
IgM and not IgG being principally involved in the clearance of Hsp27 observed. For 
example, the pentameric structure of IgM supports a more stable IC lattice structure 
facilitated by Fc-Fc interactions, whilst the serum polyclonal IgG antibodies possess 
varying affinities and may not form stable ICs with Hsp27. Besides that, the 
pentameric structure of IgM gives it higher avidity compared to IgG and especially 
for polymeric structures like those formed by Hsp27. Many of the protective 
functions of Hsp27 have been found to be mediated by the oligomeric structures of 
Hsp27 which are therefore the most likely form of Hsp27 released to the circulation. 
More importantly, with regards to the difference in structure between the IgG and 
IgM antibodies, for activation of C lq (one of the subunits in the Cl complex), at 
least 2 Fc portions of the antibody molecure are required, Fig.3.9, which would need 
two IgG molecules but only 1 IgM molecule (Borsos and Rapp, 1965; Heyman, 
2000). Furthermore, the first wave of response by the IgG and IgM antibodies could 
be mediated by polyreactive natural antibodies directed against the shared epitopes 
that are probably present on Hsp27 due to phylogenetic conservation across species. 
Since these polyreactive antibodies are predominantly of the IgM isotype (Manson et 
al, 2005), these would therefore form ICs more rapidly with Hsp27 than IgG.
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Fig.3.9 Activation of C lq  with IgM or IgG
C lq  needs to bind to at least 2 molecules of IgG for activation, while binding to only 1 of 
IgM is sufficient for its activation.
A dapted from (Janeway, Jr. e t a l ,  2001)
3.5.4 Lower IgM antibodies in chronic cardiovascular disease (CVD)
Previous studies have found an inverse association o f  IgM  antibodies w ith coronary 
artery disease and carotid atherosclerosis (K arvonen et a l ,  2003; Tsim ikas et a l ,  
2007) w hich suggests consum ption o f  the IgM antibodies w ith disease progression. 
In those studies, the antibodies w ere directed against oxLDL; another putative 
autoantigen in atherosclerosis. IgM antibodies, especially natural antibodies, have 
been suggested to provide a protective role in atherosclerosis (Lewis et al., 2009) and 
low levels have been found to be associated w ith increased risk o f  developing 
clinical atherosclerosis (S joberg et a l ,  2009). The exact m echanism  o f  this protection 
in the plaque is not yet clear though its depletion in serum  levels w hich may probably 
lead to low levels in the atherosclerotic plaque would probably have an effect on this 
role.
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3.6 Limitations of the study
The first limitation of the study was the significant age difference between the 
control and the patient group. As discussed, in a previous study of a population of 
healthy participants (Kardys et al., 2008), it was found that Hsp27 was inversely 
associated with age, which would have meant a higher level would be expected in the 
control group rather than the patient group, which was not observed in this study. 
Instead, it was the older group of patients with acute myocardial infarction that had 
significantly higher level of Hsp27. Higher Hsp27 levels in patients who had 
experienced an acute ischaemic event were also found in a previous study (Park, 
2006) and also in patients with coronary artery disease (CAD) who were age- 
matched with the control group, which was suggested to be due to myocardial 
ischaemia (Jozefowicz-Okonkwo et al., 2009).
The second limitation of the study was the small sample size for the 12-hour blood 
sample in the patient group. The main reason for the small sample size was the 
difficulty in obtaining the second sample. Four variables were compared for the 
patient group; the Hsp27 concentration, anti-Hsp27 IgG, IgM and serum complement 
C3 levels. Of these four variables, three were significantly different in the second 
sample compared to the first sample. However, there was no significant change in the 
anti-Hsp27 IgG levels despite using a similar sample number and the same group of 
patients. This seems to suggest that small sample size may not be the main factor in 
detecting differences in anti-Hsp27 antibody levels between the two timepoints.
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3.7 Conclusion
It has been found that Hsp27 released into the circulation following an AMI may be 
rapidly cleared by the formation of immune complexes with IgM antibodies. It is 
proposed that in the long term in chronic disease such as atherosclerosis, where a 
proposed antigen such as oxLDL has been found to be present at higher 
concentrations in the circulation of patients with cardiovascular disease (Ishigaki et 
al., 2009; Zhang et al., 2008), one of the reasons for the depletion of IgM antibodies 
would be due to its rapid response to antigens released from the atherosclerotic 
lesions. The results presented in this chapter support this hypothesis.
I l l
Chapter 4
Serum Heat shock protein 27 antigen and antibody levels in relation 
to the macrovascular complications associated with insulin
resistance
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4.0 Serum Heat shock protein 27 antigen and antibody levels in 
relation to the macrovascular complications associated with insulin 
resistance
4.1 Introduction
The next study was to investigate the long term immune response to Hsp27 in 
patients with established cardiovascular disease and with varying degrees of 
underlying insulin resistance.
Insulin resistance is characterised by an inadequate response of insulin sensitive 
tissues (liver, adipose tissue and skeletal muscle) to circulating insulin, resulting in 
an impaired handling of a glucose load (Ceriello and Motz, 2004). Initially, insulin 
resistance is compensated for by increased insulin secretion allowing for the 
preservation of a normal glucose tolerance (NOT) (Ceriello and Motz, 2004; Kahn, 
2003). Deterioration to impaired glucose tolerance (IGT) and impaired fasting 
glucose (IFG) occurs when insulin resistance increases further and/or when the 
compensatory insulin secretory response decreases (Camevale Schianca et al., 2003; 
Ceriello and Motz, 2004). These latter conditions are associated with a substantially 
increased risk of type 2 diabetes mellitus (T2DM) (Unwin et al., 2002). T2DM, 
defined by a high blood glucose (fasting plasma glucose >7.0 mmol/1 or 2 hour post 
glucose load >11.1 mmol/1) is the most prevalent form of diabetes mellitus (Alberti 
and Zimmet, 1998; Maiese et al., 2007).
Hyperglycaemia is associated with tissue injury that subsequently leads to diseases of 
the blood vessels. These can be broadly separated into macrovascular complications 
(coronary artery disease, peripheral arterial disease, and stroke) and microvascular 
complications (diabetic nephropathy, neuropathy, and retinopathy) (Jay et a l, 2006). 
It has been proposed that oxidative stress is one pathogenic factor underlying the 
onset and progression of insulin resistance and diabetes, and consequently of 
vascular complications (Brownlee, 2005; Ceriello and Motz, 2004; Evans et a l, 
2003). In cells exposed to hyperglycaemia, it is suggested that oxidative stress occurs 
due to overproduction of superoxide by the mitochondrial electron transport chain 
(Brownlee, 2001). These superoxides are then proposed to inhibit the activity of the 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which leads to the 
activation of several biochemical pathways (Brownlee, 2005). These pathways 
include (1) increased polyol pathway flux; (2) increased advanced glycation end 
product (AGE) formation; (3) activation of protein kinase C (PKC) isoforms; and (4) 
increased hexosamine pathway flux. Activation of these pathways produces a 
cascade of events that eventually lead to damage of the vessel wall.
Additionally, it is suggested that oxidative stress leads to depletion of antioxidants 
such as glutathione and KRR-a-tocopherol (a form of Vitamin E). Since RRR-a- 
tocopherol accounts for 90% of the protection of LDL against oxidation, its depletion 
would lead to increased susceptibility of the LDL molecule to become oxidized, 
forming oxidized (ox)LDL which is implicated in the development of atherosclerosis 
(Evans et ah, 2003; Rosen et al., 2001).
Following exposure to one of a number of environmental stressors, that include heat 
and oxidative stress, cells increase their expression of a group of highly conserved 
proteins known as the heat shock proteins (Hsps). Whilst many of these proteins 
function as molecular chaperones, facilitating the correct folding of nascent peptides 
and the refolding of denatured or mis-folded proteins (Georgopoulos and Welch, 
1993), they may also have other vital roles. Altered expression of Hsps may give rise 
to or exacerbate underlying diseases; a mechanism that has been proposed for insulin 
resistance and T2DM. This may occur through impaired insulin signaling, leading to 
reduced expression of Hsps (Atalay et al., 2004; Bruce et al., 2003), thus leaving 
tissues vulnerable to damage due to the inability of Hsps to perform their various 
protective cellular functions (Hooper and Hooper, 2009). Hsp27 is a member of the 
small HSP family, the expression of which is increased when cells are exposed to 
oxidative stress (Mehlen et al., 1995). Potential mechanisms by which Hsp27 may 
enable cells to adapt to exposure to oxidative stress include: the upregulation of 
glucose-6-phosphate dehydrogenase and glutathione peroxidase, and a decrease in 
intracellular levels of iron (Arrigo et al., 2005; Preville et al., 1999).
In vitro studies have shown that Hsps are released from cells exposed to stress (Child 
et al., 1995; Liao et al., 2000a), which would explain both their presence in serum in 
vivo and why they may stimulate an autoimmune response (Xu, 2002). Studies have 
reported that antibody titres to some Hsps, such as Hsp60, are related to circulating 
antigen concentrations (Xu et al., 2000), and that there are elevated concentrations of 
antibodies to Hsp65 in patients with atherosclerosis (Xu et a l, 1993) and of Hsp60 in 
patients with coronary heart disease (Zhang et a l, 2008b).
In a recent study investigating the possible relationship between Hsp27 and the 
presence of microvascular complication in patients with Type 1 diabetes, it was 
found that Hsp27 concentrations were independently associated with the presence of 
distal symmetrical polyneuropathy in these patients (Gruden et ah, 2008). However, 
in the same group of patients, it was found that Hsp27 antibody levels were not 
associated with the presence of complications nor with the serum Hsp27 
concentration (Burt et al., 2009).
The hypothesis was that serum Hsp27 concentrations may be a marker of 
macrovascular complications in patients with insulin resistance, and that Hsp27 
antibody levels may reflect the presence of circulating antigen. The aim of this 
present study was to investigate the relationship between the levels of serum Hsp27 
and its antibody levels (IgM and IgG) in individuals from different glycaemic 
categories either with, or without a concomitant history of CVD.
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4.2 Subjects
A total of sixty eight subjects were involved in this study, selected from two different 
populations; Caucasians (n=35) and Saudis (n=33). The subjects were divided into 
two main groups; those without CVD and those with CVD. A history of CVD was 
defined as having established coronary artery disease, stroke or peripheral artery 
disease. The groups were further sub-divided according to their glucose tolerance. 
Glucose tolerance was assessed by using an oral glucose tolerance test (OGTT) 
applying the WHO 1998 criteria (Alberti and Zimmet, 1998). This criterion is based 
on the subjects’ serum glucose level (please refer to Appendix 2 for cut-off values) 
and divides the groups into NGT and glucose intolerance (GI). Glucose intolerance 
included those with IFG, IGT and T2DM. Accordingly, the subjects were divided 
into the following groups; NGT without CVD, (NGT (-CVD)), NGT with CVD, 
(NGT (+CVD)), GI (-CVD), and GI (+CVD), shown in Fig.4.1.
Blood samples were collected from subjects between February 2005 and July 2008. 
Subjects were recruited during their routine visit to the hospital outpatient diabetic, 
cardiac or lipid clinics. Ethical permission was granted by the Saudi National Guard 
Health Affairs (NGHA) Ethical Committee and the South West Surrey Local 
Research Ethic Committee (LREC). Samples from Saudi Arabia were delivered to 
the UK in March 2006 and January 2009 respectively.
4.2.1 Inclusion criteria
Common inclusion criteria for all subjects were as follows:
a. Aged between 20 - 65 years.
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b. Body mass index (BMI) 20 - 35 kg/m2.
For subjects without cardiovascular disease (CVD)
c. The absence of symptoms of CVD on questioning.
For subjects with CVD
d. Established CVD defined as previous myocardial infarction (MI), previous 
coronary artery bypass graft (CABG) operation, angina diagnosed by exercise 
test and/or coronary angiogram, stroke or peripheral vascular disease.
4.2.2 Exclusion criteria
Common exclusion criteria for all subjects were as follows;
a. A known history of chronic diseases such as cancer which are known to cause 
increased serum levels of Hsp27 (Ciocca et al., 1993).
b. Diabetes treated with oral hypoglycaemic medications or insulin and other 
drugs likely to modify insulin sensitivity e.g. steroids (Cagnacci et al., 2003).
GI (-CVD) 
n=21
NGT (+CVD) 
n=10
NGT (-CVD) 
n=16
GI (+CVD) 
n=21
Total No. Of Subjects 
n=68
Fig.4.1 Classification of study subjects
Subjects were classified according to their glycaemic status and the presence or absence of 
cardiovascular disease (CVD)
Key: n, number; NGT, normal glucose tolerance; GI, glucose intolerance; CVD, 
cardiovascular disease
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4.3 Material and Methods
4.3.1 Materials
Consumables, reagents and antibodies for the Hsp27, anti-Hsp27 IgG and IgM 
ELISAs can be found in Chapter 2, sections 2.1.1 and 2.1.3 and buffers used in 
Appendix 1.
4.3.2 The OGTT, blood collection and serum/plasma separation
Participants were instructed to abstain from smoking, alcohol and physical activity 
from 7 pm and to fast from 10 pm the previous night. The OGTTs were performed 
between 8 and 10 am. Fasting blood samples were collected into sodium fluoride, 
EDTA and plain tubes (without anti-coagulant). A standard OGTT was performed 
with 75g glucose anhydrate in 300 mL of water taken orally over 5 minutes. After 2 
hours, further blood samples were collected into sodium fluoride and plain tubes. 
After separation of plasma or serum by centrifugation (3000 x g) for 10 minutes 
specimens were sent to the Pathology Laboratory, Royal Surrey County Hospital for 
plasma glucose analysis. For glycated haemoglobin (HbAlc) analysis, whole blood 
was collected into an EDTA tube and analysed at the same laboratory. Serum 
aliquots for insulin, Hsp27 and its IgG and IgM antibodies were stored at -8O°C until 
analysis.
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4.3.3 Glucose, HbAlc and insulin analyses and insulin sensitivity determination
Glucose was assayed by the hexokinase method using a Bayer Advia 1650 analyser, 
while HbAlc, was analysed by high performance liquid chromatography technique 
on a Biorad Variant II instrument. Plasma insulin concentrations were determined 
using a solid phase two-site enzyme immunoassay kit (Mercodia). The assay had a 
sensitivity of 7.0 pmol/1 and a maximum analytical CV of 4.9%. Insulin sensitivity 
was assessed using indices derived from the homeostasis model assessment of 
sensitivity (HOMA-S), which calculates insulin sensitivity using fasting glucose 
(mU/1) and insulin concentrations (mmol/1) using the formula; HOMA-S = 
1/[(insulin x glucose)/22.5], and the insulin sensitivity index for glycaemia (ISI-gly), 
which calculates the sum of fasting and 2 hour insulin (insulinp) in pU/ml and fasting 
and 2 hour glucose (glucosep) in units of mg/dl using the formula, ISI- 
gly=2/[(insulinp x glucosep) +1].  HOMA-S reflects hepatic insulin sensitivity since 
only fasting values are used in the calculation while ISI-gly provides an estimate of 
whole-body insulin sensitivity since the additional 2 hour component, provides 
information on peripheral insulin resistance (Borai et a l, 2007). Both insulin analysis 
and insulin sensitivity determination were performed by a colleague, Dr. Anwar Al- 
Borai.
4.3.4 Determination of serum Hsp27 and anti-Hsp27 IgM and IgG
Serum Hsp27 and anti-Hsp27 IgM and IgG were analysed by ELISAs as described 
previously in Chapter 2, section 2.3.
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4.3.5 Statistical analysis
Statistical analysis was mainly performed with Graphpad Prism version 5.0 for 
Windows (Graphpad Software Inc, USA) except for multivariate regression analysis 
which was carried out using SPSS software version 16 (SPSS Inc, Chicago, Illinois, 
USA). Continuous variables were assessed by one-way analysis of variance 
(ANOVA), with post-hoc analysis using the Bonferroni multiple comparisons test 
and data reported as mean with standard deviation (SD). For analysis of Hsp27 and 
anti-Hsp27 IgM and IgG antibodies, comparison between groups for skewed data 
was performed using the Mann-Whitney test, and data reported as median and inter­
quartile range about the median while comparison between groups for normally 
distributed data was analyzed using the t-test, and data reported as mean with SD. 
Spearman’s rank correlation analysis was used to investigate the relationship 
between variables and stepwise multiple linear regression analysis was used to 
investigate the influence of variables on Hsp27 concentration. Results were 
considered significant with p<0.05. The statistical tests performed on the data are 
indicated in the figure legends for each result.
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4.4 Results
4.4.1 Demographic and clinical characteristics of the study groups
The GI group comprised individuals with isolated IFG/IGT, combined IFG with IGT 
and T2DM patients. There was no significant difference in the distribution of the 
different categories of glucose intolerance between the -CVD and +CVD groups. 
Though the four groups differed for all variables, both the two NGT (-CVD and 
+CVD) and GI (-CVD and +CVD) groups were matched between them for most of 
the variables except for age, Table 4.1.
The mean body mass index (BMI) for both NGT groups was in the overweight 
category, while the mean BMI for the glucose intolerant groups was just above the 
cut off value for overweight and into the obese category (WHO, 2004).
The -CVD groups (NGT and GI) differed except for weight, while the +CVD groups 
were matched for all variables.
Table 4.1 also shows subjects in the control group, with neither CVD nor GI, NGT (- 
CVD), differed significantly from the group which has CVD and GI, GI (+CVD), for 
all variables tested here.
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4.4.2 Glucose, HbAlc, insulin levels and indices of insulin sensitivity
Table 4.1 shows that the four groups also differed significantly for glucose, HbAlc, 
insulin levels and indices of insulin sensitivity. However, both of the NGT groups 
were matched for all of these indices. Both the GI groups were also matched in this 
respect except for their fasting plasma insulin. The NGT (-CVD) and GI (-CVD) 
groups differed for all the indices except for fasting plasma insulin, whilst the NGT 
(+CVD) and the GI (+CVD) groups differed only for their two hour post 75 glucose 
(2hPG) and their two hour serum insulin levels.
As with the demographic and clinical variables, subjects in the control group, with 
neither CVD nor GI, NGT (-CVD) also differed significantly from the group that had 
both CVD and GI, GI (+CVD) in terms of HbAlc, both glucose and insulin, fasting 
and 2 hour levels, and indices of insulin sensitivity. Though the NGT groups did not 
differ significantly for their mean HbAlc values, the mean HbAlc value for the NGT 
(+CVD) group was within the range that identifies individuals at increased risk of 
developing CVD (Jesudason et ah, 2003). Also, except for the two hour plasma 
insulin and glucose level, the NGT (+CVD) group did not differ with the GI (+CVD) 
groups for all the other variables tested.
Amongst the groups, the HOMA-S and the ISI-GLY were matched for 3 groups 
except for the control group without GI or CVD, NGT (-CVD), which differed 
significantly with both GI groups.
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4.4.3 Serum Hsp27 and anti-Hsp27 IgM and IgG levels
GI subjects with CVD had the highest serum Hsp27 concentrations, significantly 
higher than the GI (-CVD) group [3.83 (1.92-4.85) vs 1.42 (1.01-2.65) ng/ml, 
p=0.03], the NGT (-CVD) group [3.59 (1.80) vs 2.15 (1.41) ng/ml, p=0.02] and the 
NGT (+CVD) group [3.83(1.92-4.85) vs 1.62(0.90-2.28) ng/ml, p=0.04], Fig.4.2. 
The serum Hsp27 concentrations for the GI (-CVD) and NGT (+CVD) groups were 
not significantly different with the control NGT (-CVD) group.
There was a trend to a lower serum Hsp27 IgM antibody concentration for both CVD 
groups compared to corresponding groups without CVD, though statistical 
significance was not attained. Statistical significance however, was reached when 
comparing the GI (+CVD), with the NGT (-CVD) group [0.29 (0.11) vs 0.42 (0.18), 
p=0.02], Fig 4.3(a).
No obvious trend or statistical significance was found with regards to serum Hsp27 
IgG antibody levels among the groups, Fig.4.3(b). Only borderline significance was 
achieved in the GI group, with GI (+CVD) subjects having higher antibody levels 
compared to those in the GI (-CVD) group, [0.16 (0.11-0.30) vs 0.11 (0.04-0.21),
p=0.06].
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Fig.4.2. Scatter plot of the distribution of serum Hsp27 antigen concentrations in 
individuals with normal glucose tolerance (NGT) and glucose intolerance (GI) with and 
without established cardiovascular disease (CVD).
Serum Hsp27 in the GI (+CVD) group was significantly higher compared to the GI (-CVD) 
group [3.83 (1.92-4.85) vs 1.42 (1.01-2.65) ng/ml, p=0.03], the NGT (-CVD) group [3.59 
(1.80) vs 2.15 (1.41) ng/ml, p=0.021 and the NGT (+CVD) group [3.83(1.92-4.85) vs 
1.62(0.90-2.28) ng/ml, p=0.04].
Horizontal lines represent the median o f the distribution. Comparison between GI (+CVD) 
group with the NGT (-CVD) group was performed using the unpaired t-test while other 
comparisons were performed using the Mann-Whitney test and p-values are shown for 
significant results.
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Fig.4.3. Scatter plots of the distribution of serum (a) IgM and (b) IgG in individuals 
with normal glucose tolerance (NGT) and glucose intolerance (GI) with and without 
established cardiovascular disease (CVD).
With unpaired t-test, it was found that there was significantly lower IgM antibody levels in 
the GI (+CVD) group compared to the NGT (+CVD) group, [0.29 (0.11) vs 0.42 (0.18),
p=0.02].
With Mann-Whitney test, it was found that anti-Hsp27 IgG antibody level was higher, 
borderline significance, in the GI (+CVD) group compared to that in the GI (-CVD) group, 
[0.16 (0.11-0.30) vs 0.11 (0.04-0.21), p=0.06]
Horizontal lines represent the median for the distribution.
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4.4.4 Correlation analysis between Hsp27, anti-Hsp27 IgG, IgM antibodies and 
clinical and biochemical variables
Spearman’s Rank correlation analysis was carried out to investigate the relationship 
between serum Hsp27 antigen, its IgM and IgG antibodies with other biochemical 
variables and the results reported in Table 4.2. It was found that Hsp27 was 
positively associated with the FPG values when all the groups were combined 
(r=0.28, p=0.03). In the CVD groups, serum Hsp27 concentrations were positively 
correlated with the 2hPG values (r=0.42, p=0.04). For the groups combined, the IgM 
concentrations were inversely related to fasting insulin concentrations (r=-0.30, 
p=0.02) and the 2 hour insulin level (r=-0.29, p=0.03). The IgM level was also 
associated with the insulin sensitivity indices HOMA-S (r=0.28, p=0.03), and ISI-gly 
(r=0.27, p=0.04), but these associations were lost when fasting insulin was the 
control variable in a partial correlation analysis. For the CVD groups, the IgG level 
was positively associated with the FPG values (r=0.37, p=0.04). Though CVD 
subjects were significantly older than their non-CVD counterparts there was no 
correlation between age and Hsp27 and its IgM and IgG antibodies. Neither was 
there a relationship between BMI and Hsp27 or its IgM and IgG antibodies.
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Table 4.2. Summary of Spearman’s rank correlation analysis between Hsp27, IgM, IgG 
and associated variables for all groups combined and CVD groups.
All Groups Combined CVD Groups Only
Correlation . Correlation ,
rv- . , p-value rr . . p-valuecoefficient r  coefficient r
Hsp27 antigen
FPG 0.28 0.03
2hPG
H sd27 Is M
Fasting Insulin -0.30 0.02
2 Hour Insulin -0.29 0.03
HOMA-S 0.28 0.03
ISI-Gly 0.27 0.04
Hsd27 IgG
FPG
Key, FPG: Fasting Plasma Glucose; 2hPG, 2 hour Post Glucose; HOMA-S, Homeostasis 
Model Assessment of Sensitivity; ISI-gly: Insulin Sensitivity Index for glycaemia.
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4.4.5 Relationship between Hsp27 and clinical and biochemical variables
Stepwise multiple linear regression analysis was used to investigate the relationship 
between Hsp27 concentrations and the clinical and biochemical data obtained in this 
study. Categorical variables such as gender, presence of CVD and glucose 
intolerance were coded dichotomously. From the analysis, it was found that the 
association between FPG and Hsp27 concentrations remained the only significant 
relationship among the variables entered into the analysis (Table 4.3) and accounted 
for 8.1% of the variation in Hsp27 concentration.
From the above, adjustment of the Hsp27 concentration for FPG can be made using 
the following regression model using the unstandardised B coefficient;
Predicted Hsp27 concentration = 0.095 + 0.423(FPG)
Mean FPG values for NGT (+CVD) and GI -CVD and +CVD groups were not 
significantly different. It is therefore unlikely that FPG is a confounding factor in the 
comparison of means between the groups. After adjusting for the FPG values, the GI 
(+CVD) group Hsp27 concentrations remained significantly higher than that of the 
NGT (-CVD) group (p=0.02).
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Table 4.3 Fasting plasma glucose as a predictor of Hsp27 concentration from stepwise 
multiple linear regression analysis showing the unstandardised B and the standardised 
P coefficients.
Model B Standard Error of B P
Constant 0.095 1.270
Fasting Plasma 
Glucose 0.423 0.203 0.285
0.04
4.5 Discussion
In this study, it was proposed that Hsp27 concentrations may be associated with the 
presence of macrovascular complications in patients with insulin resistance and that 
the autoimmune response to Hsp27 may be enhanced as a consequence of this. The 
aim was to investigate the relationship between the levels of serum Hsp27 and its 
IgM and IgG antibody levels in individuals with different degrees of insulin 
resistance either with or without a concomitant history of CVD. It was found that 
serum Hsp27 concentrations were significantly higher, and Hsp27 IgM antibody 
titres were lower in individuals with a combination of GI and CVD, compared to 
subjects with either condition separately, or who had neither condition. IgG antibody 
levels also tended to be higher in the former group compared to individuals with GI 
only.
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4.5.1 Indices of insulin resistance do not differ significantly among the groups 
with either CVD or GI or both
The four groups included in the study were divided according to their glycaemic 
status and their medical history of CVD. Mean HbAlc of 5.7% for the NGT (+CVD) 
group was found to be not significantly different compared to levels in both GI 
groups. This value is in the range suggested to identify individuals at high risk to 
develop CVD and future diabetes (Jesudason et al., 2003). Serum glucose level is 
controlled mainly by the hormone insulin. In terms of serum insulin level, the GI 
groups only differed significantly with the NGT (+CVD) group for the 2 hr serum 
insulin level, whilst the fasting insulin level did not differ between the two GI groups 
and the NGT (+CVD) group. This suggests that the insulin levels in the NGT group 
with CVD were high enough to maintain a normal glycaemic status in this group in 
the fasting state. This seems to suggest the presence of insulin resistance in the NGT 
group with CVD and appears to be supported by their indices of insulin sensitivity 
which do not differ significantly with the GI groups for both HOMA-S and ISI-gly. 
The presence of insulin resistance is expected in the GI groups; however its 
suggested presence in the NGT (+CVD) presents the possibility that it may play a 
role in the development of CVD.
4.5.2 Higher serum Hsp27 in individuals with a combination of GI and CVD
The positive association of serum Hsp27 with FPG suggests that hyperglycaemia 
may be related to an increased cellular expression of Hsp27 followed by its 
subsequent release into the serum, thus accounting for the higher levels. The likely
cellular source of Hsp27 in this case could be the endothelial cells, since Hsp27 is 
constitutively expressed in many normal adult human tissues including endothelial 
cells of the vasculature (Ciocca et al., 1993; Portig et al., 1996). When 
hyperglycaemia occurs there is increased endothelial intracellular glucose 
concentration since glucose transport into these cells takes place by insulin- 
independent facilitated diffusion (Mueckler, 1994). In vitro studies also show that 
high ambient glucose concentration leads to increased intracellular reactive oxygen 
species (ROS) formation in endothelial cells (Giardino et al., 1996). When cells are 
unable to scavenge the ROS formed, the excess free radicals result in oxidative 
stress. The stress response then results in increased Hsp27 expression, as has been 
demonstrated in endothelial cells exposed to oxidative stress in vitro (Dreher et al., 
1995).
Thus, in glucose intolerant subjects with a history of CVD, hyperglycaemia may 
result in oxidative stress leading to the release of Hsp27 into the extracellular fluid 
causing higher serum Hsp27 levels in these individuals (Liao et al., 2000a; Vega et 
al., 2008). Since both groups of GI subjects had comparable fasting and 2 hour 
plasma glucose levels, one possible reason for the difference in serum Hsp27 
concentration is that endothelial cells of GI subjects without CVD may not be 
exposed to oxidative stress due to differences in antioxidant status (Atli et al., 2004; 
Bhatia et al., 2003; Ceriello, 2000; Ozdemir et al., 2005). The same explanation may 
also apply to the NGT (+CVD) group whose FPG level is also not significantly 
different with that of the GI (+CVD) group.
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The generation of free radicals, which leads to oxidative stress, has also been shown 
to cause endothelial dysfunction in vitro (Tesfamariam and Cohen, 1992) and 
endothelial dysfunction is a key feature in diseases like atherosclerosis and CVD 
(Victor et a l, 2009). The positive correlation observed between serum Hsp27 and 2 
hour post glucose for the CVD groups is in agreement with the concept that the 2 
hour post glucose concentration is an independent risk factor of CVD (Ceriello, 
2006), which has been suggested due to oxidative stress generated after a meal.
4.5.3 Lower anti-Hsp27 IgM antibody levels in individuals with a combination 
of G land CVD
Once released into the circulation, Hsp27 may be recognised by the immune system 
and elicit an autoimmune response. In GI subjects with a history of CVD, who had 
significantly higher serum Hsp27 levels compared to the control group of NGT (- 
CVD); the lower level of IgM antibodies seems to support the scenario that was 
found in the study done in the previous chapter i.e. that the released Hsp27 is cleared 
via the formation of IgM immune complexes which in the long term may cause the 
reduction of its level in the serum. Although significance is not achieved, the same 
trend of lower IgM is also observed in CVD patients who are normoglycaemic, NGT 
(+CVD). As mentioned earlier, with comparable HbAlc values within the GI groups, 
individuals with NGT (+CVD) may be exposed to periods of acute hyperglycaemia. 
This could occur since HbAlc is a measure of glycaemic control over an 8-20 week 
period, which could comprise of peaks and troughs. Peaks in glucose concentration 
could leading to oxidative stress (Marfella et ah, 2001), the resultant release of 
Hsp27 and finally, the consumption of IgM antibodies. The level of oxidative stress
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in the NGT (+CVD) group may not be as high as that found in the GI (+CVD) group, 
may be due to the lower glucose level as observed for the 2hPG, which maybe why 
the Hsp27 serum concentration in the NGT (+CVD) group is not significantly 
different with the NGT (-CVD) group, and thus no significance achieved either for 
the IgM level when compared with the NGT(-CVD) group.
The correlation found between insulin and IgM levels may be indirectly related to the 
acute response of insulin towards the high serum glucose and the IgM to high serum 
Hsp27. Once insulin is secreted into the blood to lower the serum glucose 
concentration, the period of acute oxidative stress is over. Hsp27 is released into the 
extracellular fluid and consumption of IgM occurs. Higher insulin levels would be 
required to facilitate glucose disposal in insulin resistant subjects, while the inverse is 
the case for insulin sensitive individuals. Thus in insulin sensitive individuals less 
consumption of antibodies means higher IgM level. The HOMA-S and the ISI-gly 
and were found to be positively associated with the IgM levels. Since serum insulin 
and glucose values are included in the calculation of both indices, this observation 
appears to support the mechanism explained above.
4.5.4 Higher anti-Hsp27 IgG antibody levels in individuals with a combination 
of GI and CVD
Sustained hyperglycaemia, as is the case in GI subjects, and the subsequent release of 
Hsp27, may lead to further production of IgG antibodies that are involved in the 
secondary adaptive immune response. Repeated exposure to released Hsp27 would 
lead to frequent production of the IgG antibodies and thus higher levels of this
antibody class in the circulation. Although only borderline significance was 
achieved, this trend is observed in GI subjects with CVD. The IgG class of 
antibodies can promote inflammation through the formation of immune complexes 
that can activate Fc receptors on mononuclear cells (Ravetch and Clynes, 1998). 
Considering that atherosclerosis is a chronic inflammatory disease (Ross, 1999), the 
higher IgG levels may also be involved in the accelerated development of 
macrovascular complications in GI subjects. The positive correlation observed 
between IgG levels and FPG in the CVD groups may be related to the positive 
association between the level of Hsp27 and FPG. This suggests that a higher Hsp27 
serum level leads to higher IgG levels, though it is not clear why an association 
between anti-Hsp27 IgG with the 2hPG was not observed.
An outline of the possible events as discussed above is presented in Fig.4.4.
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Fig.4.4. Outline of the possible events in which Hsp27 is induced and subsequently 
recognised by the immune system.
In hyperglycemia, glucose diffuses into the endothelial cells which are not dependent on 
insulin action for glucose transport. The increased intracellular glucose concentration leads 
to oxidative stress which causes induction of Hsp27 expression. Hsp27 subsequently gets 
released into the circulation and is recognized by the adaptive immune system. Anti-Hsp27 
IgM antibodies are depleted over time while anti-Hsp27 IgG antibody levels are increased 
with repeated exposure.
4.6 Lim itations of the study
The main lim itation o f  the study is the significantly different m ean age between m ost 
o f  the groups, w ith the CVD groups being older than the non-C V D  groups, in 
general. W ith regards to the results obtained in which Hsp27 was found to be 
significantly low er in all three groups com pared to the GI (+C V D ) groups, age 
should not be a confounding factor for several reasons. Firstly, a previous study has
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reported that age is inversely associated with serum Hsp27 levels (Kardys et al., 
2008) in a population of healthy controls. This implies that in this study, the NGT (- 
CVD) group with the lowest mean age should have the highest mean Hsp27, which 
was not the case in the study. Secondly, significantly lower Hsp27 level in the NGT 
(+CVD) group, which was was not significantly different in terms of age with the GI 
(+CVD) group, also suggests that results are valid with regards to the other groups 
which had significantly different mean age with the GI (+CVD) group. Finally, both 
the correlation analysis and the linear regression analysis have not found any 
relationship between age and Hsp27, thus supporting the reasoning that age does not 
influence the serum level of Hsp27 in the study groups used here.
4.7 Conclusion
In conclusion, serum Hsp27 was significantly higher and the autoantibody levels to 
Hsp27 were found to be altered in patients with established cardiovascular disease. 
IgM was significantly low whereas IgG was high in comparison to the controls. This 
study further supports the concept that oxidative stress is related with 
hyperglycaemia, insulin resistance and the development of macrovascular 
complications associated with these conditions. Hsp27 and its immune response may 
be a marker for abnormal glucose metabolism leading to cardiovascular diseases.
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Chapter 5
Serum Heat shock protein 27 antigen and antibody levels and their 
relation to the inflammatory markers CRP and ICAM-1
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5.0 Serum Heat shock protein 27 antigen and antibody levels and 
markers of inflammation
5.1 Introduction
The role of chronic inflammatory processes in atherogenesis is now well established 
(Hansson, 2001; Libby et ah, 2009; Ross, 1999). Immune cells, which include 
macrophages, T-cells and mast cells, involved in inflammation are present in the 
atheroma at every stage of disease progression. Proinflammatory mediators such as 
the proinflammatory cytokines interferon (IFN)-y, tumor necrosis factor (TNF)-a 
and interleukin (IL)-l have also been found in the atheroma (Hansson, 2001) and 
experiments with gene-targeted mouse models of atherosclerosis crossed with 
knockout mice lacking immunoregulatory genes have also shown the importance of 
inflammatory mechanisms in atherogenesis (Hansson, 2001; Smith and Breslow, 
1997).
Since inflammatory processes accompany all stages of atherosclerosis, measurement 
of serum concentrations of circulating inflammatory biomarkers have received great 
attention. These markers include adhesion molecules such as intercellular adhesion 
molecule (ICAM)-l, cytokines such as TNF-a and the acute phase protein, C- 
reactive protein (CRP) (Pearson et al., 2003).
ICAM-1 belongs to the group of cell-surface receptors that mediate the adhesion of 
cells to each other or to components of the extracellular matrix (Jang et al., 1994).
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During the inflammatory process, leukocyte recruitment to the sites of inflammation 
involves adhesion to molecules such as ICAM-1 on the endothelial surface (Carlos 
and Harlan, 1994), Fig. 5.1. Similarly, in atherosclerosis, one of the earliest 
detectable cellular responses in the formation of lesions of atherosclerosis is the focal 
recruitment of leukocytes (Faggiotto et al., 1984; Hansson, 2001), which is 
associated with the upregulation of adhesion molecule expression, such as ICAM-1 
(Nakashima et al., 1998). Several prospective studies have also suggested circulating 
soluble ICAM-1 as a potential biomarker for predicting CVD risk (Haim et al., 
2002; Tanne et al., 2002) and may serve as a marker for atherosclerosis (Hwang et 
a l, 1997).
CRP belongs to the pentraxin family of proteins and is produced by hepatocytes 
during acute phase inflammation in response mainly to the cytokine IL-6 and other 
cytokines such as IL-1 and TNF-a (Paffen and DeMaat, 2006), Fig.5.1. Several 
prospective clinical studies have independently shown that modest elevations in 
baseline CRP levels, as detected by high-sensitivity assays, can predict future 
cardiovascular events (Calabro et a l, 2009; Koenig et a l, 1999; Tsimikas et a l, 
2006). It has also been shown that elevated levels occur in patients with unstable 
angina (Berk et a l, 1990) and is associated with a poor prognosis for patients with 
unstable angina (Liuzzo et a l, 1994).
Regarding studies on oxidised low density lipoprotein (oxLDL); the putative antigen 
for atherosclerosis, it was found that serum oxLDL is positively correlated with CRP 
in individuals with subclinical atherosclerosis (Hulthe and Fagerberg, 2002). OxLDL 
antibody levels are also positively correlated to CRP levels in patients with CVD
(Doo et al., 2004). ICAM-1 was found to be positively associated with anti- ox-LDL 
IgG antibodies in hypercholesterolaemic subjects (Hulthe et al., 2001b) and patients 
with CVD (Doo et al., 2004).
Though Hsp27 has been suggested as a marker for atherosclerosis, no previous study 
has reported an association between Hsp27 and its antibodies with either CRP or 
ICAM-1. The aim of this study was therefore to explore the association of Hsp27 and 
its antibodies with the two aforementioned inflammatory markers, in the sample 
population of normal and glucose intolerant subjects.
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Fig.5.1. An overview of some key steps in the inflammatory cascade
Some of the key steps involved in inflammation are 1) Mononuclear cells are recruited to the 
site o f inflammation, chemotactically attracted by substances produced by resident 
macrophages in the inflamed tissue, e.g. the chemokine monocyte chemoattractant protein-1, 
(MCP-1). 2) Activated endothelial cells express adhesion molecules such as VCAM-1 and 
ICAM-1 to facilitate attachment of leucocytes to blood vessel walls. 3) Substances such as 
chemokines, e.g. MCP-1, in the inflamed tissue promote the migration o f leucocytes across 
the endothelial wall to the site of inflammation. 4) Monocytes differentiate into macrophages 
under the influence of cytokines such as macrophage colony-stimulating factor. 5) 
Macrophages produce proinflammatory cytokines such as IL-1, IL-6 and TNF-a 6) These 
cytokines are released into the circulation and 7) stimulate the liver to release acute phase 
reactants, such as CRP
143
5.2 Subjects
The study group that was used in the previous chapter (chapter 4) was also used in 
this study. Please refer to section 4.2 for details on subject classification and 
recruitment criteria.
5.3 Materials and Methods
5.3.1 Materials
Consumables, reagents and antibodies used for the Hsp27, anti-Hsp27 IgG and IgM 
ELISAs can be found in Chapter 2, sections 2.1.1 and 2.1.3 and buffers used in 
Appendix 1.
The ICAM-1 ELISA development kit was purchased from R&D systems, Abingdon, 
UK
The following refers to materials for the CRP ELISA:
Tween-20, bovine serum albumin and carbonate buffer and phosphate-citrate buffer 
tablets were purchased from Sigma-Aldrich, Poole, UK. Phosphate-buffered saline 
tablets were purchased from Oxoid Ltd, Hampshire, UK. The 96-well Maxisorp 
microtitre plate was purchased from Nunc, Fisher Scientific, Loughborough, UK,
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and the tetramethylbenzidine (TMB) substrate reagent pack was from R&D systems, 
Abingdon, UK.
Rabbit polyclonal anti-human CRP coating antibody (A0073), peroxidase-conjugated 
rabbit anti-human CRP antibody (P0227) and CRP standard (X0926) was obtained 
from Dakocytomation, Cambridgeshire, UK.
5.3.1.1 ELISA buffers
Please refer to Appendix 1 for buffers used for the CRP ELISA.
5.3.2 The Oral Glucose Tolerance Test (OGTT), blood collection and 
serum/plasma separation
The OGTT, blood collection and serum/plasma separation were performed as 
described in the previous chapter, section 4.3.2.
5.3.3 Routine biochemical analyses
All routine biochemistry screening tests were performed on an Advia 1650 auto­
analyser using commercial kits (Bayer reagent). Blood glucose was assayed using the 
principle of the glucose hexokinase enzymatic reaction (SLEIN et al., 1950). 
Cholesterol measurement was based on an enzymatic method utilizing cholesterol 
esterase (Allain et al., 1974). Triglycerides were measured using a method based on
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the Fossati three-step enzymatic reaction (Fossati and Prencipe, 1982). HDL- 
cholesterol was measured using a direct method using a colorimetric endpoint based 
on the Trinder reaction (Wamick et al., 1982). LDL-cholesterol was estimated by 
calculation from total cholesterol, HDL-cholesterol and triglycerides using the 
Friedewald formula (Friedewald et al., 1972). Uric acid measurement was based on 
an enzymatic reaction using uricase (Fossati et al., 1980). Hemoglobin A le was 
measured using ion exchange high-performance liquid chromatography; Biorad 
Variant II (Kondo et al., 1989).
5.3.4 Insulin sensitivity determination
Insulin sensitivity was determined as described in the previous chapter, section 4.3.3.
5.3.5 Determination of serum Hsp27 and anti-Hsp27 IgM and IgG
Serum Hsp27 and anti-Hsp27 IgM and IgG were analysed by ELISAs as described 
previously in Chapter 2, section 2.3.
5.3.6 Determination of serum CRP
Serum CRP was measured using a sandwich ELISA as follows.
A 96-well microtitre plate was coated with 50 pl/well of rabbit polyclonal anti­
human CRP (1:4000 in 0.1M carbonate-bicarbonate coating buffer pH 9.6) and 
incubated overnight at 4°C. Following overnight incubation, the plate was then
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washed 3 times with washing buffer (0.05% Tween 20 in PBS) and 200 fil of 
blocking buffer (1% BSA in PBS) was added. The plate was then incubated at 37°C 
for 1 hour. The plate was washed again 3 times and 50 pi of CRP standards (0.01 -  
900 ng/ml) and serum samples (dilution range; 1:200 -  1:3000) in sample dilution 
buffer was added. The plate was then incubated for 1 hour at 37°C. After 4 wash 
cycles, 50 pi of rabbit anti-human HRP- conjugated CRP antibody (1:2000 in 0.2% 
BSA) was added and incubation performed for 1 hour at 37°C. The plate was then 
washed 3x with 0.05% Tween20 in PBS, Ix with PBS and 2x with citrate-phosphate 
buffer (0.05M, pH 5.0). 50 pi of TMB substrate solution was then added and 
incubation done for 3 minutes. The reaction was stopped by the addition of 12.5 pi of 
2M HC1 and the absorbance of the plate read at 450 nm. The intra-assay CV was 4.4- 
8.3% and the inter-assay CV was 6-6.6%.
5.3.7 Determination of soluble ICAM-1
A 96-well microtitre plate was coated with 100 p 1/well of mouse anti-human ICAM- 
1 (4.0 pg/ml) antibody diluted in PBS and incubated overnight at room temperature. 
After overnight incubation, the plate was washed 3 times with washing buffer 
(0.05% Tween20 in PBS) and 300 pi of blocking buffer (3% BSA in PBS) was 
added. The plate was then incubated for 2 hours at room temperature.
The plate was washed again 3 times and 100 pi of ICAM-1 standards (31.25 -  2000 
pg/ml) and serum samples (dilution range; 1:200 -  1:400) diluted in blocking buffer 
was added. The plate was then incubated for 2 hours at room temperature. After 3 
wash cycles, 100 pi of biotinylated sheep anti-human ICAM-1 antibody (1:180 in
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blocking buffer) was then added and incubation performed for 2 hours at room 
temperature. The plate was then washed 3 times and then 100 pi streptavidin 
conjugated to HRP (1:200 in blocking buffer) was added. Incubation was then 
performed for 20 minutes. After washing the plate, 100 pi of TMB substrate solution 
was added and incubation performed for 20 minutes. The reaction was stopped with 
50 pi of 2M HC1 and the absorbance of the plate read at 450 nm. The intraassay and 
the interassay coefficient of variation were 5.2% and 5.4% respectively.
5.3.8 Statistical Analysis
Statistical analysis was undertaken with Graphpad Prism version 5.0 for Windows 
(Graphpad Software Inc, USA). For categorical demographic variables, differences 
were evaluated by the Fisher’s exact test for independence. Continuous variables 
were analysed by ANOVA, with post-hoc analysis using the Bonferroni multiple 
comparisons test. Data are reported as mean with standard deviation (SD). For 
analysis of inflammatory markers, comparison between groups for skewed data was 
performed using the Mann-Whitney test and data reported as median and inter­
quartile range about the median. Comparison between groups for normally 
distributed data was analysed using the t-test and data reported as mean with SD. 
Spearman’s rank correlation analysis was used to investigate the relationship 
between variables. Results were considered significant with p<0.05. The statistical 
test employed in each instance is indicated in the result figure legends.
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5.4 Results
5.4.1 Biochemical characteristics of study subjects
Demographic, clinical and biochemical (FPG, 2hPG, HbAlc, Fasting plasma insulin, 
2h plasma insulin and indices of insulin sensitivity) characteristics of study subjects 
have been described in the previous chapter and presented in Table 4.1. Table 5.1 
shows the lipid profile that includes total cholesterol, LDL-cholesterol, HDL- 
cholesterol and triglycerides, and urate status of study subjects. The four groups were 
matched in terms of their lipid profile apart for the significant difference in 
triglyceride levels between the NGT (-CVD) and the GI (+CVD) group. In addition, 
only the GI (-CVD) group differed significantly in its urate levels from the GI 
(+CVD) group, Table 5.1.
The mean HDL-cholesterol level was highest in the group without glucose 
intolerance and CVD, NGT (-CVD), and lowest in the group with glucose 
intolerance and CVD, GI (+CVD). The converse was true for triglycerides, which 
was lowest in the NGT (-CVD) group but highest in the GI (+CVD) group. The CVD 
groups had higher urate levels compared to their non-CVD counterparts, though 
significance was only achieved between the glucose intolerant groups.
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5.4.2 Serum CRP levels do not differ significantly among the groups while 
serum ICAM-1 levels differ significantly between the NGT groups
It was found that the serum CRP levels did not differ significantly among the four 
groups, Table 5.2 and Fig.5.2(a). Cut-off values for hs-CRP measurements have 
been recommended for assigning risk to developing CVD (Pearson et al., 2003). 
The mean serum CRP level for the NGT (-CVD) group was found to lie in the low 
relative cardiovascular risk range (<1 mg/1) category, whilst the mean CRP levels 
for the other three groups was in the average relative cardiovascular risk range 
(between 1 and 3 mg/1) category.
Meanwhile, the serum ICAM-1 level was significantly higher in the NGT (+CVD) 
group compared to the NGT (-CVD) group, [932 (671 -  1107) vs 694 (602 -  756) 
pg/ml, p=0.005], as shown in Table 5.2 and Fig.5.2(b). There was no significant 
difference in the ICAM-1 levels for other comparisons as shown in Table 5.2.
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Fig.5.2 Scatter plot of the distribution of (a) C-reactive protein and (b) ICAM-1, in 
individuals with normal glucose tolerance (NGT) and glucose intolerance (GI) with and 
without established cardiovascular disease (CVD).
There was no significant difference in the CRP levels between the four groups.
With Mann-Whitney test, it was found that the NGT (+CVD) group had significantly higher 
ICAM-1 level compared to the NGT(-CVD) group, p=0.005.
Horizontal lines represent the median of the distribution.
153
5.4.3 Association of inflammatory markers with other cardiovascular risk 
factors and Hsp27 parameters
To assess the relationship between CRP and ICAM-1 with demographic and clinical 
variables and Hsp27 parameters (Hsp27 and anti-Hsp27 IgM and IgG) in study 
subjects, a Spearman’s rank correlation analysis was performed, Table 5.3.
CRP showed a positive association with: BMI, systolic blood pressure, 3 lipid 
parameters (Total cholesterol, LDL-chol and Triglycerides) and 2 glucose parameters 
(HbAlc and 2hPG). Meanwhile, ICAM-1 was positively associated with weight, 
BMI, fasting insulin and anti-Hsp27 IgG.
Interestingly, both inflammatory markers show different associations with the 
variables but both are significantly correlated with each other.
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Table 5.3. Spearman’s rank correlation analysis between CRP and ICAM-1 with 
demographic and clinical variables and Hsp27 parameters for all subjects.
CRP ICAM-1
Age -0.09 (0.45) 0.19 (0.14)
Weight 0.14(0.26) 0.26 (0.04)
Body Mass Index 0.34 (0.005) 0.34 (0.007)
Systolic Blood Pressure 0.25 (0.04) 0.05 (0.70)
Total Cholesterol 0.41 (0.0005) 0.07 (0.61)
HDL-Cholesterol -0.04 (0.74) -0.20 (0.13)
LDL-Cholesterol 0.46 (0.0001) 0.08 (0.53)
Triglycerides 0.25 (0.04) 0.20 (0.11)
Urate 0.07 (0.58) -0.07 (0.59)
HbAlc 0.36 (0.003) 0.15 (0.26)
Fasting Plasma Glucose 0.19 (0.12) 0.19(0.13)
2h Plasma Glucose 0.30 (0.02) -0.02 (0.91)
Fasting Insulin 0.16(0.18) 0.26 (0.04)
2h Insulin 0.13 (0.32) 0.11 (0.43)
HOMA-S -0.20 (0.10) -0.21 (0.09)
ISI-gly -0.14(0.30) -0.15 (0.29)
Hsp27 0.12 (0.37) -0.22 (0.12)
IgM Hsp27 0.12 (0.35) -0.05 (0.72)
IgG Hsp27 0.11 (0.37) 0.28 (0.03)
C-reactive protein 0.36 (0.003)
Data are presented as the correlation coefficient (r), with the p value in brackets. Significant 
values are presented in bold type. Key: HDL: High density lipoprotein; LDL: Low density 
lipoprotein; HbAlc: Hemoglobin A le; HOMA-S: Homeostasis model assessment of 
sensitivity; ISI-gly: insulin sensitivity index for glycaemia;
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5.4.4 Association of Hsp27 and its IgG and IgM antibodies with cardiovascular 
risk factors and inflammatory markers
Spearman’s rank correlation analysis was used to investigate the possible 
relationship between Hsp27, its IgG and IgM antibodies with cardiovascular risk 
factors and inflammatory markers, Table 5.4. It was found that besides the 
associations observed in the previous study for glucose and insulin indices, there 
were no further significant associations found for other cardiovascular risk factors. 
The only exception was between Hsp27 IgG antibodies and ICAM-1, r=0.28, p=0.03. 
This association was also present when analysis was performed on the GI groups 
only, r=0.41, p=0.01, but not on the CVD groups, Table 5.5.
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Table 5.4 Spearman’s rank correlation analysis of Hsp27, its IgG and IgM antibodies 
with demographic and clinical variables
Hsp27 Hsp27 IgG Hsp27 IgM
Age -0.04 (0.97) 0.02 (0.87) -0.21 (0.09)
Weight 0.04 (0.76) -0.04 (0.75) -0.13 (0.30)
Body Mass Index 0.09 (0.49) -0.02 (0.85) -0.11 (0.37)
Systolic Blood Pressure 0.07 (0.63) -0.03 (0.80) -0.09 (0.45)
Total Cholesterol -0.03 (0.80) -0.07 (0.57) 0.14 (0.28)
HDL-Cholesterol -0.01 (0.95) 0.02 (0.86) 0.14 (0.26)
LDL-Cholesterol -0.10 (0.47) 0.03 (0.81) 0.20 (0.12)
Triglycerides 0.20 (0.14) -0.07 (0.58) -0.13 (0.30)
Urate 0.22 (0.12) 0.03 (0.85) -0.02 (0.89)
HbAlc 0.09 (0.51) -0.05 (0.68) -0.04 (0.77)
Fasting Plasma Glucose 0.28 (0.03) 0.17(0.18) -0.07 (0.56)
2h Plasma Glucose 0.25 (0.07) -0.12 (0.35) -0.02 (0.89)
Fasting Insulin 0.05 (0.72) 0.16(0.18) -0.30 (0.02)
2h Insulin 0.10(0.48) -0.01 (0.97) -0.29 (0.03)
HOMA-S -0.12 (0.37) -0.19(0.12) 0.28 (0.03)
ISI-gly -0.13 (0.37) 0.11 (0.43) 0.27 (0.04)
C-reactive protein 0.12(0.37) 0.11 (0.37) 0.12(0.35)
ICAM-1 -0.22 (0.12) 0.28 (0.03) -0.05 (0.72)
Data are presented as the correlation coefficient (r), with the p value in brackets. Bold text 
indicates significant associations. Key: HDL: High density lipoprotein; LDL: Low density 
lipoprotein; HbAlc: Hemoglobin A le; HOMA-S: Homeostasis model assessment of 
sensitivity; ISI-gly: insulin sensitivity index for glycaemia;
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Table 5.5 Association of ICAM-1 with anti-Hsp27 IgG between all study groups and 
their subsets.
Anti-Hsp27 IgG vs ICAM-1 Correlation coefficient p value
ALL GROUPS 0.28 0.03
GI (-CVD), GI (+CVD) 0.41 0.01
NGT (+CVD), GI (+CVD) 0.26 ns
Spearman’s Rank correlation analysis was performed to investigate the association between 
anti-Hsp27 IgG with ICAM-1 levels for all subjects in the study group and subsets within 
the study group. Significant values are indicated by bold type. Key: ns: not significant
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5.5 Discussion
In this study, it is proposed that Hsp27 and its IgG and IgM antibody levels might 
have a relationship with markers of inflammation, specifically CRP or ICAM-1. It 
was found that only the Hsp27 IgG antibodies had a relationship with ICAM-1 in the 
sample population studied.
5.5.1 Biochemical characteristics of study subjects
The subjects were matched for most of the lipid parameters except for triglycerides. 
Hypertriglyceridaemia is a risk factor for CVD and is also associated with insulin 
resistance (Koyama et al., 1997; Morrison and Hokanson, 2009). This relationship 
explains the significantly high levels of triglycerides found in the group with both 
CVD and GI compared to the NGT group without CVD.
Hyperuricaemia has been suggested to be related to atherosclerosis and CVD (Gaffo 
et al., 2009); a relationship that could explain the higher mean uric acid levels found 
for the CVD groups. However, significance was only achieved for the group with GI 
compared to the non-CVD group with GI, which could be due to the lower sample 
number for the NGT (+CVD) group.
5.5.2 Levels of inflammatory markers in study groups
There was no significant difference in the level of CRP among the study groups, 
though the mean CRP level for the NGT (-CVD) group tallies with the established
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CVD risk stratification guidelines for individuals with low risk to develop CVD 
(Bard et al., 2005). Since CRP may be raised in other inflammatory conditions 
besides CVD and has also been associated with inflammation in patients with insulin 
resistance (Pesta et al., 2000; Gabay and Kushner, 1999; Yudkin et al., 1999) this 
may explain why no significant difference in the CRP levels among the groups was 
observed.
The NGT (+CVD) group had the highest average ICAM-1 level compared to the 
other groups, and was significantly higher compared to the NGT group without 
CVD. Since atherosclerosis and CVD is associated with inflammation this result was 
not unexpected. Soluble adhesion molecules such as ICAM-1 have also been found 
to be associated with insulin resistance and may therefore explain why the mean 
ICAM-1 levels between the GI groups were not significantly different (Chen et al., 
1999b; Leinonen et al., 2003).
5.5.3 Association of Hsp27 and its IgG and IgM antibodies with cardiovascular 
risk factors and inflammatory markers
No further associations were found with cardiovascular risk factors, except for the 
positive correlation found between Hsp27 IgG antibodies and ICAM-1. Since 
previously Hsp27 IgG was found to correlate only with fasting plasma glucose (PPG) 
among all the variables tested in this study and ICAM-1 is not correlated with PPG 
therefore there are no potential confounders for this association. A few studies have 
suggested that oxidative stress leads to increase in ICAM-1 expression (Ksiazek et 
al., 2010; Roebuck, 1999) and oxidative stress induced by hyperglycemia has been
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implicated in increased circulating ICAM-1 levels (Ceriello, 2000; Ceriello and 
Motz, 2004). As was suggested in the previous study oxidative stress due to 
hyperglycemia may also cause the increase in Hsp27 expression leading to increased 
levels in the circulation leading to increased IgG production, which might explain the 
positive association found between ICAM-1 and anti-Hsp27 IgG, though there was 
no significant association found with the protein. A positive association was also 
found for ICAM-1 with IgG antibodies against oxLDL in patients with 
hypercholesterolaemia (Hulthe et al., 2001b).
When the study group was divided into different categories, a similar association was 
also found for the GI groups only. However, no association was found when only the 
CVD groups were analysed. Since glucose intolerance (diabetes mellitus and 
impaired glucose tolerance) are risk factors for the development of atherosclerosis, 
Hsp27 could be related to the inflammatory response in the early stages of 
atherosclerosis. It is not clear why there was no association found with the protein 
itself, which was also the case for a previous study which found no association 
between Hsp27 and ICAM-1 (Hardys et al., 2008).
The lack of association between Hsp27, its IgM and IgG antibodies and CRP found 
in this study is similar to that found in previous studies looking at healthy and Type 1 
diabetic subjects (Burt et al., 2009; Hardys et al., 2008). This could be due to the 
involvement of CRP further down the inflammatory process that no direct 
association was found with Hsp27 in this study, see Fig.5.1.
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5.6 Conclusion
Between the two inflammatory markers studied here, an association was only found 
between ICAM-1 and anti-Hsp27 IgG which is the main finding of this study. 
Previous studies have shown that oxidative stress can cause an upregulation of both 
ICAM-1 and Hsp27 and that ICAM-1 is an inflammatory marker for atherosclerosis. 
However, it is shown here for the first time that there is an association between 
ICAM-1 and the Hsp27 IgG antibody which might suggest that the autoimmune 
response to Hsp27 is related to inflammatory mechanisms in atherogenesis and 
probably in the early stages of disease pathogenesis.
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6.0 Serum Heat shock protein 27 antigen, its IgM and IgG antibody 
levels and markers of inflammation in relation to physical activity
6.1 Introduction
The next study was to investigate the immune response to Hsp27 in physically active 
individuals, compared to less active subjects, both of whom at adolescent age and 
therefore were unlikely to have significant atherosclerosis.
Previous studies have shown that the type and the degree of exercises both increases 
oxidative stress, which, in turn causes the generation of reactive oxygen species 
(ROS) which influences the expression of inflammatory markers including C- 
reactive protein (CRP) (Kasapis and Thompson, 2005; Majka et al., 2009). Athletes 
have also been reported to have better endothelial function than sedentary controls 
(Franzoni et al., 2004), although, prolonged, brisk exercise is still reported to 
transiently raise markers of endothelial activation, such as ICAM-1 and E-selectin in 
this group (Bartzeliotou et al., 2007). In the light of these studies it is hypothesized 
that intensive training alters the markers of inflammation, endothelial functions and 
autoimmunity in adolescent females.
ROS are generated during exercise from several sources including leakage from the 
electron transport chain. These ROS may cause cellular damage that may 
subsequently lead to lipid oxidation, protein dénaturation or DNA damage (Droge, 
2002). However, exercise is also reported to enhance the endogenous antioxidant
164
defences (Rousseau et al., 2006). For example, repeated episodes of aerobic exercise 
has been reported to induce the expression of antioxidant enzymes (Ji, 2002), and 
several studies have shown a relationship between extent of physical activity and 
plasma antioxidant concentrations (Dekany et al., 2006; Carlsohn et al., 2010). 
Furthermore Pialoux and his colleagues have reported that the intensity of exercise 
and exposure to hypoxia may have a cumulative effect on oxidative stress (Pialoux et 
al., 2006) and that though antioxidant defences are enhanced in elite athletes, there is 
an insufficient buffering capacity to counterbalance the over-production of free 
radicals during exercise (Pialoux et al., 2009).
The potential damaging effects of reactive oxygen species can be partially reversed 
by molecular chaperones, such as Heat shock protein 27 (Hsp27). Protection afforded 
by Heat shock proteins may be mediated by their involvement in the processes of 
protein renaturation, upregulation of cellular antioxidants such as glutathione and 
enhanced activity of antioxidant enzymes such as glucose-6-phosphate 
dehydrogenase, glutathione reductase and glutathione transferase (Ferns et a i, 2006; 
Preville et al., 1999).
The aim of this current study was to determine whether intensive exercise alters 
markers of inflammation, endothelial activation and autoimmunity by comparing 
adolescent female gymnasts, engaged in high physical activity with age-matched 
controls of sedentary girls. Using this young age group of subjects removed the 
potential confounding effects of existing vascular disease. The term intensive 
training/exercise refers to physical activity related to the average number of hours 
per day of gymnastic training which incorporates impact exercise including
evaluating jumping, tumbling and strength work. The specific objectives of this study 
were to to assess their serum levels of CRP, sICAM-1, Hsp27 antigen and its 
antibodies, and to determine their association with age, clinical data (height, weight 
and BMI), physical activity and inflammatory markers (CRP and ICAM-1).
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6.2 Subjects
Subjects were recruited as part of a three-year longitudinal investigation of the 
effects of exercise on peak bone mass (PBM) development as previously reported 
(Nurmi-Lawton et al., 2004). Twenty-five female gymnasts, 8-17 years of age were 
originally recruited from five athletics clubs in the South of England. The gymnasts 
were eligible to join the study if they trained > 10  h/week and regularly took part in 
competitions (at club regional level). Nineteen female healthy normally active 
controls were randomly recruited through the database of local General Practices 
(GPs) in Surrey, South England. Controls were involved in normal activities 
(including walking to school and PE classes) for an average of 5.6 ± 2.6 h/week 
(determined by a checklist), but not in sports requiring all year training at 
competition level.
Physical activity was estimated as previously described (Nurmi-Lawton et al., 2004). 
None of the subjects had evidence of acute infection, or inflammation at the time of 
recruitment, or at the time of blood sample collection. Each gymnast was matched to 
a non-active control, initially by age and then subsequently by pubertal age once 
Tanner staging had been completed and analysed (Nurmi-Lawton et al., 2004). The 
baseline data were collected between the months of October and December of the 
year for both gymnasts and controls.
Ethical approval was obtained from the SouthWest Surrey local research ethics 
committee, Guildford, Surrey, and from University of Surrey ethics committee.
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6.3 Materials and Methods
6.3.1 Materials
Consumable, reagents and antibodies for the Hsp27, anti-Hsp27 IgG and IgM 
ELISAs can be found in Chapter 2, sections 2.1.1 and 2.1.3 and buffers used in 
Appendix 1.
Consumables, reagents and antibodies for CRP and ICAM-1 ELISAs can be found in 
Chapter 5, section 5.3.1 and buffers used in Appendix 1.
6.3.2 Blood collection and serum separation
Blood samples were collected from both control subjects and gymnasts. Samples for 
control subjects were taken in the afternoon/early evening when they attended the 
University of Surrey Clinical Investigation Unit (CIU).
Collection of blood samples from the gymnast group was carried out before training 
began and not during competition week.
Blood samples were centrifuged at 3000g at room temperature to obtain serum. 
Serum was then separated from the cells and frozen at -80 °C until they were 
assayed.
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6.3.3 Determination of serum Hsp27 and anti-Hsp27 IgM and IgG
Serum Hsp27 and anti-Hsp27 IgM and IgG were analysed by ELISAs as described 
previously in Chapter 2, section 2.3.
6.3.4 Determination of inflammatory markers CRP and ICAM-1
Serum CRP and ICAM-1 were analysed by ELISAs as described previously in 
Chapter 5, sections 5.3.6 and 5.3.7.
6.3.5 Statistical analysis
Statistical analysis was performed using SPSS (version 15). Data are expressed as 
standard error of mean (SEM) unless otherwise stated. Normality of the distribution 
of variables was tested using the Kolmogorov-Smimov test, and parametric or non- 
parametric tests were applied accordingly. Comparisons of anthropometric and other 
data at baseline between gymnasts and controls were performed using independent t- 
tests or Mann-Whitney tests. Pearson’s correlation analysis was used to investigate 
the association between CRP, sICAM-1, Hsp27 antigen and antibody titres with 
demographic data and physical activity. A p<0.05 was considered to be statistically 
significant. The statistical tests employed for each data set is stated in the figure 
legend.
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6.4 Results
6.4.1 Demographic, clinical and physical activity characteristics of the study 
groups
The physical activity (PA) and clinical data: height, body mass index (BMI), weight 
and age of study subjects are shown in Table 6.1. As may have been expected the 
gymnasts showed higher (4 fold) physical activity compared to controls. Compared 
with healthy adolescent females, the gymnasts have a lower BMI and mean weight. 
These differences were statistically significant.
Table 6.1. Comparison of demographic and clinical data between control subjects and 
gymnasts.
Variable Controls (n=19) Gymnasts (n=25)
Age (y) 12.0 (0.5) 13.0 (0.7)
Height (m) 1.50 (0.03) 1.40 (0.02)
Weight (kg) 42.6 (3.1) 34.0 (1.4)**
BMI (kg/m2) 19.2 (0.8) 17.0 (0.3) **
PA (mins/wk) 304.0 (31.2) 1308.6 (38.1)***
Independent t-tests were used to compare Age and Height, while Mann-Whitney tests were 
used to compare Weight, BMI and PA between the groups. Data are presented as mean 
(SEM). Significance level, ** p<0.01, *** p<0.001.
Key: PA, physical activity; BMI, body mass index.
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6.4.2 Comparison of serum Hsp27 and anti-Hsp27 IgM and IgG levels and 
inflammatory marker levels in study subjects
It was found that there was no significant difference in the levels of serum Hsp27 and 
its autoantibodies between control subjects and gymnasts, Table 6.2. With regards to 
the inflammatory markers, there were contrasting results when comparing the two 
groups. CRP was significantly lower in gymnasts compared to control subjects, 
pO.OOl, and ICAM-1 was significantly higher in gymnasts compared to control 
subjects, p<0.01, Table 6.2.
Table 6.2. Comparison of Hsp27, its IgM and IgG autoantibodies and inflammatory 
markers between controls and gymnasts.
Variable Controls (n=l 9) Gymnasts (n=25)
Hsp27 (ng/ml) 7.0 (1.8) 7.1 (1.9)
Hsp27 IgM (Abs) 0.43 (0.06) 0.38 (0.03)
Hsp27 IgG (Abs) 0.14 (0.01) 0.13 (0.02)
CRP (mg/1) 1.38(0.19) 0.49 (0.03) ***
ICAM-1 (mg/1) 0.23 (0.01) 0.29 (0.02) -
Independent t-tests were used to compare Hsp27 IgM, Hsp27 IgG and ICAM-1, 
while Mann-Whitney tests were used to compare Hsp27 and CRP, between the 
groups.
Data are presented as mean (SEM). Significance level, **p<0.01, *** pO.OOl.
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6.4.3 Correlation analysis between Hsp27, anti-Hsp27 IgM and IgG antibodies 
and clinical and biochemical variables in study groups
Pearson’s correlation analysis was used to investigate the association between Hsp27 
and its autoantibodies with variables investigated in this study, for all subjects 
combined, Table 6.3, and for the 2 study groups separately, Table 6.4.
For all subjects, it was found that there was a significant association between Hsp27 
levels and age (r=0.47, p<0.05) and height (r=0.39, p<0.05). There was no significant 
association found for the IgM and IgG antibodies with any of the variables.
It was found that in gymnasts, there was no significant association between Hsp27 
and its autoantibodies with any of the variables, Table 6.4. However, in controls, 
significant positive associations were found between Hsp27 with age (r=0.60, 
p<0.05) and height (r=0.58, p<0.05), between Hsp27 IgM with physical activity 
(r=0.42, p<0.05) and between Hsp27 IgG with age (r=0.52, p<0.05). Additionally, a 
significant inverse association was found between between Hsp27 IgG with physical 
activity (r=-0.43, p<0.05).
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Table 6.3. Association of Hsp27, its IgM and IgG antibodies with demographic, clinical 
variables, physical activity and inflammatory markers for all subjects
Variable Hsp27 Hsp27 IgM Hsp27 IgG
Age (y) 0.47* -0.10 0.13
Height (m) 0.39* 0.03 0.18
Weight (kg) 0.22 -0.12 0.14
BMI (kg/m2) -0.12 -0.25 0.01
PA (mins/wk) -0.01 -0.01 -0.17
CRP -0.37 -0.12 -0.01
ICAM-1 -0.02 -0.04 -0.01
Pearson’s correlation analysis was used to analyse the relationship between Hsp27, its IgM 
and IgG antibodies with the variables listed above. Significant correlation, * p<0.05.
Key; BMI: body mass index, PA: physical activity, CRP: C-reactive protein, ICAM-1; 
intercellular adhesion molecule-1.
Table 6.4. Pearson’s correlation analysis between Hsp27, anti-Hsp27 IgM and IgG 
antibodies and clinical and biochemical variables for gymnasts and controls separately.
Variable
Gymnasts Controls
Hsp27 Hsp27IgM Hsp27 IgG Hsp27
'
i
l Hsp27 IgG
Age (y) 0.33 0.04 -0.13 0.60* -0.23 0.52*
Height (m) 0.37 0.15 -0.03 0.58 * -0.10 0.35
Weight
(kg)
0.22 0.21 -0.09 0.33 -0.35 0.30
P -0.02 0.26 -0.14 -0.17 -0.53 0.05
PA
(mins/wk) -0.10 0.17 -0.17 0.05 0.42* -0.43 *
CRP 0.55 0.15 0.33 -0.26 -0.25 -0.11
ICAM-1 0.48 0.13 0.14 -0.15 -0.08 -0.11
Key; BMI: body mass index, PA: physical activity, CRP: C-reactive protein, ICAM-1; 
intercellular adhesion molecule-1 
Significant correlation, * p<0.05
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6.5 Discussion
In this study, the effect of intensive training (>15 hours of gymnastic training per 
week for competitive events) was investigated, on serum Hsp27 and its antibody 
titres and its impact on markers of inflammation (CRP) and endothelial activation 
(ICAM-1).
It was found that there was no significant difference in Hsp27 and its autoantibody 
levels when comparing the control group and gymnasts. As mentioned earlier, 
physical activity has been found to cause the generation of ROS. However adaptative 
mechanisms involving antioxidant defense in response to increased ROS may not be 
solely reliant on Hsp27 expression. Thus, protective mechanisms in cells against 
oxidative stress may still be occurring without a significant difference in Hsp27 
levels found between the two groups.
For the inflammatory markers, the control group had significantly higher levels of 
CRP compared to gymnasts while ICAM-1 levels in the control group were 
significantly lower compared to gymnasts. Previous studies have reported lower CRP 
levels with increase in physical activity (Colbert et al., 2004; Geffken et al., 2001) 
which is consistent with the result obtained in this study. The precise mechanism of 
how exercise training reduces CRP levels is not well defined. However, a mechanism 
that is suggested to be involved is modification of the production of the cytokines, 
IL-1, IL-6 and TNF-a, which stimulate hepatic CRP production, from sites such as 
skeletal muscle (Gielen et al., 2003) and mononuclear cells (Smith et al., 1999). 
Higher ICAM-1 levels have also been associated with regular exercise (Baum et al..
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1994; Rehman et al., 1997), which could be due to the exercise-induced production 
of ROS which leads to upregulation of ICAM-1 expression (Ksiazek et ah, 2010; 
Roebuck, 1999; Traore et ah, 2007), which may account for the significantly higher 
ICAM-1 level in gymnasts.
In this study a positive association was observed between Hsp27 and age. This is in 
contrast to the study by Kardys et al which found an inverse correlation between 
Hsp27 and age (Kardys et al., 2008). The mean age for the study group in the study 
by Kardys et al was 61 years while in this study the mean age was 11 years. The 
significantly younger subjects selected for this study may not have yet undergone the 
age-related decrease in Hsp27 expression suggested in older individuals. The positive 
association observed in the adolescent group of adolescents between Hsp27 with age 
and height could suggest a developmental role for Hsp27 since Hsp27 has been 
suggested to regulate cell differentiation and cell growth (Ciocca et al., 1993; 
Mairesse et al., 1996).
When the 2 groups were analysed separately for association between Hsp27 and its 
IgM and IgG autoantibodies, a different pattern of relationships were observed with 
the variables investigated. In the control group, there was a contrasting relationship 
with physical activity, with the IgM autoantibody being positively associated and the 
IgG autoantibody being negatively associated with physical activity. This pattern of 
association could imply that the lower the physical activity the higher the oxidative 
stress. With no adaptive mechanism in place, as is present in individuals with regular 
exercise, reliance on Hsp27 expression for protection against oxidative stress may 
cause its induction. When Hsp27 is released into the circulation, as discussed in the
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previous chapter, leads to consumption and lower IgM antibodies and increased in 
production of IgG. However, it is not clear why no association was found with 
Hsp27 itself.
Meanwhile, there was no significant association found in the gymnast group between 
Hsp27 parameters and all variables investigated, specifically physical activity. 
Despite a significantly higher level of ICAM-1 in gymnasts compared to controls, 
this finding could imply that gymnasts are utilizing Hsp27-expression independent 
antioxidant systems in response to oxidative stress, such as the antioxidant enzyme 
superoxide dismutase (SOD). SOD is reported to be increased in response to exercise 
(Berzosa et al., 2011; Pushpalatha et al., 2007; Rush et al., 2003), and thus is a likely 
candidate for this protective response.
6.6 Conclusion
Hsp27 and its autoantibodies are not significantly different in young active 
individuals compared to their less physically active peers. However, different 
relationships are observed between Hsp27 autoantibodies with physical activity 
between the two groups.
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7.0 Effect of exogenous Hsp27 on macrophage basal cytokine 
production
7.1 Introduction
Heat shock proteins (Hsps) represent a group of proteins whose increased expression 
in cells exposed to stress such as heat, has been shown to protect the cells from the 
damaging effects of such stress. Stress also leads to the release of Hsps into the 
extracellular space where they can interact with adjacent cells or enter the circulation 
(Bassan et al., 1998; Hightower and Guidon, Jr., 1989; Hunter-Lavin et al., 2004; 
Liao et al., 2000b). Once outside the cells, Hsps have been found to stimulate both 
the innate and adaptive immune response, probably by molecular mimicry 
(Calderwood et al., 2007). In the innate immune response, various studies have 
shown the pro-inflammatory effect of Hsp60 and Hsp70 when monocytes, 
macrophages and dendritic cells are treated with these proteins (Asea et al., 2000; 
Asea et al., 2002; Chen et al., 1999c; Flohe et al., 2003; Kol et al., 2000). These 
studies have shown that Hsp60 can stimulate macrophages and dendritic cells to 
produce the pro-inflammatory cytokine tumour necrosis factor (TNF)-a, and 
similarly Hsp70 was shown to induce production of the proinflammatory cytokines 
TNF-a, interleukin-1 (IL-1) (3 and IL-6.
Hsp27 belongs to the small HSP protein family and has been shown to perform a 
variety of protective functions in the cell. Intracellular protective functions ascribed 
to Hsp27 include; molecular chaperone function, providing increased resistance to
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cells against oxidative stress, control of F-actin cytoskeletal integrity and providing 
increased cellular resistance to apoptosis (Arrigo, 2000; Bryantsev et al., 2007; 
Mounier and Arrigo, 2002; Preville et al., 1999). Hsp27 can also be found 
extracellularly and serum Hsp27 and its autoantibodies were found to be increased in 
patients with acute coronary syndrome (Ghayour-Mobarhan et al., 2008; Shams et 
al., 2008; Park et al., 2006). In the coronary arteries, Hsp27 is expressed in the 
smooth muscle and endothelial cells of the arteries (Robinson et al., 2010) and in 
diseased arteries, there was increased expression of Hsp27 in areas near to the plaque 
core (Park et al., 2006).
In tissues, macrophages play an important role in the inflammatory response and are 
the predominant immune cells found in the atherosclerotic plaque (Jonasson et al., 
1986). Depending on the stimulating signals, macrophages can be activated to 
produce proinflammatory cytokines such as TNF-a or anti-inflammatory cytokines 
such as IL-10 (Hansson, 2001; Mosser, 2003). It is suggested that a ‘macrophage 
balance’ exists in atherosclerotic plaques which can be tipped to be proatherogenic or 
antiatherogenic depending on the environmental signals (Mantovani et al., 2009).
Lipopolysaccharide (TPS), also known as endotoxin, is a constituent of the outer 
membrane of the cell wall of Gram-negative bacteria. It is a complex glycolipid 
composed of a hydrophilic polysaccharide region and a hydrophobic domain known 
as lipid A, that is responsible for most of the LPS-induced biological effects 
(Schletter et al., 1995). Recognition of TPS is a key event in host antimicrobial 
defence reactions. TPS elicits its responses through stimulation of host cells such as 
monocytes and macrophages to produce and release endogenous mediators including
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the proinflammatory cytokines IL-1, IL-6 and TNF-a (Schletter et al., 1995). For 
many cell types, this involves binding of LPS through a receptor complex, which 
consists of Toll-like receptor (TLR)4, CD 14, and MD2 (Kawai et al., 1999; Poltorak 
et al., 1998). Formation of this complex on the cell surface leads to intracellular 
activation of transcription factors such as NF-kB (Mackman et al., 1991). Besides 
production of proinflammatory cytokines, LPS has also been shown to stimulate 
monocytes and macrophages to produce the anti-inflammatory cytokine, IL-10 
(Chanteux et al., 2007), the release of which was found to be mediated via another 
transcription factor, the Spl transcription factor (Brightbill et al., 2000; Chanteux et 
a l, 2007).
In our study Hsp27 was found to be increased in patients with established CVD, 
which we have speculated to be released from the arterial endothelium (Pengiran 
Burnt et al., 2010a). Hsp27 has also been shown to be expressed in atherosclerotic 
plaques (Park et a l, 2006; Robinson et a l, 2010) which comprise macrophages as 
the principal immune cell (Jonasson et a l, 1986). The aim of this study was to 
investigate whether Hsp27 has pro or anti-inflammatory effects on macrophages 
under in vitro conditions by investigating the production of the inflammatory 
cytokine, TNF-a, and the anti-inflammatory cytokine IL-10 by macrophages exposed 
to Hsp27.
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7.2 Materials and methods
7.2.1 Materials
J774.2 murine macrophages were obtained from the European Collection of Cell 
Culture (ECACC, Sigma). These cells were isolated from a tumour that arose in 
BALB/c mouse and do not synthesize apoE (Kruth, 2001; Ralph and Nakoinz, 1975).
Low endotoxin (<50 EU/mg purified protein by Limulus amebocyte lysate test) 
recombinant human Hsp27 was obtained from Cambridge Bioscience, UK. 
Dulbecco’s modified Eagle’s medium (DMEM), foetal calf serum (ECS), penicillin, 
streptomycin and glutamine were obtained from Gibco-Invitrogen, UK, TNF-a and 
IL-10 ELISA kits were obtained from PeproTech EC Ltd, UK, CellTiter 
96® AQueous One was obtained from Promega, UK. E. coli Lipopolysaccharide (LPS) 
was obtained from Sigma, UK.
Mouse seroblock FcR antibody, rat anti-mouse CD1 lb-RPE and rat IgG2b-RPE were 
obtained from AbD Serotec, UK. Mouse anti-mouse TLR2-Alexa 647 and mouse 
IgGl-Alexa 647 were obtained from BioLegend, UK. Mouse anti-mouse TLR4- 
Alexa 488 and mouse IgGl-Alexa 488, anti-mouse functional grade purified TLR2 
and anti-mouse functional grade purified TLR4 were obtained from eBioscience, 
UK.
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7.2.3 Murine macrophage (J774) cell culture
Murine macrophage cell lines were cultured in DMEM supplemented with 10% (v/v) 
PCS, (penicillin (100 U/ml), streptomycin (100 pg/ml) and glutamine (2mM). Cells 
were maintained at 37°C in 5% CO2 atmosphere. Media was replaced every 2 days. 
The cells were passaged when 95% confluence was reached.
7.2.4 Cell count for seeding of macrophage J774 cells
Adherent cells were detached from the flask manually using a cell scraper. The 
contents of the flask were collected into a 50 ml universal tube and the tube was 
centrifuged at 400x g for 5 minutes. The supernatant was discarded and the pellet 
resuspended in 2 ml of prewarmed media by gentle pippetting. A 2 pi aliquot of cell 
suspension was mixed with 50% Trypan Blue (18 pi). A 10 pi aliquot of this mixture 
was then removed and loaded onto a haemocytometer for cell counting, see Fig. 7.1.
The four comer squares of the counting chamber were used to count viable cells. 
Viable cells appeared colourless while non-viable cells were stained blue, since 
Trypan Blue readily enters dead cells. Each of the comer square has a volume of 10"4 
cm3; therefore cell counts are calculated as the average number of viable cells/ml per 
corner square,
= total number of cells counted for all comer squares x 104 /4 x dilution factor (0.1)
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Fig.7.1 Diagrammatic representation of a haemocytometer
The pink coloured square is one of the corner squares of the chamber where the cells are 
counted. The total volume of the comer square is 10"4 cnT and since 1 cm3 = 1 ml, cells 
counted in the pink area are multiplied by 104 to give the number of cells/ml.
7.2.5 Production of TNF-a and IL-10 by macrophages stimulated with Hsp27
J774.2 cells were seeded at a density o f  1 x 106/m l into a flat-bottom  96-well plate 
(200 p 1/we 11) for ELISA and 24-well plate (500 pl/w ell) for flow  cytom etry. A fter 
incubation at 37°C in a hum idified, 5% CO? incubator for 18 h, m acrophages w ere 
treated w ith increasing concentrations o f  low endotoxin recom binant hum an Hsp27 
(0.03 -  4.0 pg/m l) and untreated cells w ere used as negative controls. Cells w ere also 
treated with E. coli LPS, 2 ng/m l for T N F -a production, and 500 ng/ml for IL-10 
production, by m acrophages, as positive controls. At the end o f  each treatm ent period 
(4, 8, 12 or 24 hrs) the contents o f  each well w ere collected and centrifuged at 400x g 
for 10 mins. The supernatant was rem oved for analysis o f  T N F -a and IL-10 by
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ELISA while the pellet was used for flow cytometry analysis. Each treatment was 
performed in triplicates and the experiment repeated 3 times.
7.2.6 The effect of pretreatment of macrophages with Hsp27 on LPS stimulation 
of macrophage IL-10 production
J774.2 cells were seeded at a density of 1 x 106/ml into flat-bottom 96-well plates 
(200 pi/ well). After incubation at 37°C in a humidified 5% CO2 incubator for 18 h, 
macrophages were pretreated with 2 pg/ml of Hsp27. After 30 mins, various 
concentrations of LPS (62.5 -  500 ng/ml) were added into appropriate wells. 
Untreated cells were used as negative controls. After 8 hours of incubation the 
supernatant was removed for measurement of IL-10 production.
7.2.7 Blocking of macrophage cell-surface TLR2 and TLR4
J774.2 cells were seeded at a density of 1 x 106/ml into a flat-bottom 96-well plate 
(200 pi/ well). After 1 hour, cells were incubated with 15 pg/ml of anti-mouse TLR2 
and anti-mouse TLR4 monoclonal antibodies (mAbs). After an overnight incubation 
at 37°C in a humidified 5% CO2 incubator, 1.0 pg/ml of Hsp27 was added into 
appropriate wells. Incubation was then continued at 37°C and 5% CO2 for a further 8 
hours. The supernatant was collected for measurement of IL-10 production by 
ELISA.
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7.2.8 Measurement of TNF-a by ELISA
The amount of TNF- a released into culture supernatants was determined by a 
sandwich ELISA. A 96-well plate was coated with 50 pi goat anti-mouse TNF-a 
mAh (1 pg/ml) and incubated overnight at 4°C. The plate was then washed 4 times 
with washing buffer (0.05% Tween20 in PBS) and blocked with 200 pi of 5% goat 
serum in PBS for 2 hours at room temperature. The plate was then washed four 
times with washing buffer and 50 pi of serially diluted TNF-a standards (31.3 -  2000 
pg/ml) and undiluted supernatants were added into appropriate wells. Incubation was 
carried out for 2 hours at room temperature and then the plate washed four times. 
Then, 50 pi of goat anti-mouse biotinylated mAh diluted 1:1000 (0.1 pg/ml) in 
blocking buffer was added into each well. The plate was incubated for 1.5 hrs at 
room temperature. After 4 washes with washing buffer, the samples were incubated 
for 30 minutes at room temperature with 50 pi peroxidase-conjugated avidin (using a 
1:2000 dilution in blocking buffer) and subsequently washed 4 times. Then, 50 pi of 
TMB substrate was added and the plate was incubated in the dark for 15 minutes to 
allow colour development. The reaction was stopped by adding 50 pi 2 M HC1 and 
the plate read at 450 nm using a plate reader (Multilabel Counter VICTOR model 
1420 from PerkinElmer, UK).
7.2.9 Measurement of IL-10 by ELISA
The amount of IL-10 released into culture supernatants was determined by sandwich 
ELISA. A 96-well plate was coated overnight at 4°C with 50 pi of rabbit anti-mouse 
IL-10 mAb (2 pg/ml). The plate was then washed 4 times with 0.05% Tween20 in
185
PBS and blocked with 200 pi of 3% BSA in PBS for 1.5 hours at 37°C followed by 
30 minutes at room temperature. The plate was then washed four times with washing 
buffer and 50 ul of serially diluted IL-10 standards (46.9 -  3000 pg/ml) and undiluted 
supernatants were added into appropriate wells. Incubation was carried out for 2 
hours at room temperature and then the plate washed four times. Then, 50 pi of 
rabbit anti-mouse biotinylated mAb diluted 1:600 (0.17 pg/ml) in blocking buffer 
was added into each well. The plate was incubated for 1 hr at room temperature. 
After 4 washes with washing buffer, the samples were incubated for 30 minutes at 
room temperature with 50 pi of peroxidase-conjugated avidin diluted 1:2000 in 
blocking buffer and subsequently washed 4 times. Then, 50 pi of TMB substrate was 
added and the plates were incubated in the dark for 15 minutes to develop the colour. 
The reaction was stopped by adding 50 pi 2 M HC1 and plate was read at 450 nm 
using a plate reader.
7.2.10 Cell viability assay
7.2.10.1 Principle of the method
Cell viability was determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay. The CellTiter 96® AQueous One Solution Reagent contains a 
tétrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- 
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazine ethosulfate; PBS). PBS has enhanced chemical stability, which allows it 
to be combined with MTS to form a stable solution. Assays are performed by adding 
a small amount of the CellTiter 96® AQueous One Solution Reagent directly to culture
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wells, incubating for 1-4 hours and then recording absorbance at 490nm with a 96- 
well plate reader. The quantity of formazan product as measured by the amount of 
490nm absorbance is directly proportional to the number of living cells in culture.
7.2.10.2 Protocol
4774.2 cells were seeded at a density of 1 x 106/ml into a flat-bottom 96-well plate 
(200 pi/ well). After incubation at 37°C and 5% CO2 for 18 hours, macrophages were 
treated with increasing concentration of low endotoxin recombinant human Hsp27 
(0.03 -  2.0 pg/ml) with untreated cells as negative controls. All cells were incubated 
for 8 hours, then 40 pi of CellTiter 96® AQueous One Solution Reagent was added into 
each well. Plates were incubated for 4 hours in a humidified 5% C02 atmosphere 
incubator. After 4 hours, absorbance was read at 490 nm.
7.2.11 Detection of macrophage cell surface expression of TLR2 and TLR4 by 
flow cytometry
7.2.11.1 Principle of the flow cytometry method
Flow cytometry was performed to investigate the expression of TLR2 and TLR4 on 
the surface of the murine macrophage cells. This method uses the principles of light 
scattering, excitation of, and emission from fluorochrome molecules to generate 
specific multi-parameter data from particles and cells in the size range of 0.5 pm to 
40 pm diameter. Cells are labelled with mAbs conjugated to fluorescent dyes which 
in this study were R-Phycoerythrin (RPE), Alexa Fluor® 488 and Alexa Fluor® 647.
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When labelled cells are passed through a light source in a single cell suspension, the 
fluorescent molecules are excited to a higher energy state. Upon returning to their 
resting states, the fluorochromes emit light energy at higher wavelengths. The light 
signals are detected by photomultiplier tubes and digitized for computer analysis.
7.2.11.2 Protocol
The pellet obtained at the end of the cell treatments (see 7.2.5) was mixed with 1 ml 
of staining buffer (1% BSA, 0.05% sodum azide in PBS), the cells were counted, and 
the numbers adjusted with staining buffer to obtain a final density of 1 x 106/ml of 
cells. Cells were then incubated with 1 pg of Seroblock (rat anti-mouse CD16/CD32 
mAbs for blocking FcyRIII and II respectively) for 15 minutes on ice. At the end of 
the incubation, 100 pi of cell suspension (1 x 105 cells) was aliquotted to a new tube 
and 0.8 pi of mouse anti-mouse-TLR4-Alexa Fluor 488, 0.8 pi of mouse anti-mouse 
TLR2 Alexa Fluor 647 and 2 pi of rat anti-mouse CD1 lb-RPE mAbs were added to 
each tube. Unlabelled cells and isotype-matched antibodies were used as negative 
controls. Isotype controls are antibodies with no specificity for the cells in question, but 
with all the non-specific characteristics of the antibodies used in the experiment. The 
isotype control used here were rat IgG2b-RPE, mouse IgGl-Alexa Fluor 647 and mouse 
IgGl-Alexa Fluor 488. Cells were incubated with antibodies or isotype controls for 30 
mins on ice. At the end of the incubation, 2 ml of washing buffer (0.5% BSA, 0.05% 
sodum azide in PBS) was added into each tube and the mixture centrifuged at 400 g 
for 5 mins at 4°C. The supernatant was then discarded and 300 pi of fixative solution 
[1% formaldehyde diluted in staining buffer] was added to the cell pellet. The whole
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preparation was then covered to protect from light and stored in the dark at 4°C until 
time for analysis using the BD FACS Canto flow cytometer (BD Biosciences, U.K.).
Samples were analysed for Alexa Fluor 488 (excitation X at 488 nm and emission X 
at 519 nm) PE (excitation X at 488 nm and emission X at 578 nm) and Alexa Fluor 
647 (excitation X at 488 nm and emission X at 668 nm) using BD FACS Canto 
(Becton Dickinson) and BD FACSDiva software (version 5.03. 2007).
7.2.11.3 Gating strategy to select C D llb +TLR2+ and C d llb +TLR4+ 
macrophages
Cells were initially gated depending on their morphological structure using forward 
versus side scatter (FCS-H vs. SSC-A) dot plots, excluding aggregated cells and 
debris from the gating sample, Fig. 7.2. The above selected population was then 
analysed using FSC-H vs CDllb-PE dot plot, and the C D llb+ population 
(P2 CD1 lb+) was selected, and later displayed on histograms either for TLR2-Alexa 
Fluor 647 or TLR4-Alexa Fluor 488, Fig.7.2. Negative controls, unstained cells and 
those stained with fluorescently labelled isotype antibodies (with the same 
fluorochrome as their matching antibodies) were used to set up the quadrants for 
each marker. Then from this population, cells co-expressing C D llb+TLR2+ or 
CD1 lb+TLR4+ were selected.
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Fig.7.2 Gating strategy to select CD1 lb +TLR2+ and C D llb  TLR4 macrophages
Events (20,000) were acquired per sample. To select for macrophages, from debris and dead 
cells, an untreated cell population was used and a region was drawn around the main cell 
population (PI) based on their morphological properties using side scatter (SSC-A) 
versus, forward scatter (FSC-H). The selected region was then applied to a dot plot 
combining forward scatter versus C D llb-PE  (FSC-H versus C D llb-PE ) and the C D llb f 
population (P2) was selected and subsequently analysed on histograms (Number o f cells vs. 
TLR2-Alexa Fluor 647 intensity or Number of cells vs TLR4-Alexa Fluor 488 intensity). 
The quadrants were set up using unstained cells and isotype controls (negative controls) for 
CD1 lb, TLR2 and TLR4 antibodies.
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7.2.12 Statistical analysis
Statistical analysis was done using Graphpad Prism version 5.0 for Windows 
(GraphPad Software Inc, USA). Data are presented as mean ± standard error of the 
mean (SEM). Comparison between two groups was performed using the Student’s t- 
test and comparison between more than two groups by a one-way ANOVA with 
post-hoc Bonferroni’s correction applied. Results were considered significant at p < 
0.05. The statistical tests employed for each data set are described in the figure 
legends where necessary.
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7.3 Results
7.3.1 Effect of Hsp27 on the production of TNF-a by macrophages over a 48- 
hour time period
M urine m acrophages w ere treated w ith increasing concentration o f  H sp27 (0.1 -  4 
pg/m l) for 4, 8, 12, 24 and 48 hours and T N F -a production w as m easured at these 
specified tim e points. There w as spontaneous production o f  T N F -a in untreated 
m acrophages as been found previously (Takasuka et ah, 1995). W ith treatm ent o f  
m acrophages w ith Hsp27, it was found that there w as no significant difference in 
T N F-a production betw een H sp27-treated and untreated cells at any o f  the tim e 
points tested, Fig. 7.3.
Control
H sp27 0.1 ng/ml 
H sp27 1 pg/m l 
- V -  H sp27 4  pg/ml
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Fig.7.3 Time-course experiment to investigate the production of TNF-a by 
macrophages at different concentrations of Hsp27 over a 48-hr period.
Macrophages were treated with FIsp27 (0.1, I and 4 pg/ml) over a 48-hour time period. 
Supernatant was removed at 4, 8, 12, 24 and 48 hours and analysed for TNF-a by ELISA. 
Using ANOVA, it was found there was no significant difference in TNF-a production 
between untreated (control) and Hsp27 treated cells at all time points tested. All conditions 
were done in triplicates and repeated 3 times. Results are representative o f 3 experiments.
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7.3.2 Effect of Hsp27 on the production of IL-10 by macrophages
Fig.7.4 show s a 48-hr tim e-course o f  IL-10 production by m acrophages treated w ith 
4 pg/m l H sp27. A t 8 hours, there was a significantly lower (1.6 fold decrease) 
production o f  IL-10 by m acrophages treated w ith Hsp27 com pared to untreated cells, 
(18.8 ±1.9 pg/m l vs 30.2 ±1.1 pg/m l, p=0.007). The decrease in IL-10 production by 
m acrophages at the 8-hour tim e point w as further investigated by treatm ent o f 
m acrophages w ith different concentrations o f  H sp27 at this tim e-point.
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Fig.7.4 Time-course experiment to investigate the production of IL-10 by macrophages 
over a 48-hr period.
Macrophages were treated with 4 pg/ml Hsp27 over a 48-hour time period. At 4,8,12,24 and 
48 hours, supernatant was removed and analysed for IL-10 production. At the 8-hr time 
point, there was a significantly lower production o f IL-10 by macrophages treated with 4 
pg/ml Hsp27 compared to untreated macrophages (control), p<0.05 (student's T-test). There 
were no other significant changes compared to untreated cells at all the other time-points. 
LPS served as a positive control. All conditions were done in triplicates and repeated 3 
times. Results are representative of 3 experiments.
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There was a decrease in m acrophage IL-10 production with increasing Hsp27 
concentration (0.06 -  2 pg/ml), Fig.7.5. W ith AN O V A and B onferroni post-hoc 
analysis revealed that significance was reached from  0.5 pg/m l concentration o f  
H sp27 onwards.
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Fig.7.5 Effect of treatment with Hsp27 on macrophage IL-10 production at 8 hours
Macrophages were treated with Hsp27 (0.06 -  2 pg/ml) for 8 hours. Supernatant was then 
removed and analysed for IL-10 by ELISA. Using ANOVA and post-hoc Bonferroni tests, it 
was found that cells treated with Hsp27 had significantly lower IL-10 production, from 0.5 
pg/ml onwards, compared to untreated cells (control). LPS serves as positive control. 
Significance,* p<0.05 and ** p< 0.01. All conditions were done in triplicates and repeated 3 
times. Results are representative of 3 experiments.
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7.3.3 Cell viability at 8 hours with increasing Hsp27 concentration
To ensure that the effect observed at this tim e point was not due to H sp27 toxicity, a 
cell viability experim ent w as done. It w as found that at increasing concentrations o f 
Hsp27 there w as no significant difference in the num ber o f  viable cells com pared to 
untreated cells, Fig. 7.6.
2 0 - i
0 0.06 0.125 0.25 0.5 1 2 4
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Fig.7.6 Effect of increasing concentration of Hsp27 (0.06 -  4 pg/ml) on cell viability.
Macrophages were treated with Hsp27 (0.06 -  4 pg/ml) for 8 hours. A cell viability assay 
was then performed using the C ellT iter 9 6 ®  A Q lieous One Solution Cell Proliferation 
Assay. With ANOVA, it was found that there was no significant difference in the number 
of viable cells between Hsp27-treated macrophages (solid fill) and untreated macrophages 
(hatched fill). All conditions were done in triplicates and repeated 3 times. Results are 
representative of 3 experiments.
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7.3.4 Hsp27 attenuated LPS-stimulated macrophage IL-10 production
Since LPS treatm ent stim ulated m acrophages to produce IL-10 and H sp27 inhibited 
IL-10 m acrophage cytokine production, it was investigated w hether H sp27 could 
override the LPS effect. W ith increasing LPS concentration (62.5 -  500 ng/m l) there 
was 3.2-fold, 4.0-fold, 4 .7-fold and 5.8-fold increase respectively, upon treatm ent 
w ith 62.5 ng/m l, 125 ng/m l, 250 ng/m l and 500 ng/m l o f  LPS on m acrophage IL-10 
production com pared to  untreated cells. H ow ever this effect was significantly 
attenuated w ith the addition o f  2 pg/m l o f  Hsp27 leading to a low er production o f  IL- 
10 by 2.3-fold, 3.0-fold, 3.7-fold and 4.4-fold respectively upon treatm ent w ith 62.5 
ng/m l, 125 ng/m l, 250 ng/m l and 500 ng/m l o f  LPS as shown in Fig. 7.7.
I I LPS + Hsp27
1 1 LPS alone
D  Hsp27 
1 1 Celts only
400-1
Control 2 62.6 62.6 125 126 250 250 500 500
Fig.7.7 Effect of Hsp27 on LPS-stimulated macrophage IL-10 production.
Macrophages were treated with Hsp27 alone, LPS alone, or LPS with Hsp27 for 8 hours. It 
was found that with increasing LPS concentration (62.5, 125, 250 and 250 ng/ml) there was 
a significant increase in macrophage IL-10 production compared to untreated cells (control). 
However this effect was attenuated in the presence of 2 pg/ml Hsp27. With ANOVA and 
post-hoc Bonferroni tests, * p<0.05 and ** p< 0.01. All conditions were done in triplicates 
and repeated 3 times. Results are representative of 3 experiments.
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7.3.5 Role of TLR2 and TLR4 on inhibition of macrophage IL-10 production by 
Hsp27
Fig. 7.8 shows the effect of adding TLR2 and TLR4 blocking antibodies on 
macrophage IL-10 production by Hsp27. Treatment of macrophages with 1.0 pg/ml 
Hsp27 only, caused a significant inhibition in macrophage IL-10 production. 
However, pretreatment of macrophages with anti-TLR2 antibodies before the 
addition of 1.0 pg/ml Hsp27 abolished this inhibition leading to a no significant 
difference in IL-10 production from these cells compared to untreated cells (control). 
This was not observed in macrophages pretreated with anti-TLR4 antibodies before 
the addition of 1.0 pg/ml Hsp27. The anti-TLR4 treated macrophages still showed 
significant difference in macrophage IL-10 production, when comparing to untreated 
cells (control). However, there was no significant difference with the addition of 
these antibodies in macrophage IL-10 production when comparing with Hsp27- 
treated macrophages alone.
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Fig.7.8 Inhibition of IL-10 production by anti-TLR2 and anti-TLR4 antibodies.
Cells were pretreated with either anti-TLR2 or anti-TLR4 blocking antibodies overnight 
before the addition o f 1.0 pg/ml Hsp27. After treatment for 8 hours, supernatant was 
removed and analysed for IL-10 by ELISA. Cells treated with 1.0 pg/ml Hsp27 alone and in 
combination with anti-TLR4 antibodies had significantly lower IL-10 secretion compared to 
untreated cells (control). With ANOVA and post-hoc Bonferroni tests, * p<0.05.
All conditions were done in triplicates and repeated 3 times. Results are representative of 3 
experiments.
7.3.6 TLR2 and TLR4 surface expression on macrophage
The effect o f  increasing concentrations o f  Hsp27 (0.03 -  2 pg/m l) on the expression 
o f  TLR2 and TLR4 was exam ined (Fig.7.9(a) and (b) respectively). It w as found that 
treatm ent with 2.0 pg/m l caused a significant increase in m acrophage surface 
expression o f  TLR2 (533 ±6 vs 471 ±9, p<0.001), as indicated by the m edian 
fluorescence intensities (M FI). H ow ever, there was no significant change in 
m acrophage TLR4 surface expression com pared to untreated cells at any o f  the 
concentrations tested.
C
O
N
TR
O
L 
+2 
n
g/
m
l 
H
sp
27
 
4-0
.5 
p
g/
m
l 
LP
S
00
ON
\
’cés oit-' '«fe1 '«Sc oil
oil-' cii' iic ojj' oil
idNVaii
ui
0_
=L
in
d
+
soi' oià 'SS «F  efe 6i!c aSi'
rM
a
to
X
E
occ
h-
zou
I
<D
1a.
2  
cd
h~
co
c.
6X
05
a
s05
E
<u
• I
S
E
co
so
!
H
13
C
05 -a
—
"ÔJ
2  
^  g
O N  ^
t~ -  V)
S 3
I
CD
,cd
§-
§oto
S)
g
1
<D~o
5
id
T3
§
kJI—1
cd O-
E h
S  o
H |
C  cd
a.
<D
i  s
•a
CD
11
<D CO
td £
<u cd
bû 
=1
<N
2  xI ^
E g
s  b
n
œ
X  
1=
-o
s
CD
•o
§
■S
§I
X )
oo01
o
d
V
S
I
CDX
bûo
CD
-O
CDI
CO
4 -O
a
CD
%
§-
g
I
TD!
è
TD
§1
8  .5
c °o ^
CO CD
cdcx
Eo
CD
CZ)
TD
§
CD
<
199
7.4 Discussion
Polarization of macrophages to the Ml phenotype by classical activation, or M2 
phenotype by alternative activation, depends on the microenvironment that they are 
exposed to. LPS and IFN-y can stimulate macrophages to adopt a Ml phenotype 
while IL-4 and TGF-p stimulation leads to the M2 phenotype. Ml-activated 
macrophages produce pro-inflammatory cytokines, e.g. IL-1 (3 and TNF-a, whilst 
M2-activated macrophages produce the anti-inflammatory cytokine IL-10. Since 
macrophages form the majority of immune cells in atherosclerotic lesions, 
macrophage phenotype would play a significant role in the evolution of the plaque 
and hence of the disease.
In this study, the effect of Hsp27 on macrophage cytokine production was 
investigated, with the aim of determining whether it is recognized as a 
proinflammatory agent. Macrophage TNF-a production was first investigated since 
this cytokine is an important mediator of inflammatory reactions and has been found 
in the human atheroma (Barath et al., 1990). Over a 48-hour time course experiment, 
it was found that there was no significant difference in the production of TNF-a 
between Hsp27-treated macrophages and untreated macrophages. This is in contrast 
to the effect on TNF-a production observed when macrophages are treated with 
Hsp60 which has also been suggested to be an autoantigen in atherosclerosis 
(Hansson, 2001). Hsp60 was found to stimulate the release of TNF-a and other 
inflammatory mediators; nitric oxide and the inflammatory cytokines IL-12 and IL- 
15, from macrophages (Chen et a l, 1999c). This result seems to suggest that Hsp27 
does not directly elicit a pro-inflammatory response by the innate immune system.
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It was next investigated whether Hsp27 serves as an anti-inflammatory signal for 
macrophage activation. This was done by assessing the production of IL-10 by 
macrophages. Previous studies have established the anti-inflammatory properties of 
IL-10, among which is its ability to inhibit the production of proinflammatory 
cytokines e.g. TNF-a and IL-6, by activated monocyte/macrophages (de Waal et al., 
1991; Fiorentino et al., 1991a; Moore et al., 2001). IL-10 has also been shown to be 
expressed in early and advanced human atherosclerotic plaques (Uyemura et al., 
1996). At the 8-hour time point, it was found that there was a significant decrease in 
IL-10 production with an increase in Hsp27 concentration. This decrease was not due 
to the possible toxic effect of Hsp27 on macrophages as confirmed by a cell viability 
test that was done at the same time point.
The possible mechanism by which Hsp27 reduced IL-10 production by macrophages 
was then studied. Since LPS can stimulate macrophages to produce IL-10 (Chanteux 
et al., 2007), it was investigated whether Hsp27 could antagonise LPS stimulation of 
macrophage IL-10 production. It was found that Hsp27 significantly inhibited LPS 
action on macrophage IL-10 production. LPS elicits its effects on macrophage 
cytokine production via binding to the LPS receptor complex which includes the 
TLR4 or TLR2 (Fujihara et a l, 2003; Dziarski and Gupta, 2000).
Next, it was investigated whether TLR4 was involved in the Hsp27 effect on 
macrophage IL-10 production. Besides TLR4, another receptor with potential 
involvement in this mechanism is the TLR2. For the suggested autoantigens, Hsp60 
and Hsp70, it was found that both TLR2 and TLR4 are involved in their actions on
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cytokine secretion (Pockley et a l, 2008). The possibility that these two receptors 
could be involved in the Hsp27 inhibition of macrophage IL-10 production was 
investigated by performing blocking experiments using antibodies against these 
receptors. It was found that with the addition of anti-TLR2 antibodies, this inhibitory 
effect on IL-10 production was reduced. However, this effect was not observed with 
the use of anti-TLR4 antibodies. Though the result with anti-TLR2 antibodies plus 
Hsp27 treatment was not significantly different with Hsp27-treated macrophages 
alone, this may tentatively suggest that TLR2 is involved in the Hsp27 inhibitory 
action on macrophage IL-10 production while TLR4 is not.
Further analysis of TLR2 and TLR4 expression on macrophages by flow cytometry 
indicated that treatment with Hsp27 significantly increased macrophage surface 
expression of TLR2. Macrophage IL-10 production can be mediated via ligation of 
TLR2 and TLR4 (Saraiva and O'Garra, 2010). Ligation of TLR2 and TLR4 leads to 
activation of extracellular signal-regulated kinase (ERK) 1 and 2, p38 and nuclear 
factor-xB (NF-kB) intracellular signaling pathways which lead to induction of IL-10 
expression. ERK and p38 belong to the mitogen-activated protein kinase (MAPK) 
group of signaling cascades which are serine/threonine kinases that are activated in 
response to an extracellular stimuli and mediate signal transduction from the cell 
surface to the nucleus (Johnson and Lapadat, 2002). Inhibition of the ERK and p38 
signaling pathways has been shown to lead to decrease in IL-10 production (Saraiva 
and O'Garra, 2010). In another study it was found that exogenous IFN-y was able to 
cause inhibition of macrophage IL-10 production (Hu et a l, 2006). IFN-y mediated 
inhibition of IL-10 production was found to be by increasing glycogen synthase
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kinase (GSK) 3 activity and suppressing MAPK activation and the transcription 
factors cAMP response element binding (CREB) and activator protein-1 (AP-1).
The above evidence from the blocking experiment with anti-TLR antibodies seems to 
suggest the involvement of TLR2 ligation in the inhibitory effect of Hsp27 on 
macrophage IL-10 production. The flow cytometry data showed significantly higher 
macrophage surface expression of TLR2 in the presence of Hsp27 compared to 
untreated cells which suggests that TLR2 might be a receptor involved in 
macrophage recognition of Hsp27 in vitro though further experiments are needed to 
confirm this. Unlike scavenger receptors, which are endocytic receptors, TLRs are 
signaling receptors. This means that ligation of these receptors initiate intracellular 
signaling events leading to transcriptional modulation of genes, such as those for 
cytokines (Aderem and Ulevitch, 2000) and also modulation of their own expression 
(Nhu et al., 2006). The intracellular signaling mechanism by which Hsp27 inhibits 
macrophage IL-10 production was not investigated, however it may possibly be via 
the GSK3 signaling pathway. GSK3 is a serine/threonine kinase that phosphorylates 
a wide array of proteins including metabolic enzymes, structural proteins 
and transcription factors and is involved in intracellular signaling pathways (Doble 
and Woodgett, 2003) . GSK-3 signaling has also been implicated in suppression of 
IL-10 production following IFN-y treatment (Hu et al., 2006).
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7.5 Conclusion
It was found that Hsp27 does not promote macrophages to produce the pro- 
inflammatory cytokine TNF-a and inhibit basal macrophage IL-10 production. Since 
IL-10 is an anti-inflammatory cytokine, this may suggests that Hsp27 may promote 
inflammation in an indirect way.
Chapter 8 
General Discussion, Conclusion 
and 
Future work
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8.1 General Discussion
Since the discovery of the Hsps in the 1960s (Ritossa, 1962), these proteins have 
been extensively studied especially with regards to their cellular localization, 
regulation and functions (Benjamin and McMillan, 1998; Hightower, 1991; 
Lindquist and Craig, 1988). Their ubiquitous presence in nature, occurring in both 
prokaryotic and eukaryotic cells in all major cellular compartments and the high 
level of amino acid sequence conservation all suggest their importance in 
fundamental cell processes. Four major cellular functions have been ascribed to 
Hsp27; molecular chaperone activity, protection against oxidative stress, modulation 
of actin dynamics and anti-apoptotic activity.
Heat shock proteins may be constitutively expressed in cells under normal 
physiological conditions, however, when they are exposed to stress, these proteins 
are overexpressed to provide protection against adverse conditions. With regards to 
Hsp27, it was found to be expressed in diseased arteries, predominantly in areas of 
the artery where inflammatory processes are believed to be most prominent (Wick, 
2006; Park et al., 2006). Arterial expression of Hsp27 was found to be localized 
particularly in endothelial and smooth muscle cells (Robinson et al., 2010). Robinson 
et al suggested that high Hsp27 expression in coronary arteries may provide 
protection from vascular disease through its ability to modulate actin dynamics. In 
this study, another mechanism is suggested by which Hsp27 might be involved in 
coronary artery disease, which is its ability to provide protection against oxidative 
stress especially in endothelial cells. In the study group consisting of healthy 
normoglycaemic individuals and patients with established cardiovascular disease
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with/without coexisting glucose intolerance, a significant positive correlation was 
found between serum glucose and Hsp27 levels. Previous studies have found that 
high intracellular glucose causes oxidative stress and leads to vascular complications 
in patients with diabetes (Brownlee, 2001; Brownlee, 2005). Since Hsp27 has been 
shown to be overexpressed in cells exposed to oxidative stress (Arrigo, 2001; Arrigo 
et al., 2005), it is suggested here for the first time, a possible mechanism for the 
overexpression of Hsp27 in arteries exposed to oxidative stress. Furthermore as 
oxidative stress is implicated in the pathogenesis of atherosclerosis, this may provide 
the connection between Hsp27 overexpression and atherosclerosis.
In this study, it was found that Hsp27 IgM antibodies were significantly lower in 
glucose intolerant patients with established cardiovascular disease compared to a 
healthy control group of normoglycaemic individuals. This pattern of lower IgM 
antibodies in patients with cardiovascular disease was also found against oxLDL, a 
strong candidate antigen for atherosclerosis (Hulthe et al., 2001a; Kita et al., 2001). 
In the study on patients who had experienced an acute myocardial infarction, it was 
found that IgM antibody levels decreased when Hsp27 was released into the 
circulation from the necrotic myocardium. This decrease was suggested to be due to 
IgM’s role in clearing Hsp27 from the circulation through the formation of immune 
complexes and subsequent activation of the classical complement pathway. This 
theory was supported by a similar fall in one of the proteins involved in complement 
activation, C3. IgG antibodies can also activate complement, however, of the two 
antibody classes, the IgM antibody is the more efficient in activating complement 
(Boes, 2000) and is supported by the change in IgM but not IgG antibody levels with 
change in Hsp27 concentration in patients with an acute myocardial infarction. With
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long term exposure to antigens, as may be the case with chronic release of Hsp27 
into the circulation, it may be expected that the IgM antibodies would decrease with 
disease progression. This was observed in the study of patients with established CVD 
who had significantly lower IgM antibodies. In the same group of patients it was also 
found that the levels of IgG antibodies to Hsp27 were higher, borderline significance, 
when compared to glucose intolerant patients without CVD. This finding was also 
expected because in the long term, exposure to antigen would lead to the mounting of 
a secondary antibody response with the IgG antibody being the predominant 
antibody class produced. With the higher IgG antibody levels and the subsequent 
formation of immune complexes with Hsp27, there is the added possibility that these 
complexes will aid in the inflammatory processes in atherosclerosis. Previously, IgG 
antibody complexes have been found to be proinflammatory in in vitro studies 
involving oxLDL immune complexes (Virella et al., 2002).
As a possible antigen implicated in atherosclerosis and with atherosclerosis being 
recognized as a chronic inflammatory disease, the relationship between Hsp27 and 
the inflammatory markers CRP and ICAM-1 was investigated in the study group of 
healthy controls and patients with established CVD with/without coexisting glucose 
intolerance. A direct relationship between Hsp27 with these inflammatory markers 
was not established, however, it was found that the IgG Hsp27 levels were positively 
associated with ICAM-1 levels. As explained above, long term exposure to Hsp27 
would lead to high IgG antibody levels, while, chronic inflammation (such as in 
atherosclerosis) would lead to regular production of soluble ICAM-1 into the 
circulation. The positive relationship between ICAM-1 and IgG Hsp27 is an 
interesting and suggestive involvement of Hsp27 in atherogenesis. The relationship
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found with ICAM-1 rather than with CRP also adds to the suggested premise that the 
possible overexpression of Hsp27 in arterial endothelial cells is related to conditions 
of oxidative stress in the cells since oxidative stress was found to enhance ICAM-1 
expression via activation of NF-kB (Ksiazek et al., 2010; Roebuck, 1999).
When further correlation analysis was undertaken within subgroups, the relationship 
between Hsp27 IgG with ICAM-1 was still found when groups with glucose 
intolerance were involved but not when those with CVD were analysed. Since 
glucose intolerance states (diabetes and impaired glucose tolerance) are risk factors 
to developing CVD (Kannel and McGee, 1979), this suggested that Hsp27 may be 
involved in the early stages of atherogenesis. When the relationship between Hsp27 
with ICAM-1 was investigated in a group of young individuals consisting of a less 
physically active group and a physically active group of gymnasts which were 
unlikely to have any significant atherosclerosis, it was found that there was no 
relationship between Hsp27 and its autoantibodies with ICAM-1. However, 
divergent relationships were found between Hsp27 IgG and IgM antibodies with 
physical activity in the control group of less active individuals, with positive 
correlation for IgM and negative correlation for IgG with physical activity. This 
seems to suggest that the lower the physical activity in the control group is associated 
with a higher level of oxidative stress. This leads to the overexpression and 
subsequent secretion of Hsp27 into the circulation leading to consumption of the 
Hsp27 IgM and production of Hsp27 IgG antibodies. It was reported that exercise 
stimulates the expression and increases the protein synthesis of antioxidant enzymes 
(Ji, 2002). This suggests a better compensation for the production of reactive oxygen 
species in individuals who are physically active, by the production of antioxidant
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enzymes and hence less dependence on Hsp27 for protection and this may explain 
why there was no relationship between Hsp27 and its antibodies with physical 
activity in the physically active group of gymnasts in the study. Physical inactivity is 
a risk factor for CVD (Williams, 2001). In this study, the relationship observed in the 
physically inactive group and the possible connection with oxidative stress and 
Hsp27 suggests the early involvement of Hsp27 in events leading to CVD.
The results obtained from the analysis of serum specimens suggest that Hsp27 is 
secreted into the circulation, from endothelial cells exposed to oxidative stress. Due 
to macrophage abundance in the atherosclerotic lesions, the production of cytokines 
from these cells has the potential to play an important part in determining the 
development of lesions in atherogenesis. In the in vitro studies, it was found that 
Hsp27 did not stimulate the production of the inflammatory cytokine TNF-a, 
however, it inhibited the production of the anti-inflammatory cytokine IL-10 from 
the murine macrophage cell line used in the study. IL-10 is not abundant in 
atherosclerotic lesions (Frostegard et a l, 1999), which is not unexpected, since the 
developing lesions would exhibit a cytokine profile supporting inflammation. 
However, studies in IL-10 deficient animals reported increased susceptibility to 
atherosclerosis in these animals (Mallat et al., 1999a), supporting a protective role in 
atherogenesis for anti-inflammatory cytokines such as IL-10. Examples of activators 
that can stimulate macrophages to produce IL-10 include IL-4 and immune 
complexes; both of which can be detected in atherosclerotic lesions (Hansson, 2001; 
Yla-Herttuala et al., 1994). The inhibitory action of Hsp27 on IL-10 production 
could potentially antagonise the actions of these stimuli. Since these activators are 
not present in large amounts in the lesions, any antagonism of their action could
further augment any inflammatory stimuli present in the lesions. The possible 
mechanism by which Hsp27 affected macrophage IL-10 production was investigated 
by studying the cell surface expression of, and, use of blocking antibodies against, 
two toll-like receptors; TLR2 and TLR4, that have been implicated in atherogenesis 
(Edfeldt et al., 2002; Shinohara et al., 2007). It was found that exposure of 
macrophages to Hsp27 leads to increased surface expression of TLR2 but not of 
TLR4 and use of blocking antibodies to TLR-2 reduced the inhibitory effect of 
Hsp27 on macrophage IL-10 production, but not with anti-TLR4 antibodies. This 
suggests the involvement of TLR2 in the macrophage immune response to Hsp27. 
This is different to that found in a previous study; TLR4 was suggested to be 
involved in the Hsp27-stimulation of dendritic cells to produce inflammatory 
cytokines (Yusuf et a l, 2009). In that study, the possible involvement of TLR2 was 
not investigated and thus could still be part of the inflammatory response in dendritic 
cells towards Hsp27, however, the involvement of TLR4 oberved in that study and 
not here, may also mean that different TLRs may be involved in the recognition of 
Hsp27 by different innate immune cells.
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8.2 Conclusion
The aim of these studies was to determine the potential role of Hsp27 as an antigen 
in the inflammatory response involved in atherogenesis. The data obtained suggested 
a possible route through which Hsp27 is linked to atherosclerosis, which is the 
overexpression of Hsp27 by endothelial cells of susceptible/high risk individuals 
exposed to oxidative stress. Once overexpressed and secreted into the circulation, the 
results showed a pattern of antibody levels that reflected long term exposure to the 
presence of Hsp27 in the circulation in these individuals. The results have also 
shown that Hsp27 may also be recognised by innate immune cells, namely 
macrophages, via upregulation of the TLR2 with concomitant inhibition of IL-10 
production.
In summary, atherosclerosis is a multifactorial disease developing over a long period 
of time before it manifests as clinical events. Inflammatory processes aid in the 
development of the lesions and multiple inflammatory agents may be involved in 
pathogenesis over this period. Though the studies suggest that there may be a 
possibility that Hsp27 is involved in atherosclerosis, further studies are needed to 
confirm whether it may be one of the agents contributing to the inflammatory process 
or may be a marker for the disease.
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8.3 Future W ork
Murine macrophage cell lines have been used in numerous studies as in vitro models 
of the innate immune response in atherosclerosis. However, these experiments have 
been complemented with further research using human monocyte-derived 
macrophages. Thus, repeating the in vitro experiments in human monocyte-derived 
macrophages is a logical next step in these studies.
Since this study has suggested the involvement of hyperglycaemia in Hsp27 
overexpression, in vitro experiments using endothelial cells can be carried out to 
investigate the effect of hyperglycaemia and oxidative stress and the production of 
Hsp27.
T cells can be isolated from fresh human plaques, cloned, expanded in culture, and 
challenged with candidate antigens such as Hsp27. This approach has been used to 
identify oxLDL and Hsp60 among the antigens recognised by the heterogenous 
population of T cells found in lesions. A similar approach could be used for Hsp27, 
to further confirm its functions as an autoantigen.
We have suggested oxidative stress as a causative factor for the involvement of 
Hsp27 in atherosclerosis. To study this effect in an animal model, ideally we would 
use a model which is exposed to predisposing risk factors such as an atherogenic 
diet. Such a model could be used to study the time-course relationship between 
lesion formation and Hsp27 expression. Streptozocin-induced diabetic mice have 
already been used to investigate the effect of hyperglycaemia in atherosclerosis
(Kunjathoor et al., 1996). These disease models can be compared with non-diabetic 
atherosclerosis-prone mice to investigate the direct role of Hsp27 and its antibodies, 
as well as to investigate possible vaccination strategies.
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Appendix 1: Buffers 
Western blotting buffers
All buffer preparations described below are for running a single gel/membrane. 
Running Buffer fix'):
Fifty millilitres of NuPAGE® MOPS SDS running buffer [50mM 3-(N-morpholino) 
propanesulfonic acid (MOPS), 50mM Tris-Base, 0.1% Sodium dodecyl sulphate 
(SDS), l.OmM ethylenediaminetetraacetic acid (EDTA), pH 7.7] were added to 950 
ml distilled water.
Transfer Buffer (1x1:
Fifty millilitres of NuPAGE® transfer buffer (25mM bicine, 25mM Bis-Tris, ImM 
EDTA, pH 7.2), were added to 100 ml methanol (99.9% for HPLC gradient grade) 
and 850 ml distilled water.
Blocking Solution:
Two millilitres of Blocker/Diluent A, was added to 3 ml Blocker/Diluent B and 5 ml 
distilled water
Hsn27 Monoclonal Antibody Diluent:
Two millilitres Blocker/Diluent A was added to 1 ml Blocker/Diluent B and 7 ml 
distilled water
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ELISA buffers
The following buffers were used for the ELIS As:
Phosphate buffered saline (PBS) buffer pH 7.4 
0.05M carbonate-bicarbonate coating buffer pH 9.6 
Wash buffer, 0.05% Tween20 in PBS 
Blocking Buffer, 4% Goat Serum (GS) for Hsp27 ELISA:
Blocking Buffer, 3% Bovine Serum Albumin (BSA) for anti-IgM and anti-IgG 
Hsp27 ELISA
0.1M Carbonate-bicarbonate coating buffer (pH9.6):
Sodium bicarbonate (NaHC03, 0.2M) was added to 50 ml of sodium carbonate 
(Na2C03, 0.2M).
Wash buffer 1 (0.05% Tween20)
Wash buffer 2 (phosphate-citrate buffer):
One tablet of phosphate-citrate buffer was added to 100 ml of distilled water.
CRP ELISA buffer
CRP ELISA blocking buffer (1% BSA): 
1 g/100 ml PBS
ICAM-1 ELISA blocking buffer (3% BSA):
3 g/100 ml PBS.
CRP ELISA Standard and sample dilution buffer (0.2% BSA in Tween20) 
One ml of 10% BSA was added to 49 ml of 0.05% Tween20.
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Appendix 2: WHO recommendations for the diagnostic criteria for diabetes 
and intermediate hyperglycaemia
Normoglycaemia
Fasting plasma glucose <6.1 mmol/1
2h plasma glucose <7.8 mmol/1
Diabetes
Fasting plasma glucose >7.0 mmol/1
2b plasma glucose >11.1 mmol/1
Impaired Glucose Tolerance (IGT)
Fasting plasma glucose <7.0 mmol/1
2h plasma glucose >7.8 and <11.1 mmol/1
Impaired Fasting Glucose (IFG)
Fasting plasma glucose 6.1 to 6.9 mmol/1
2h plasma glucose <7.8 mmol/1
